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STUDIES ON THE MOTOR OF MODS 
I.I PREFACE 
In his classic editorial in 1975, Baue1 drew a parallel between the 
progressive successive organ dysfunction in the multiple organ dysfunction 
syndrome (MODS) and the organ systems determining survival after major 
injury and operations, during the major wars of this century Before Wor ld 
War II, the cardiovascular system was the limiting factor for survival, its failure 
resulting in shock By the end of this war, when shock was adequately treated 
with the transfusion of blood and plasma, the kidney emerged as the most 
limiting organ After the Korean war, kidney failure was prevented by an 
increased administration of cnstalloids, and supported by haemodialysis In the 
Vietnam War, progressive pulmonary failure (Adult Respiratory Distress 
Syndrome, ARDS) or the " Da Nang Lung" emerged as the limiting organ 
system which needed ventilatory support on the ICU In the I970's, critically 
ill patients were identified which developed a typical syndrome of progressive 
sequential organ systems that fail ι e the lungs, liver, gut, kidney and eventually 
the heart, which has been defined as the multiple organ dysfunction 
syndrome1 2 
Now, 20 years after MODS has been recognized as an entity, wars still 
dominate our society, however while fighting external aggressors in the 
former wars, we are now fighting internal conflicts in Rwanda, former 
Yugoslavia, Afghanistan and Somalia This parallels our attention towards the 
12 pathophysiology of MODS While formerly our attention was directed 
towards the prevention and treatment of external factors like occult infection, 
early stabilization of fractures, adequate treatment of shock, we are now 
realizing that the most important factor in the pathophysiology in MODS is an 
excessive, self-destructive, generalized inflammatory reaction, termed as a 
"generalized autodestructive inflammation"3 In our struggle against MODS we 
are now fighting the deterioration of the host's homeostasis by internal 
aggressors, like "angry neutrophils", "mad macrophages"4 and endothelial 
cells, that release cytokines, nitric oxide, oxygen radicals and proteases that 
can destroy our organs5 6 Furthermore, recent attention is directed to the 
dysregulation of apoptosis of inflammatory cells, resulting in a continuous 
stimulation of cells injurious to the organisms7 Hence, we are now facing the 
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problems of an internal civil war that endangers our critically ill patients, 
termed by Baue as the "Hor ro r Autotoxicus"8 . 
Despite our improved understanding and advanced support of biological 
systems on the intensive care unit (ICU), MODS still remains the major cause 
of death in surgical patients. The incidence of MODS in the surgical intensive 
care unit (SICU) varies between 8 and 42% , with a mortality rate of 3-100%, 
depending on the number and duration of organs dysfunctioning9"1 '. It has 
been estimated that MODS is responsible for 50-80% of all surgical deaths and 
costs more than $ 150.000 per patient12. It should be clear that MODS has an 
enormous impact on surgical practice. Despite the fact that surgeons have 
become able to perform more difficult and extensive operations, 
postoperative MODS remains a major risk, without specific treatment. Hence, 
elucidating the scientific conundrum of MODS will have major consequences 
on the prognosis of the surgical patient, and on the possibilities of performing 
major surgery. 
1.2 T E R M I N O L O G Y A N D D E F I N I T I O N S 
To allow for a clear discussion on the pathophysiology of MODS, terms 
like MODS and clinically related entities like inflammation, infection, 
bacteremia, SIRS, sepsis, and ARDS have to be defined. Recent reports of the 
consensus conference of the American College of Chest Physicians (ACCP) & 
the Society of Critical Care Medicine (SCCM) and of the American-European | 3 
consensus conference on ARDS, have tried to establish a taxonomy to 
characterize the complex physiological derangements of critical illness13, l4. 
Their conclusions will be discussed below. 
Inf lammation 
This term is derived from the Latin, in which infiammare means to burn. 
Currently, it has been defined as a localized protective response elicited by 
injury or destruction of tissues, which serves to destroy, dilute, or sequester 
both the injurious agent and the injured tissues '6. It is important to realize 
that inflammation and infection are different entities. 
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Infection 
A microbial phenomenon which is characterized by an inflammatory res-
ponse to the presence of microorganisms or the invasion of normally sterile 
host tissue by those organisms 
Bacteremia 
The presence of viable bacteria in the circulation 
Sepsis and SIRS 
The term sepsis has its origin in ancient Greek, in which two terms were 
used for tissue breakdown Pepsis was associated with life and good health and 
exemplified by the fermentation of wine Sepsis, on the other hand was 
associated with death and disease and described the process of putrefaction 
and decay l 7 Wi th the recognition of microorganisms being the agents of 
putrefaction, sepsis was traditionally considered to be synonymous with 
disseminated infection However, due to the evolution of intensive care 
medicine, the characteristics of sepsis have expanded and were associated 
with hemodynamic instability and organ dysfunction18 Furthermore, it became 
apparent that as many as 30% of patients developing this systemic response 
did not have a demonstrable infectious focus, bacteremia or endotoxemia3 l 9 
To end this confusion, the term "systemic inflammatory response syndrome" 
or SIRS was introduced to indicate that the development of this syndrome 
does not necessarily depend on the presence of bacteria20 
SIRS 
14 The systemic inflammatory response syndrome (SIRS) is defined as the 
systemic inflammatory response to a variety of severe clinical insults which is 
manifested by two or more of the following conditions 
• Temperature > 38 °C or < 36°C 
• Heart rate > 90/min, 
• Respiratory rate > 20 breaths/mm or PaC0 2 < 32 mmHg (< 4 3 kPa) 
• Blood leukocytes > I2x l0 9 / I or < 4x l0 9 / l , or > 10% immature neutrophils 
Sepsis 
The systemic response to infection which is characterized by the same 
criteria as SIRS but with evidence of infection 
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Severe sepsis or SIRS 
Sepsis or SIRS associated with organ dysfunction, hypotension (systolic BP 
< 90 mmHg or > 40 mmHg below the baseline), hypoperfusion or perfusion 
abnormalities that may include lactic acidosis, oliguria and a acute alteration of 
mental state. 
Septic Shock 
Sepsis with hypotension, despite adequate fluid resuscitation, along with 
the presence of perfusion abnormalities that may include lactic acidosis, 
oliguria and a acute alteration of mental state Patients who are on inotropic 
or vasopressor agents may not be hypotensive at the time that perfusion 
abnormalities are measured. 
A R D S 
Pulmonary insufficiency in critically ill patients, after a variety of infectious 
and non-infectious insults, has already been described by surgeons some 30 
years ago21 Asbaugh and colleagues, were the first that introduced the term 
"Acute Respiratory Distress Syndrome" (ARDS)22. There has been an 
extensive discussion about definitions, risk factorsmcidence and validity as a 
clinical entity 23. Recently the American-European consensus conference on 
ARDS has defined ARDS as a syndrome of pulmonary inflammation and 
increasing permeability that is associated with a constellation of clinical, 
radiological, and physiological abnormalities that cannot be explained by, but 
may coexist with left atrial or pulmonary hypertension14. Furthermore, they 
introduced the term "acute lung in|ury" (ALI), being less severe than ARDS 15 
The criteria for ALI and ARDS were: 
• Timing: acute onset 
• Oxygenation: Pa0 2 /F i0 2 300 mmHg (ALI) or PaO 2'^0i 2 0 0 m m H S 
(ARDS) , regardless of PEEP 
• Chest radiograph: bilateral infiltrates 
• Pulmonary artery wedge: 18 mmHg, or no clinical evidence of left atrial 
hypertension. 
The histopathological correlate of this syndrome has been termed "diffuse 
alveolar damage", which is characterized by an early "exudative phase" with 
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alveolar epithelial cell damage, resulting in an increased lung vascular 
permeability, inflammatory cell infiltration (early of polymorphonuclear 
leukocytes (PMN) and later of macrophages), protemaceous alveolar and 
interstitial edema, alveolar hyaline membranes and mtra-alveolar hemorrhage 
These early events are followed by the "proliferative phase" with proliferation 
of type II pneumocytes and fibroblasts resulting in mtra-alveolar and interstitial 
remodeling In the late "fibrotic phase" the lung is completely remodeled by 
sparsely cellular collagenous tissue24 25 The incidence of ARDS on the ICU 
varies considerably, from 1-80%, depending on the definitions and patient 
population23 Mortality rates have been reported in the range of 36% to 60%, 
with some indications that mortality may be decreasing the last years23 26 
Teleologically, ARDS is the expression of a systemic disease with generalized 
increased endothelial permeability and the first apparent organ that fails in the 
sequence of MODS2 7 
MODS 
The original denomination "progressive multiple systems failure"2, later 
changed to "multiple organ failure" (MOF)28, has been recently coined as the 
"multiple organ dysfunction syndrome"20 The term dysfunction describes the 
inability of an organ system to maintain homeostasis without intervention 
Dysfunction, rather than failure, was considered to better describe the 
continuum of physiologic derangements in an organ system13 Furthermore, 
the terms primary MODS and secondary MODS were introduced to identify 
I 6 the difference between the development of MODS after a well-defined severe 
insult (primary MODS) or as a consequence of the host response to the initial 
insult, within the context of SIRS13 This correlates well with the observation 
of a bimodal distribution of the occurrence of MODS, with early MODS as a 
result of severe SIRS and late MODS as a result of infections due to a severe 
delayed immunodepression29 MODS develops after various insults including 
severe infection, like peritonitis9, trauma and major surgery30, burn injury31, 
shock32 and pancreatitis33 Regardless of the cause, MODS typically consists of 
the sequential dysfunction of various physiological systems, beginning with the 
lungs and followed by hepatic, intestinal, renal, hematological and eventually 
cardial dysfunction Furthermore, during MODS, coagulation, immunological, 
central nervous, metabolic and musculoskeletal system dysfunction may 
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occur' '. Criteria of dysfunction or failure differ among studies, making it 
difficult to compare clinical studies. Furthermore, it has become clear that 
organ dysfunction is difficult to define , since dysfunction of an organ system 
has to be related to the functional demands for that specific organ. Several 
scoring systems have been employed to define and grade the severity of 
MODS". The most frequently used score is the MOF score developed by 
Goris et al. which grades the severity of dysfunction of seven organs on a 
three point scale. This score demonstrates a good correlation with survival3. 
M U L T I P L E O R G A N FAILURE SCORE 
Organ System 
Pulmonary 
Cardiac 
Renal 
Hepatic 
Hematological 
Gastrointestinal 
Central nervous 
Grade I Grade 2 
Mechanical ventilation with PEEP < 
lO^m НЮ, Fi02 < 0!4 
Hypotension > 100 mmHg 
Dopamine < 10 μg/l<g/min 
Nitroglycerin < 20 μg/kg/min 
Serum creatinine < 2 mg/dl 
Serum billirubin < 2 mg/dl or 
ASAT < 25 U/l 
Platelets < 50x I O'/l and/or 
leukocytes > 30x I O'/l 
Acalculous cholecystitis 
Stress ulcer 
Diminished responsiveness 
Mechanical ventilation with PEEP > 
10cm НЮ, R02 >_U4 
Hypotension < 100 mmHg 
Dopamine > I0μg/kg/m¡n 
Nitroglycerin > 20 μg/l<g/min 
Dialysis 
Serum billirubin > 6 mg/dl or 
ASAT > SO U/l 
Disseminated intravascular 
coagulation and/or 
leukocytes < 2.5x1 O'/l or > 60x1071 
Perforation of galbladder 
Bleeding from ulcer > 2 units 
blood/24 hr. 
Necrotising enterocolitis 
Pancreatitis 
No Failure = grade 0; moderate failure = grade I ; severe failure = grade 2. 
MOF score is total of 7 organ failure scores, with a maximum of 14 points. 
Goris RIA, et al Arch Sur? 1985;120: 1109-11 IS. 
Severely disturbed responsiveness 
and/or diffuse neuropathy 
17 
Whatever scoring system is used for organ dysfunction, a common 
observation is an increasing risk for mortality with an increasing number of 
dysfunctioning organs9, ' ' '3 4. For example, combining several scoring systems, 
mortality for one organ failure is 22%, two organs 33%, three organs 65%, 
four organs 75% and five organs 94%' '. In addition, mortality rates appear to 
be 10-20% higher for elderly patients34. 
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Next to organ specific changes, histopathological postmortem data reveal a 
remarkable similarity in signs of a generalized inflammatory response i.e. signs 
of interstitial edema, infiltration with PMN and macrophages and cell necrosis 
It is important to realize that SIRS, ARDS and MODS represent a 
pathophysiological continuum of increasing severity. Furthermore, SIRS 
describes a process and MODS describes the outcome o f tha t process . Since 
various conditions, like infection, trauma and shock can evoke the same 
clinical syndrome, it is to be expected that similar pathophysiological 
mechanisms are involved in the pathogenesis of SIRS, ARDS and MODS . In 
the next section, considerations on those pathophysiological mechanisms will 
be discussed. 
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S tots ON HE MO OR OF MODS 
2.1 I N T R O D U C T I O N 
The gut is an important organ with many functions under normal 
conditions including the digestion and absorption of nutrients and the 
secretion of endocrine products; in addition it forms a barrier against 
intraluminal bacteria. Under pathological conditions, however, gut function 
may fail. 
Evidence is accumulating that the gut is not simply a bystander organ in 
critically ill patients but may also serve as an initiator and stimulator of a 
generalized systemic inflammatory response, and functions as the "motor" of 
sepsis and MODS MODS was initially described as a distinct entity by Baue 
in the 1970s3. Since then, despite major advances in supportive care of organ 
functions, MODS still develops in about 15% of patients admitted to an 
intensive care unit (ICU) , and remains the major cause of death in critically ill 
patients4 
If gut failure is an important phenomenon in critically ill patients who 
develop MODS, some questions must be clarified. Firstly, infections caused by 
enteric bacteria should be a major problem in critically ill patients and should 
be related to morbidity or mortality, or both Secondly, these infections 
should be related to loss of barrier function ( as measured by intestinal 
permeability or bacterial translocation ) or to abnormal colonization of the 
gut, or both Furthermore, interventions to reduce this "autointoxication" of 
22 the host by the gut (for example by selective decontamination of the digestive 
tract (SDD)) should reduce morbidity and mortality 
In this review we will discuss the issues of nosocomial infections, bacterial 
translocation and the results of SDD, and try to correlate the development of 
sepsis and MODS with failure of gut barrier function. 
2.2 N O S O C O M I A L I N F E C T I O N S 
Nosocomial infections remain a common and important problem among 
patients admitted to an ICU and cause high morbidity, mortality and hospital 
costs5· 6 Nosocomial infections are those infections that are caused by the 
specific microbiological environment in the ICU. ICU-acquired infections are 
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defined as those infections that develop at least 48 hours after admission to 
the ICU. Because of their impaired host defenses, multiple invasive procedures 
in which normal epithelial barriers are disrupted, and the extensive use of 
broad-spectrum antibiotics, patients in the ICU are at increased risk of 
developing nosocomial infections7. Infections that are present at the time of 
admission to the ICU are classified as primary or community-acquired 
infections8 9 , and are primarily caused by enteric Gram-negative bacilli, 
anaerobes, or enterococci ICU-acquired nosocomial infections, however, are 
caused mainly by potentially pathogenic microorganisms, which are frequently 
resistant to many antibiotics. Most commonly recovered isolates in ICU-
acquired infections are Gram-negative microorganisms such as P. aeruginosa, 
Serratia marcescens and Aanetobacter spp., enterococci, S epidermide and aureus 
and yeasts such as Candida albicans7'^ 
The reported incidence of nosocomial infections vanes considerably among 
several studies. For example, in mixed medical-surgical ICUs, the reported 
incidence of nosocomial infections has ranged from 7 2% to 28%7 8 " • l 2 l5"18. 
Surgical intensive care units (SICU's) seem to have a higher incidence of 
infection, which has been reported to be between 14% and 4I .4%8 9 l 2 , l 5 , ' 7 ' 
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 Furthermore, infection rates tend to increase with the length of stay in the 
ICU. A 19% infection rate reported after three days of admission, increased to 
85% after 10 days of admission18. The development of a nosocomial infection 
might contribute to a fatal outcome In a case-control study, nosocomial 
infections were present in 33% of the patients who died and in I 3% of the 
patients who survived , and in a study in a SICU, three quarters of the 
infected patients died in contrast to only 3.9% of the uninfected patients . 
This observation was confirmed by others, who reported a mortality of 3.3% 
among uninfected patients and 23.5% when an ICU-acquired infection 
developed8. Craven et al calculated that the relative risk of death following the 
development of a nosocomial infection was increased 3.5-fold for a mixed ICU 
population 
Lower respiratory tract infections are the leading cause of death from 
nosocomial infections21, and crude infection rates ranging f rom 4.6% to 21 3% 
have been reported in ICU patients7 l5 , l 7 , 22"25. Rearranging data from two 
meta-analyses of control groups of trials with SDD shows that in the studies in 
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which historical controls were used the incidence of respiratory tract 
infections was 24.4% while in the randomized control trials the incidence was 
44.7%26. When the diagnosis of pneumonia was made by bronchoscopy or 
protected brush specimen, the incidence was 23.1% whereas if the diagnosis 
was based on clinical criteria the incidence was 30.6%27. The risk of 
developing nosocomial pneumonia increases with the length of admission to 
the ICU. In a prospective study of 567 patients who had been receiving 
mechanical ventilation, pneumonia (diagnosed by bronchoscope protected 
specimen brush) developed in 9% of the patients23. The actuarial risk was 6 5% 
after 10 days and increased to 28% after 30 days23. Overall crude mortality 
rates for patients with nosocomial pneumonia ranged from 20-55% but 
increased to 70-80% when P. aeruginosa was the infecting microorganism and 
in patients who required long term ventilatory support20 22 23 28"31, 
Several studies have documented that the development of pneumonia is 
associated with a decreased survival. In one study the mortality rate of ICU 
patients with pneumonia was 50%, compared with 3.5% for patients without 
pneumonia31. This result was confirmed by others who reported that the 
mortality rate was more than doubled (55% compared with 25%) in ICU 
patients who required continuous mechanical ventilation and developed 
pneumonia Although the development of pneumonia was one of the variables 
in the univariate analysis that was associated with mortality after logistic 
regression, pneumonia was not an independent factor after multivariate 
analysis . In a case-control study it was concluded that the mortality 
attributed to pneumonia was 33%29, and the development of nosocomial 
pneumonia seems to increase the length of stay in the ICU by a week32. Risk 
factors associated with the development of nosocomial pneumonia are the use 
of H2 blockers, respiratory support, impaired airway reflexes, coma, and 
multiple trauma22 23 
Both the development of nosocomial infections in general and nosocomial 
pneumonia in particular have been associated with the overgrowth of 
potentially pathogenic micro-organisms in the proximal gastrointestinal tract, 
which provides a reservoir for colonization of the respiratory tract in patients 
in the ICU. Colonization of the oropharynx and the intestine have also been 
associated with the development of nosocomial pneumonia33 and this 
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colonization has preceded the appearance of Gram-negative bacteria in the 
trachea3 4. A prospective study of patients in a SICU showed that on admission 
23% of the patients had oropharyngeal and 23.3% had tracheal colonization 
with Gram-negative bacteria. The incidence of colonization had increased to 
100% and 87%, respectively after 15 days in the ICU. Colonization with the 
same microorganism preceded infection in two thirds of the respiratory tract 
infections3 . In a prospective cohort study, Marshall et al confirmed this 
strong correlation between colonization of the proximal gastrointestinal (Gl)-
tract and the development of ICU-acquired infections3 6. This was particularly 
true for infections caused by P. aeruginosa and S. epidermide. Furthermore, they 
showed that mortality in the ICU significantly increased in patients colonized 
with Ρ .aeruginosa compared with those who were not (70% compared with 
26%). Because colonization of the Gl tract with Candida, P. Aeruginosa and S 
.epidermide was associated with high multiple organ failure (MOF) scores, they 
suggested that the proximal Gl tract could be viewed as the "undrained 
abscess" of MODS 3 6 . 
Uncontrolled infection has been associated with the development of 
MODS. In the late 1970s Polk and Shields described a group of patients in 
whom MODS was reversed by surgical drainage of occult foci of intra­
abdominal sepsis . In a study of 553 patients, Fry et al documented that 89% 
of the 38 patients who developed MODS had evidence of infection. These 
authors concluded that MODS was the most common fatal expression of 
uncontrolled infection3 8. In other studies, the MOF score correlated well with 
the incidence of ICU-acquired infections. This was particularly true for 
infections caused by S. epidermide and Candida spp.i9. Since then, several 
studies have found less close correlations between infection and MODS and 
indicated that a focus of uncontrolled infection was found in only about half of 
the patients who developed MODS. For example, in only 56% of severely 
injured patients with MODS was an infectious focus present3 9 , and in a study 
of I 10 patients with multiple trauma injuries it was shown that infection was 
of no importance in a quarter of the patients, while in three quarters of the 
patients MODS had already started before infection developed4 0. In a study of 
21 patients with confirmed intra-abdominal abscesses, drainage of these 
abscesses did not reverse the course of MODS or increase survival4 1. 
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Although patients with infection have a higher mortality, and infection is found 
in an appreciable number of those who die, outcome was influenced more by 
the host's response t o this infection (as measured by a sepsis score) than by 
the infection itself8. It has been postulated that in some patients infection is 
the expression of failing host defenses, and it seems that many critically ill 
patients die with, rather than because of, infection4 2. On the other hand, this 
apparent paradox of why no septic focus can be identified in more than 30% of 
bacteremic patients, has led t o the concept that the gut is the source of 
translocation of bacteria and endotoxin, thereby acting as the "motor" of 
MODS 2 . This concept will be discussed below. 
In conclusion, nosocomial infections, which are often caused by enteric 
bacteria, are a major problem in critically ill patients, but it remains unclear to 
what extent these infections are related to the development of MODS or to 
mortality in the ICU. Clearly in some patients infection seems t o be directly 
related to the development of MODS and mortality, while in others it is a 
secondary phenomenon and a symptom rather than a cause of MODS. 
2.3 B A C T E R I A L T R A N S L O C A T I O N 
The concept that bacteria and endotoxin escaping from the gut, together 
with reduced host defenses, could lead to systemic infection and irreversible 
post-injury shock was originally proposed by Fine more than 30 years ago4 3. 
26 The failure of the gut as an effective barrier to intraluminal microorganisms, 
leading t o the passage of viable enteric bacteria and endotoxin across the 
intestinal mucosal barrier t o the mesenteric lymph nodes (MLN) and distant 
organs, has been termed bacterial translocation ( В Т ) 4 4 · 4 5 . The mechanism by 
which microorganisms reach the lamina propria of the gut has been proposed 
t o be paracellular4 6"4 8 or transcellular, in which it is suggested that the 
enterocyte has an active, energy-consuming, role 4 · 5 0 . The pathways by which 
the MLN and systemic organs are reached are uncertain. Macrophages may 
transport bacteria from the gut t o the M L N 5 1 ' 5 2 , and the route by which 
bacteria reach the systemic circulation, could be by both the lymphatic system 
and by direct vascular invasion in the capillaries with subsequent transport 
through the portal system to the liver. The lymphatic route, however, seems 
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to be the primary route of BT5 3 , 5 4 . 
It has been shown in experimental animal models, that BT to the 
mesenteric lymph nodes and to organs such as the liver and spleen is 
promoted by various pathological conditions. These include the administration 
of oral antibiotics55"58, and the use of total parenteral nutri t ion59 , 60 , 
elemental diets61, 62 or protein malnutrition63, 64. BT is also induced by 
hemorrhagic shock65"69, burns70"75, surgical trauma and anesthesia76 , 
abdominal irradiation , intestinal obstruction78 , and obstructive jaundice ' 80. 
The induction of a generalized inflammatory response by endotoxin81"83 or 
zymosan54, 84"86 , as well as the induction of a generalized immunosuppressed 
state with prednisolone or cyclophosphamide87 or the induction of impaired 
cell-mediated immunity88, 89 have been reported to promote BT. Mucosal 
injury and BT caused by burns48, hemorrhagic shock90 or endotoxin 
challenge82 could be limited experimentally by inhibiting the production of 
xanthine oxidase-generated oxygen radicals, which suggests that mucosal 
injury mediated by ischemia-reperfusion injury is a common pathway that 
promotes BT in these circumstances. 
From these experimental studies, we conclude that BT is a phenomenon 
that exists in animals under certain pathological conditions. Furthermore, from 
a pathophysiological point of view, BT seems to be promoted by one of three 
factors: disruption of the normal ecology of the indigenous microflora 
resulting in bacterial overgrowth; impaired host immune defenses; and physical 
disruption of the mucosal barrier of the gut. In critically ill or severely injured 
patients most of these factors are impaired, possibly promoting the passage of 
bacteria and endotoxin across the intestinal mucosal barrier. 
The hypothesis that BT could be important in sepsis and MODS was 
originally proposed because of the observation that bacteremia with enteric 
bacteria was regularly found without an identified infectious focus in patients 
who were dying of MODS and sepsis39 as well as in patients with trauma ' 9 I 
or extensive burns92. The phenomenon of BT could therefore explain why in 
more than 30% of patients with and MODS no septic focus could be 
identified39. The concept that a close relationship exists between retained 
necrotic tissue, macrophage activation, and failure of gut barrier function has 
been defined by Border et al as "gut origin septic states"1. Because it has been 
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shown experimentally that alterations in the flora of the gastrointestinal 
tract93 94 and translocation of bacteria and endotoxin by itselr can alter 
the host's immune response, it has also been postulated that BT could initiate, 
exaggerate, and perpetuate the systemic inflammatory response that leads to 
MODS and could be viewed as "the motor of MODS" 2 
Animal studies that have tried to correlate BT with mortality have given 
conflicting results In a zymosan-mduced animal model of MODS, mortality 
was significantly lower in germ-free animals but organ damage was present in 
all animals, suggesting that BT has only a partial role in the development of 
MODS9 7 In another study of low-dose zymosan peritonitis, mortality was 
reduced by cefoxitin, but this effect was lost when higher doses of zymosan 
were given The correlation between survival and BT seems, therefore, to 
be related to the magnitude of the inflammatory insult It has recently been 
shown that elimination of macrophages in the zymosan model led to an 
increase in systemic BT but an improvement in survival98 So, bacteremia and 
survival do not always correlate, particularly in systemic inflammatory states 
On the other hand, an elegant study, in which gavaged £ coli labeled with 
carbon-14 oleic acid were used, showed that after severe hemorrhagic shock 
all animals with positive blood cultures died compared with only 17% of the 
animals with no bacteremia, suggesting a positive correlation between BT and 
mortality69 
Human data on the barrier function of gut mucosa and translocation of 
bacteria and endotoxin are limited and conflicting Loss of gut mucosal barrier 
function has been studied in humans by measuring intestinal permeability 
Increased permeability has been described after endotoxin has been given to 
healthy volunteers99 and after burns and correlated positively with septic 
complications100 l 0 2 Intestinal permeability was recently described by Roumen 
et al to be increased after severe trauma and hemorrhagic shock in humans , 
but there was no causal relationship between increased intestinal permeability 
and the severity of the insult, infectious complications or MOF-scores 
Interestingly, they found no correlation between endotoxin concentrations 
and the severity of intestinal permeability, which suggests that clinically 
measurable translocation of endotoxin and changes in intestinal permeability 
are independent processes103 
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In the early 1970 s, systemic endotoxemia had already been reported in 
various septic and non-septic conditions in man 1 0 4 . Although early 
translocation of endotoxin was shown postburn in humans and was related t o 
burn size , it was shown in a prospective randomized trial of patients with 
severe burns that neutralizing circulating endotoxin with polymyxin В did not 
reduce either the sepsis score or mortal i ty 1 0 6 . Endotoxemia has been 
associated with septic shock l 0 8 , but in a large multicenter randomized 
double blind placebo-controlled trial, treatment of patients with septic shock 
with anti endotoxin decreased mortality only in the subgroup of patients with 
109 
gram-negative . 
Data on ВТ in humans, which are summarized in Table I , and discussed 
below, are sparse. Ambrose et al sampled mesenteric lymph nodes (MLN) of 
patients undergoing laparotomy for non-contaminated Crohn's disease or for 
other indications. Intestinal bacteria were recovered significantly more often 
from the MLN in patients with Crohn's disease (33%) than f rom those of 
controls ( 2 % ) ' l 0 . Deitch showed that in patients with simple intestinal 
obstruction, 59% of the MLN contained viable bacteria compared with 4% in 
patients operated on for other reasons' ' '. Moore et al inserted portal venous 
catheters at laparotomy in severely m|ured patients and found bacteria in a 
quarter 25% of the MLN and only 2% of portal blood samples' l 2 Brathwaite 
et al sampled MLN and portal venous blood at laparotomy for blunt abdominal 
t r a u m a " 3 . In 5% of the patients cultures of the MLN and in 9% of the portal 
venous blood samples bacteria were recovered. Interestingly, in this study all 
the macrophages within the MLN were positive for E coli ß-galactosidase, 
which suggested that most of the bacteria that reached the MLN were 
ingested and killed by macrophages' '3. 
Peitzman et al observed that all the MLN cultured at laparotomy from 
patients with abdominal trauma were sterile as were three quarters of those 
from patients operated on for gastrointestinal disease' '4 . Moore et al biopsied 
liver and MLN in patients with abdominal trauma. Of the MLN cultures 15 % 
recovered bacteria, but half of these patients had injured hollow viscera. In 
I 1% cultures of liver specimen recovered bacteria, all wi thout injured hollow 
viscera' '5. Reed et al studied patients with abdominal trauma and found that 
when regular culture techniques were used only 6% of the MLN contained 
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bacteria, but with electron microscopy this figure rose to 8 I % " 6 . A recently 
published study found BT and absorption of endotoxin in multiple organ 
donors' '7. Specimens of MLN, liver, spleen, lung, and gut were harvested 
during explantation. Gl-tract integrity was confirmed by light and electron 
microscopy. Bacteria were recovered from 79% of the MLN specimens, 14% 
of the liver specimens and half of the lung specimens. Positive blood cultures 
were found in 7% of the donors and elevated systemic endotoxin 
concentrations in 19%. There was no correlation between culture specimens 
and endotoxin concentrations in the portal and systemic circulations. These 
data show that bacteria and endotoxin can translocate in humans with an 
anatomically intact Gl-tract. 
30 
Table 1. 
First author 
Ambrose 
Deitch 
Moore 
Brathwaithe 
Peitzman 
Moore 
Reed 
van Goor 
Year 
1984 
1989 
1991 
1993 
1991 
1992 
1994 
1994 
HUMAN STUDIES ON BACTERIAL TRANSLOCATION 
Groups of patients 
studied 
Crohn 
Intestinal obstruction 
Abdominal trauma 
Abdominal trauma 
Abdominal trauma 
Abdominal trauma 
Abdominal trauma 
Organ donors 
Translocation to 
MLN (%) 
Cases 
33 
59 
25 
5 
0 
15 
6 
79 
Controls 
0 
4 
-
-
-
-
• 
• 
Translocation to 
portal system or 
-
¡J|i' 
II 
• 
14 
Relation with 
septic 
complications or 
mortality 
No 
No 
No 
No 
No 
No 
No 
No 
These studies have clearly shown that BT definitely occurs in various 
human pathological conditions and that the variability of the incidence could 
be the results of possible concurrent use of antibiotics and also the culturing 
techniques. The observed incidence of BT seems to underestimate the actual 
incidence, because classic culturing techniques measure only the bacteria that 
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can escape from the normal host defenses. Other techniques, such as 
measurement of a specific bacterial enzyme or using electron microscopy to 
identify bacteria, measure also the non-viable bacteria and so estimate better 
the actual incidence of BT. N o single study has been published however, that 
has correlated septic complications or mortality with BT. 
Although BT has been associated with mortality and septic complications in 
various animal models, the question still remains whether it is an important 
pathophysiological event in human disease or just an epiphenomenon of 
severe disease. One interesting aspect that can be viewed in this perspective is 
the observation that the enterocyte has an active role in BT 4 9 , 5 0. So, on the 
one hand, BT may be seen as a normal biological process functioning t o 
sample antigens from the gut and to prime the host's immune response. On 
the other hand, one explanation for the discordant results between 
experimental studies may be that intestinal bacteria or endotoxin, or both, do 
not need to reach the portal circulation to induce or contribute t o a systemic 
inflammatory state. Instead, loss of gut barrier function to bacteria or 
endotoxin (especially if superimposed on gut injury) could induce a local 
intestinal inflammatory response and lead t o the subsequent release of 
cytokines from the gut associated lymphatic tissues. If this is the case, then it 
would not be necessary t o recover bacteria from the portal or systemic 
circulations t o prove that gut injury contributes t o a systemic inflammatory 
response. There is some information to support the concept that the gut can 
be a cytokine-generating organ after hemorrhagic shock, and that gut-derived 31 
cytokines can be liberated even in the absence of detectable bacteria or 
endotoxin in the portal c irculat ion' l 8 . This study, plus a number of studies that 
have indicated that the gut can produce important amounts of immuno 
inflammatory factors, and that intestinal injury predisposes t o distant organ 
injury even in the absence of detectable bacteria or increased concentrations 
of e n d o t o x i n " 9 " 1 2 1 , suggests that the potential relationship between gut 
barrier failure function or injury and MODS may be more complex than 
initially assumed. 
In conclusion, BT is an interesting phenomenon, which occurs both 
experimentally and clinically under various pathological conditions, but its 
pathophysiological importance needs further study. 
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2.4 SELECTIVE D E C O N T A M I N A T I O N O F T H E DIGESTIVE 
T R A C T (SDD) 
Colonization resistance is one of the first host defenses against intruding 
microorganisms. The concept of colonization resistance was introduced by 
van der Waaij et al122. Normal colonization resistance is provided by the 
following physiological mechanisms: mechanical factors, including the integrity 
of the cellular lining, mucosal cellular functions, saliva and mucus production, 
plus other functions such as swallowing, peristalsis and coughing123; humoral 
factors, such as the secretion of immunoglobulin A, cell surface fibronectin and 
bile123, l 24; and microbiological factors such as the presence of anaerobic 
microorganisms in the gut. 
The latter mechanism describes the pivotal role of colonization of the Gl tract 
by anaerobes, which prevent competitive overgrowth by potentially 
pathogenic microorganisms122. Others have confirmed that anaerobes have an 
important role in limiting colonization of the gut by potentially pathogenic 
microorganisms and have also discovered that a polymicrobial flora maximizes 
this protective mechanism125. In patients in the ICU, most of the mechanisms 
involved in colonization resistance are impaired; these patients have depressed 
consciousness and therefore lack the normal swallowing and coughing 
mechanisms, their mucosal lining is atrophic because they are not being fed 
enterally and paralytic ileus is common. Furthermore, endotracheal tubes 
damage the tracheal mucosa and provide a route for descending bacteria. As a 
result of the use of antacids for stress ulcer prophylaxis, the gastric pH is 
raised. In addition, the extensive use of antibiotics, means that the normal 
microbial flora is quickly altered after admission to the ICU and subsequently 
replaced by hospital-acquired, potentially pathogenic, microorganisms (often 
enteric Gram-negative bacilli) . This is particularly true for the 
immunocompromized, critically ill patients10, l 26 , l 27. 
Selective decontamination of the digestive tract (SDD) is a technique 
designed to suppress selectively potentially pathogenic microorganisms in the 
oropharynx and upper Gl tract with topically applied, non-absorbable 
antibiotics which leave the anaerobic flora intact. Its rationale is based on the 
concept of colonization resistance, as sparing the normal, predominantly 
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anaerobic, flora prevents overgrowth by pathogens. Both the development of 
ICU-acquired pneumonia and mortality have been associated with 
oropharyngeal colonization with Gram-negative microorganisms It was 
hypothesized that prevention of overgrowth of oropharyngeal and intestinal 
bacteria by potentially pathogenic microorganisms with SDD might reduce the 
incidence of ICU-acquired infections and mortality. 
SDD was first used to control infection in patients with granulocytopenia, 
with encouraging results128 Its use in critically ill patients in the ICU was 
introduced by Stoutenbeek et al129, who used a SDD protocol in trauma 
patients who required mechanical ventilation for more than five days. A 
regimen of non-absorbable antibiotics (polymyxin E, tobramycin and 
amphotericin B) was used to eliminate selectively aerobic Gram-negative 
organisms and fungi from the oropharynx and gut while leaving the anaerobic 
flora intact To prevent the occurrence of primary Gram-negative pneumonia 
in the first 48 hours after admission, when SDD was not fully established 
systemic cefotaxime was added to this regimen129 l 3 ° . Gram-negative 
colonization of the oropharynx was reduced from 86% to almost 0 and the 
incidence of Gram-negative bacteria in rectal cultures was reduced from 77% 
to 7%. A t the same time, the total infection rate was reduced significantly 
from 81% to 16%, with an overall decrease in respiratory tract infection rate 
from 59% to 8%, and a decrease in the secondary respiratory tract infection 
rate form 20% to 0%. A significant reduction in mortality, however, was not 
achieved129. The results of this study were debatable, because historical 33 
controls were used. 
Since then some 40 studies have been published in which the clinical 
efficacy of SDD was tested in different groups of patients in the ICU, with 
different goals and study designs The mam characteristics of these studies are 
summarized in Table 2. Ten non-randomized studies131"140 and 21 randomized 
studies131, l40"158 were done on surgical, medical, and mixed surgical and 
medical ICUs. Seven studies were randomized, double-blind, placebo-
controlled trials145 l 4 6 l 4 9 · 1 5 0 l 53 l 5 6 l 5 7 Nine studies have been performed 
in specific homogeneous groups such as patients with multiple injuries 
l 59
, cardiopulmonary bypass surgery160 '162, liver transplantation163, burns164 , 
esophageal resection165 , neurosurgery166 , or neurological disorders167. 
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S t u d y 
Ledingham 
S y d o w 
Brun-Buisson t 
H u n e f e l d 
K o n r a d 
Thulig 
M c C l e l l a n d 
H a r t e n a u e r 
Winter I 
T e t t e r o o 
Randomised trials 
Table 2. M A I N CHARACTERISTICS OF TRIALS O N SDD 
S t u d y S D D 
d e s i g n r e g i m e n 
C o n s 
His 
C o n s 
C o n e 
C o n e 
C o n s 
His 
D B P C 
His 
O b s C o n 
P T A / C 
P T A / C 
P N e N a j / -
Ρ Τ Α Λ 
P T A / C 
PTA/C 
P T A / C 
P T A / C 
PTA/Cefca 
P T A / C 
< 0 . 0 I 
< 0.001 
N S 
N S 
< 0 . 0 0 l 
< 0 . 0 0 l 
< 0 0 5 
< 0.001 
24 
15 
20 
94 
21 
4 7 
42 
47 
24 
0 
2 2 
63 
3 0 
3 8 
4 0 
38 
NS 
< 0 . 0 5 
NS 
< 0 0 0 l 
NS 
N S 
N S 
NS 
Ή 
U n e r t l 
K e r v e r 
Brun-Buisson II 
IHrlch 
G o d a r d 
R о d r igeuz- Ro 1 dan 
A e r d s 
Blair 
Pugin 
C e r r a 
C o c k e r i l l 
F e r r e r 
Gast inne 
H a m m o n d 
Jacobs 
Palomar 
Rocha 
Sanchez-Garcia 
Verhaegen I 
V c r h a e g e n II 
W i n t e r II 
1987 
1988 
1989 
1989 
1990 
1990 
1991 
1991 
1991 
1992 
1992 
1992 
1992 
1992 
1992 
1992 
1992 
1992 
1992 
1992 
1992 
Specific patient grouj 
Stoutenbeek 
Flaherty 
Τ e t t e r o o 
Fox 
Mackie 
H a m m o n d 
Mart inez-Pel l LIS 
K o r i n e k 
R o l a n d o 
H a m m o n d 
1984 
1990 
1991 
1992 
1993 
1993 
1993 
1993 
1993 
1994 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
Mpxed 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
Surg 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
M i x e d 
P» 
T r a u m a 
CS 
ER 
CS 
Burns 
N e u r o 
CS 
N e u r o s u r g 
U v e r T x 
T r a u m a 
R C o n c 
R C o n c 
R C o n c 
R C o n c 
D B P C 
R D B P C 
R C o n c 
R C o n c 
R D B P C 
R D B P C 
R C o n c 
R C o n c 
R D B P C 
R D B P C 
R C o n c 
R C o n c 
R D B P C 
R D B P C 
R C o n c 
R C o n c 
R C o n c 
H.s 
R C o n c 
R C o n c 
C o n s 
O b s C o b 
R D B P C 
R C o n c 
R D B P C 
R C o n c 
R D B P C 
PGA/-
P T A / C 
P N e N a ] / - X 
P N A / T r 
PTJ/. X 
PTA/-
P N A / C -
P T A / C 
P N e V 
N N y / -
P G N y / C 
P T A / C X 
PTA/- X 
P T A / C 
P T A / C 
P T A / C X 
P T A / C 
P G A / C e t r 
P T A / C 
O A / O 
PTA/Cefta X 
P T A / C 
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P T A / C e p 
P T A / C 
P T A / C 
Р Т А Л 
PTA/- X 
C o T A / C e 
PTA/-
7 0 
4 0 
12 
44 
8 
73 
6 2 
22 
78 
100 
16 
24 
19 
19 
9 
53 
46 
43 
22 
22 
18 
20 
27 
14 
50 
2 7 
527 
42 
10 
18 
21 
6 
8 
6 
0 
0 
6 
7 
16 
56 
4 
23 
14 
IS 
0 
21 
15 
24 
16 
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3 
0 
12 
2 
6 6 
7 
15 
24 
6 
26 
Al 
« 0 . 0 1 
< 0.001 
N S 
< 0 . O 0 l 
< 0 . 0 5 
< 0 . 0 0 l 
< 0 0 0 l 
< 0 0 l 
«OOOI 
< 0 . 0 0 t 
< 0 . 0 5 
N S 
NS 
NS 
NS 
< 0 . 0 l 
< 0 . 0 0 l 
< 0 . 0 I 
N S 
< 0 . 0 5 
< 0 . 0 5 
<o.ooi 
•C0.0S 
< 0 . 0 5 
N S 
< 0 . 0 5 
NS 
-
< 0 . 0 4 
N S 
NS 
breviatit 
30 
32 
24 
54 
18 
30 
10 
19 
27 
48 
21 
2 8 
36 
17 
50 
29 
44 
46 
18 
18 
43 
8 
5 
67 
21 
15 
8 
18 
55 
9 
3ns in SDD 
25 
2 8 
2 2 
31 
12 
33 
12 
IS 
26 
52 
IS 
29 
40 
21 
39 
20 
21 
36 
0 
. 
3 
17 
3 
15 
3 
13 
3 6 
13 
regimen 
NS 
NS 
NS 
< 0 . 0 S 
NS 
N S 
N S 
N S 
NS 
NS 
NS 
N S 
N S 
N S 
N S 
NS 
NS 
N S 
N S 
N S 
N S 
NS 
NS 
< 0 . 0 5 
•=0.05 
NS 
NS 
NS 
N S 
N S 
ER = Esophageal r 
CS = Cardiac surgery 
His = H i s t o r i c a l c o n t r o l s 
C o n e = C o n c u r r e n t c o n t r o l s 
C o n s - C o n s e c u t i v e c o n t r o l s 
O b s C o h * O b s e r v a t i o n a l c o h o r t 
D B = D o u b l e bl ind 
PC = Placebo c o n t r o l l e d 
R = R a n d o m i z e d 
PCS = P r o t e c t e d c a t h e t e r specimen 
RTI = R e s p i r a t o r y t r a c t in fect ion 
O r o p h a r y n g e a l and intest inal regimen/systemic ant ib iotcs 
A = A m f o t e n e i n В 
С = C e f o t a x i m e 
C e • C e f u r o x i m 
Cefa = Cefazol in 
C e f t a = Cef taz id ime 
C e f t r = C e f t r i a x o n e 
С е р = C e p h r a d i n 
C o = C o l i s t i n 
G • G e n t a m y c i n 
J = Pov idone lodine 
Ν - N o r f l o x a c i n 
N a • Nal id ix ic acid 
N e - N e o m y c i n 
N y - N y s t a t i n 
О • O f l o x a c i n 
Ρ = Polymyx in 
Τ = T o b r a m y c i n 
Т г = T r i m e t h o p r i m 
V = Vancomycin 
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Control groups consisted of historical, consecutive (with or without cross 
over) or concurrent control groups. The rationale for consecutive or 
historical groups was t o eliminate the possible influence of cross-infection1 6 8. 
The SDD antibiotic protocols showed great variability. That used most 
commonly was the one that was originally introduced by Stoutenbeek et al 
that is, polymyxin, tobramycin and amphotericin В and systemic antibiotic 
prophylaxis with cefotaxime1 2 9. Other non-absorbable antibiotic regimens 
were used in other studies. For example, polymyxin with neomycin, nalidixic 
acid and povidone-iodine or the substitution of tobramycin by gentamycin or 
norfloxacin. Furthermore, systemic antibiotic prophylaxis also differed widely 
among the clinical trials. The dose cefotaxime varied from 1.5 to 6 g/ day. 
Other systemic antibiotics used were cefazolin, ceftazidime, ceftriaxone, 
cefuroxime, cefotaxime with tobramycin, cephradine and tr imethoprim. Ten 
studies did not use systemic antibiotic prophylaxis1 2 9 , m · l 3 3 ' l 4 4 , l 4 5 , l 4 9 , l 5 3 , 
159, 162, 166 j ^ e r o | e 0f S y S t e m ¡ c antibiotic prophylaxis must be clarified, as 
studies without systemic prophylaxis did not show any unfavorable results and 
Stoutenbeek et al showed that the addition of systemic antibiotic prophylaxis 
significantly reduced primary infections . Based on the clinical results, the 
optimal antibiotic protocol remains to be established. 
Inclusion criteria also differed widely. Some studies included all patients 
admitted to the ICU1 3 5 ' l 4 4 1 4 6 · l 6 2 1 6 5 . but most included only patients wi th a 
prolonged ICU-stay (more than 2-6 days) or those patients requiring chronic 
mechanical ventilation (more than 3-5 days). This is important because it takes 
four to five days for SDD to establish oropharyngeal decontamination and at 
least 10 days before reductions in the rectal flora are seen consistently. 
Decontamination of the rectal flora is often not complete in the early period 
after SDD has been instituted, and also tends to decrease with long term 
use129· l30· l33· l 35· ,40· l43· ,46· l56· l57· l 59 . Patients with primary infections have 
not been excluded consistently, thereby furtherconfounding interpretation of 
the data. Only one study excluded patients who were already infected on 
admission . 
The goal of most studies was to compare the efficacy of SDD in reducing 
abnormal bacterial colonization and nosocomial infections, particularly lower 
respiratory tract infections. The diagnosis of respiratory tract infection was 
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based on different criteria in different studies. Most studies used clinical and 
radiological criteria, whether or not they were assessed by an independent 
observer, combined with cultures of the tracheal aspirate. Only seven studies 
used the more accurate method of culture of protected catheter specimens to 
diagnose pneumonia1 2 3 , l 3 3 - l 3 7 , l 4 5 , l 4 6 , I S I ' I S 9 . An important shortcoming in 
some studies was the lack of documentation of whether or not infections 
were primary or ICU-acquired. Furthermore, mortality was a main variable in 
most studies and mortality alone may not be the best indicator of efficacy. 
All studies reported that SDD caused a significant reduction in the 
colonization rates of Gram-negative bacteria of the oropharynx and trachea 
within 48 hours. All reported colonization rates of 0-5% after seven days. 
Rectal decontamination of Gram-negative organisms took longer and was 
usually about 10 t o 12 days. Furthermore, rectal decontamination was never 
as complete as oropharyngeal decontamination, as the rectal colonization rate 
was never below 2 0 % l 6 9 . 
Respiratory tract infection rates reported in the control groups varied 
considerably from study to study and ranged between 8% and 100 %, although 
most studies showed a significant reduction in the incidence of lower 
respiratory tract infections. There were no beneficial effects in studies in 
which the incidence of lower respiratory tract infections was low in the 
control group, however. So, SDD seems t o be effective in reducing infection 
rates in ICUs with high but not low incidence of infect ion 1 7 0 . All studies 
36 showed that the reduction in the infection rate resulted from a reduction of 
infections caused by Gram-negative bacteria. The observed reduction of the 
total infection rate was mainly a result of the reduction in lower respiratory 
tract infections, as the incidence of other infections were not significantly 
reduced. For example both urinary tract infections1 2 9· l 3 2 , l 3 8 , l 4 3 , l 5 6 and 
bacteraemia'2 9 , l 3 8 , , 4 2 , l 5 4 , ' 6 4 were significantly reduced in only five studies. 
Although in non-SDD studies the ICU-stay was three t o five times higher 
in infected patients compared with uninfected patients1 7 - ' 7 I , only three 
studies showed that SDD reduced the length of ICU stay or the number of 
days on the venti lator 1 3 8 , l 4 9 ' . On the other hand, it seemed to reduce the 
incidence of nosocomial infections and so also the requirements for parenteral 
antibiotics1 3 5 , 136. H I . и г 147.148. I M . 165
 W h e n t h e c o s t s 0 f m i c r o b i o l o g i c a l 
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surveillance were taken into account, there was a significant reduction in the 
overall costs/ patient after SDD had been established in the ICU by one 
group168. This concept has been disputed by others, who did not observe a 
reduction in the therapeutic use of systemic antibiotics143, l 4 4 l 53 . One 
detailed study on the costs of SDD confirmed the reduction in the use of 
systemic antibiotics, but the savings were canceled out by the extra costs of 
SDD. In this study, the average costs/ patient/ day were 1.4 times higher in the 
SDD group l 5 6 This observation was confirmed by a French group, who 
calculated that the total charges for antibiotics were 2.2 times higher in the 
SDD group, not including the extra cost of microbiological surveillance153. 
Remarkably, the incidence of MODS was not reduced in any study in which 
it was assessed. 
Although the occurrence of lower respiratory tract infection has been 
associated with an increase in mortality, and SDD achieved in most studies a 
reduction in the rate respiratory tract infection, most studies did not show 
that SDD reduced mortality. Mortality was only significantly reduced in only 
three non-randomized studies133, l 37 , l 38 , one randomized study143 , one study 
on burned patients164 and one study on cardiopulmonary bypass surgery161 
The deaths in the control group of the study by Sydow et al were mainly 
because of severe brain damage, which is unlikely to be prevented by SDD1 3 7 
An interesting point in the studies of Hunefeld133, Ulrich et al.143 and Mackie 
et al.164 was that the reduction in mortality was achieved mainly by a 
reduction in infection related deaths, infection being a common cause of death 
in the control groups133, l43 , l 64 This is in accordance with the study by Kerver 
et al, because despite the fact that they did not observe a reduction in overall 
mortality, the occurrence of infection-related deaths was significantly reduced 
from 15% to 0142 . Godard et al also observed a reduction of mortality m a 
subgroup of patients who stayed in the ICU a long time The study by 
Tetteroo et al is difficult to interpret because the control group consisted of 
patients in whom SDD was unsuccessful, with no explanation for this 
failure138 A study that contradicts the other studies is that of Fox et al.161, 
which reported that mortality was significantly reduced by SDD, although the 
infection rate was even higher in the SDD group; however, the groups studied 
were small161. 
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Table 3. META ANALYSES ON RANDOMIZED TRIALS WITH SDD 
First author Year Respiratory tract infections Mortality rate 
Vandenbroucke-Grauls 
SDD Triallist' Collaborative Group 
Heyland 
Kollef 
1991 
1992 
1994 
1994 
Relative Risk 
(95% conf. interval) 
0.12(0.08-0.19) 
0.37(0.31-0.43) 
0.46 (0.39-0.50) 
0.34 (0.27-0.42) 
No. of 
patients 
491 
3836 
2555 
2128 
Relative Risk 
(95% conf. interval) 
0.70(0.45-1.09) 
0.90(0.79-1.04) 
0.87 (0.79-0.97) 
0.93(0.81-1.02) 
No. of 
patients 
491 
4142 
3298 
2270 
To date there have been published four excellent meta-analyses of 
randomized clinical trials with SDD26' 27, l72· l73; and the main results are 
summarized in Table 3. All four show significant reductions in the incidence of 
respiratory tract infections by SDD with relative risks ranging from 0.12 to 
0.46. Although these reductions were consistent in all subgroups analyzed, 
some criticism can be made. The results of the studies analyzed were 
extremely heterogeneous, suggesting that systematic methodological 
variations existed. This was particularly true for the definition of pneumonia · 
, so effects of SDD on respiratory tract infections should be interpreted 
cautiously. Furthermore, when subgroups were analyzed, there was a less 
dramatic effect when adequate criteria were used to assess respiratory tract 
infection (protected brush specimen or bronchoscopy) or when mortality was 
less than 20%. This is in accordance with the earlier observation that SDD 
seems to be more effective in ICU's in which the incidence of infection is 
high170 
With regard to the effect on mortality, no significant differences were 
found, with relative risks ranging from 0.70 to 0.93. Testing for heterogeneity 
of these results showed no significance, so with regard to this effect of SDD, 
methodological differences were of less importance. Some interesting 
observations can also be made from subgroup-analyses. Although in significant 
effects were not found in any subgroup, the largest difference between relative 
risks was observed in studies with or without the use of systemic antibiotics. 
This effect was greater than the effect of SDD alone, suggesting that if any 
effect had been observed, giving systemic antibiotics early could have had the 
largest effect on mortality. One meta-analysis observed a significant effect of 
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SDD on infection-related mortality, but this effect was mainly from the results 
of one single study143· l 72. 
The total number of acquired infections could be obtained from only three 
studies included in these meta-analyses141, l 4 5 , l 46. These studies showed 
significantly less Gram-negative and Gram-positive infections. SDD had no 
significant favorable effect on the length of hospital stay ( 15.5 days in SDD 
patients compared with 17 days in control patients) . 
Results of meta-analyses should be interpreted cautiously, as the results 
may be biased because of the heterogeneity of the studies with respect to 
their design, randomization and groups of patients studied. A meta-analysis on 
updated data from individual patients would be more reliable174. 
The long term adverse effects of SDD should also be mentioned. Although 
it has been used successfully to reduce rates of infections with highly resistant 
Gram-negative microorganisms131 there are concerns about the possible 
emergence of bacterial resistance. Although initially no bacterial resistance 
was reported175, it has recently been shown that SDD is associated with 
dramatic changes in the ecology of the ICU and bacterial antibiotic 
resistance176"178. For example, resistance of S aureus and Acinetobacter spp. 
against tobramycin and cefotaxime, both components of SDD regimens, seems 
to be increasing156' l 77 . The introduction of SDD in one ICU was associated 
with the appearance of methicillin-resistant S. aureus . Furthermore, an 
increase in Gram-positive infections has been shown both experimentally 
and clinically with the use of SDD181· l 82. 
In summary, it is clear that SDD reduces the infection rate, particularly of 
lower respiratory tract infections, although this reduction seems to be limited 
to studies in which there is a high infection rate in the control group. In 
contrast, mortality does not seem to be reduced by SDD, although in some 
subgroups with high infection rates there was a reduction in the incidence of 
infection-related deaths. 
A striking observation is the difference between the effect of SDD on 
lower respiratory tract infections and on mortality; there are several 
explanations for this difference. Firstly, it could be the result of an inaccurate 
diagnosis of pneumonia. For example, as non-protected tracheal aspirates can 
easily be contaminated by bacteria in the oropharynx, the over-diagnosis of 
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lower respiratory tract infections could be reduced in patients receiving SDD 
as a result of the reduction in oropharyngeal colonization. Another possibility 
is that systemic and topical antibiotics, by inhibiting bacterial growth in culture 
media, would make the usual microbiological criteria for diagnosing infection 
less reliable. This concept is consistent with the observation that SDD is 
associated with substantial concentrations of antibiotics in tracheal and 
bronchial aspirates183. The failure of SDD to reduce mortality could be 
interpreted as evidence that the wrong groups of patients have been studied, 
and that SDD could be of value for certain subpopulations in the ICU. If only 
infection related-deaths were examined, the effect of SDD on survival might 
be more favorable. It is also possible that there is no relation whatsoever 
between infection and mortality in patients in the ICU with MODS. This 
hypothesis is strengthened by the observation that after multivariate analysis in 
patients receiving continuous mechanical ventilation, pneumonia was not a 
variable associated with death28. The development of nosocomial infection in 
these patients could be an expression of the failure of the hosts immune 
system and therefore viewed as part of the sequential organ failure in MODS. 
Because SDD could not improve the incidence of MODS, it could again be 
hypothesized that these patients in the ICU die with infection rather than of 
infection. 
In contrast to the large number of clinical trials conducted, few animal 
studies have tried to correlate SDD with survival in models of sepsis or 
40 MODS. None the less, some interesting effects of SDD were observed in an 
animal model of MODS induced by intraperitoneal inoculation of zymosan . 
Two regimens of SDD with tr imethoprim or streptomycin, respectively, were 
used in this study. Organ damage was present in all groups, but overall 
mortality was significantly lower in the streptomycin group compared with the 
tr imethoprim group and the controls. This was remarkable, as trimethoprim 
achieved far better decontamination of enterobacteriaceae from the gut than 
streptomycin. So, in this study it seems that decontamination was not related 
to mortality and that other factors, such as the influence of streptomycin on 
macrophage functions may be more important184. A recent study with 
zymosan peritonitis showed that a regimen of tobramycin and polymyxin E 
reduced endotoxin concentrations and four day mortality. Unfortunately no 
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information about late mortality or organ damage was given . 
In conclusion, studies on SDD vary considerably in study design and 
methods, but it seems to be clear that SDD reduces nosocomial colonization 
and respiratory tract infections. The beneficial effect on mortality, cost 
reduction, length of stay in the ICU, days on the ventilator and mortality, 
remains t o be resolved in well conducted, prospective, double blind, placebo-
controlled studies. Serious concerns have been raised about the emergence of 
bacterial resistance and Gram-positive infections. So from a risk benefit point 
of view no legitimate argument can be made to implement SDD routinely on 
an ICU with mixed groups of patients, although certain homogenous 
subpopulations may benefit. 
2.5 S U M M A R Y A N D C O N C L U S I O N S 
The gut is an important reservoir of potentially pathogenic micro­
organisms and endotoxin. Under various pathological conditions, enteric 
bacteria and endotoxin have been shown t o cross the intestinal border, a 
process termed bacterial translocation. In the immune compromised host, this 
process leads t o the systemic spread of bacteria and infection. Experimentally 
and clinically it has been shown that BT occurs, but its relationship with 
mortality and the development of MODS remains uncertain. Although the 
gastro intestinal tracts of critically ill patients in the ICU are rapidly colonized 
by such microorganisms and nosocomial infections caused by them are an 41 
important cause of morbidity on the ICU, the results of studies that have tried 
t o correlate infection rate with mortality or the development of MODS are 
conflicting. Furthermore, interventions directed at eliminating this occult 
reservoir of microorganisms, by SDD, have shown that although it seems to 
reduce the rate of respiratory tract infections, it does not have any impact on 
the duration of ICU stay, mortality, or the development of MODS. 
In conclusion, it seems that the causal relationship of abnormal 
colonization, infection, or BT to the development of organ function or MODS 
is complex. Clearly, in some patients, these phenomena reflect a failure of the 
host's immune and mechanical defense systems and can be viewed as 
epiphenomena of critical illness. Recognition that the development of BT or 
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infection after the onset of MODS is of no importance supports this concept. 
On the other hand, there is a clinical subgroup of patients in whom loss of 
intestinal barrier function or the onset of infection precedes the development 
of MODS In many of these patients, early control of infection is associated 
with clinical recovery. Lastly, there is also a third group of patients in which it 
is difficult to assess the contribution of bacteria to organ failure The relative 
percentage of ICU patients in each of these three groups varies from ICU to 
ICU and is related, at least to some extent, to the type of patients and the 
underlying disease processes. 
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STUDIES ON THE MOTOR OF MODS 
3.1 I N T R O D U C T I O N 
Inflammation is defined as a localized protective response elicited by injury 
or destruction of tissues, which serves to destroy, dilute, or wall off 
(sequester) both the injurious agent and the injured tissues'. Briefly, this 
response is characterized by the activation of different cascade systems (com-
plement, coagulation, kinin and fibrinolytic), cells (like endothelial cells, 
macrophages, monocytes and polymorphonuclear leukocytes (PMNs)) and the 
release of mediators ( like anaphylatoxins, proteolytic enzymes, oxygen 
radicals, histamine, eicosanoids, coagulation factors and cytokines) . All these 
processes are related and interconnected by regulatory mechanisms. An 
injurious stimulus leads to the activation of the complement system, with a 
subsequent release of anaphylatoxins (C3a and C5a), leading to the activation, 
aggregation, margination and migration of PMNs. This is enhanced by the 
expression of endothelial adherence molecules (i.e. ICAM-I and ELAM-I), 
which enhance the adherence of PMNs and the subsequent endothelial pas-
sage to the site of injury. Activated PMNs release proteolytic enzymes and 
oxygen radicals5. Subsequently monocytes are entering the site of injury, 
regulating the inflammatory response by releasing various secretory products6. 
Teleologically, inflammation is an adequate response. However, substantial 
evidence exists that an excessive inflammatory response can have detrimental 
consequences for the host. Because patients with MODS display the typical 
characteristics of inflammation, i.e. rubor (generalized vasodilatation), calor 
(fever), tumor (generalized edema), dolor (pain) and functio laesa (organ 
dysfunction), MODS has been hypothesized to result from a dysregulated 
autodestructive generalized inflammatory response7. In MODS, inflammation is 
not localized, but present in tissues remote from the primary site of the insult, 
affecting the function of otherwise normal organs. Indeed, post mortem 
examination of patients dying of ARDS and MODS have revealed a generalized 
inflammatory reaction in almost every organ8, 9. Furthermore, several markers 
of this inflammatory response are markedly elevated during the development 
of MODS, while some also correlate with outcome · ' . 
The next section will focus on the involvement of inflammatory mediators 
in the development of SIRS, ARDS and MODS, relevant for this thesis, i.e. the 
complement system, PMN-endothelial interaction and macrophages. 
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3.2 THE COMPLEMENT SYSTEM 
3.2.1 Biological background 
The complement system plays a central role in the humoral immune 
system by defending the host against microorganisms and allowing 
discrimination between self and non-self . It is a cascade system that consists 
of at least 25 plasma proteins, formed by the liver and macrophages13. It 
interacts with several other inflammatory pathways like the coagulation, 
kallikrein-kinin, arachidonic and cytokine pathways1 4 , l s . Currently t w o 
pathways of complement activation are recognized: the classical pathway 
which is activated by micro-organisms i.e. antigen-antibody complexes. Via 
complement factor (C) I, C2 and C4, it forms the C4bC2a complex or C3 
convertase, that splits C3 into C3a and C3b l 6 .The alternative pathway is 
activated by foreign material and tissue injury. Via factor В and D it forms again 
an alternative pathway C3 convertase1 7. Both pathways converge at the 
breakdown of C3, the subsequent cleavage of C5 and the activation of the final 
common pathway1 3 , l 8 . C5 is divided enzymatically into C5a and C5b. C5a is 
both an anaphylatoxin and a chemotactic agent. The latter function is probably 
the most important since C5a is rapidly converted into C5a desarginine (C5a-
des Arg) with concomitant loss of its anaphylatoxic activity. Its chemotactic 
property stimulates activation, aggregation and adherence of PMNs to the 
endothelium with subsequent degranulation and release of oxygen radicals'9, 
vasoactive substances and a variety of proteinases which can cause endothelial 
damage resulting in generalized edema1 8 . Pro-inflammatory cells possess a 
receptor for C5a2 0. Next to many inflammatory functions, C5a also has 
immunoregulatory activities. There exists a close relationship between the 
complement system and cytokines and Platelet Activating Factor (PAF), in 
which they bilaterally influence their production and function and have 
synergetic pro-inflammatory effects1 5. For example, C5a induces the release of 
IL-6 by stimulated monocytes and stimulates the production of IL-1 after 
binding t o macrophages21. C5b will participate together with C6, C7, C8 and 
C9, in the formation of the terminal complement complex (TCC), which 
exists in t w o analogous forms. One fluid phase form in combination with the 
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S-protein, that is non-lytic and can be detected in plasma and inflammatory 
fluids22. The other form is the membrane attack complex, which can cause 
cell-lysis by penetrating lipid membranes such as the endothelium3. Hence, the 
complement system is one of the starting points of the activation of an 
inflammatory reaction with endothelial leakage and the activation of 
inflammatory mediators and cells, which have to defend the host against 
injurious insults. Excessive complement activation could thus lead to a 
generalized inflammatory reaction and organ injury23. 
3.2.2 Complement and the development of SIRS, ARDS or 
MODS 
Both clinical and experimental data have suggested a relationship between 
excessive activation of the complement system and the pathogenesis of SIRS, 
ARDS and MODS. During the evolution of SIRS, various clinical studies have 
shown a concurrent activation of C5a3, 24"28. For example, C3a/C3 ratio was 
one of the most significant parameters in a study of polytraumatized patients 
to differentiate between survivors and non-survivors29. However, data are 
conflicting when complement activation is correlated with severity, incidence 
of MODS or outcome30"33. Clinical studies on complement inhibitors are 
sparse. Recently improved hemodynamics were demonstrated in septic 
patients treated with СI-esterase inhibitor3 4. 
In order to explore a possible causal relationship between complement 
activation and the development of septic shock and ARDS, various 
experiments have been performed in models of lung injury, endotoxic shock 
and sepsis. Modulation of the activation of the complement system with 
complement depletion 3 5 , 3 6 using C5-deficient animals 3 7 ' 3 8 , anti-CSa-
antibodies or soluble complement receptor type I 4 2 have shown to 
attenuate, but not fully prevent, the course of these modalities. The role of 
complement in the development of MODS in particular, however, has not yet 
been evaluated experimentally. 
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3.3 P M N - E N D O T H E L I A L I N T E R A C T I O N S A N D 
PERMEABIL ITY C H A N G E S 
A generalized inflammatory response induces profound functional changes 
to the barrier function of the vascular endothelium leading to a capillary 
leakage syndrome and subsequent generalized edema formation. Endothelial 
damage and subsequent increased vascular permeability have been considered 
to be major events in the development of MODS. Indeed, post-mortem 
examination of organs of patients with MODS reveals increased organ wet 
weights and morphological evidence of a systemic inflammatory response, with 
pronounced PMN and monocytic invasion and diffuse microvascular damage 
with concurrent severe interstitial edema and cell necrosis in the lungs, liver, 
spleen, kidneys and heart8, 9. 
3.3.1 PMN-Endothelial interactions and the development of 
SIRS, ARDS or M O D S 
As already noticed by Cohnheim in 1889, in his classical description of 
acute inflammation, endothelial damage is induced by a close interaction 
between the endothelium and adhering PMNs43. Endothelial-leukocyte 
interactions appear to result in tissue injury44 ' Shortly after injury, the local 
endothelium is responding to mediators like histamine, thrombin, leukotrienes, 
C5a and oxygen radicals with the secretion of nitric oxide and PAF, resulting 
in a vasodilatation45,46. Additionally, cytokines like interleukin (IL)-1, tumor 
necrosis factor (TNF) and Interferon-' (IFN), but also endotoxin and immune 
complexes activate endothelial cells6. Activated endothelial cells demonstrate 
an increased surface expression and production of adhesion molecules like 
endothelial leukocyte adhesion molecule (ELAM)-I, GMP-140, intercellular 
adhesion molecule (ICAM)-I and mediators like PAF and granulocyte 
macrophage colony stimulating factor (GM-CSF)47"50. Chemotactic factors like 
C5a, leukotriene B4 (LTB4), IL-8 and PAF also induce a migration and 
activation of PMNs that express counterparts, such as PAF-receptors, CD I I/ 
CD 18, sialyl-Lewis-X and LFA-I 5. Activated endothelial cells are not a simple 
bystander, and also produce pro-inflammatory cytokines like IL-1, IL-6 and IL-8 
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and express pro-coagulatory factors, inducing microvascular thrombosis . 
Later in this process, monocytes enter the inflammatory site, interacting 
through an association with ligands as LFA-I, Mac-1 and VLA-4 and the 
increased expression of endothelial cell molecules as ELAM-I and ICAM-I . 
In addition, those activated monocytes, transforming to macrophages, regulate 
and perpetuate this process by producing cytokines like IL-1, TNF and IFN, 
which augment the leukocyte-endothelial interaction and alter endothelial anti-
protease activity, making endothelial cells more susceptible to injury by PMN-
derived proteases . 
Finally, this interaction between leukocytes, monocytes and endothelial 
cells induces a profound migration, adherence, activation and infiltration of 
PMNs, that produce oxygen radicals and proteases injuring endothelial cells, 
eventually leading to an increased capillary permeability and subsequent 
generalized edema4 4 , 5 4 . It may be clear that those processes evolve in a time-
dependent matter and that all factors have interregulatory connections, which 
have to be further elucidated (reviewed in 5 ). For example, proteolytic 
enzymes exert an important synergistic interaction with reactive oxygen 
metabolites and oxygen radicals activate anti-proteases5 5. In patients with 
SIRS, the relative contribution of stimulated endothelial cells in the process of 
PMN-endothelial adherence, appears t o be far more important than from 
activated PMNs5 6. Dysregulation of these processes, leading to endothelial 
damage, might have an important role in the generalized inflammatory res­
ponse, as observed in MODS 7 . 
The importance of activated PMNs in the development of MODS has been 
established by the observation that plasma concentrations of the proteolytic 
enzyme elastase positively correlate with the severity and mortality of 
MODS 1 1 , 2 9 · 5 7 . The respiratory burst capacity of PMNs correlated with 
outcome in critically ill patients5 8. In multiple trauma patients, early PMN 
sequestration and an increased C D I lb/CD 18 expression correlated well with 
the development of MODS 5 9 . This suggests that PMN mediated endothelial 
damage is a central mechanism of end-organ injury and MODS after major 
trauma. 
Experimentally, oxygen free radical formation has been shown to induce 
endothelial injury, while scavengers of oxygen free radicals appear to attenuate 
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the course of MODS60 ' 6 I . Furthermore, PMN-LTB4 production predicted 
subsequent ARDS in ICU-patients62. In a model of zymosan induced MODS, 
PMN-proteinase and oxygen radical formation closely correlated with the 
development of the clinical syndrome and organ damage63. 
Cyclophosphamide-induced neutrophil depletion could prevent multiple organ 
damage, defined as an increased permeability, in a model of TNF induced 
MODS64. 
The relevance of the neutrophil-endothelium interaction as a mediator of 
ARDS and MODS has been supported by the observation of increased 
CD I lb /CD 18 expression on PMNs in patients developing ARDS65. 
Experimentally, tissue injury in the liver and lung has been limited by the 
administration of anti-CD I lb/CDI8-antibodies in a model of intestinal 
ischemia-reperfusion66. Experimental endotoxic shock in baboons induced an 
increased ELAM-1 expression in almost every organ, suggesting that a 
generalized inflammatory response induces generalized endothelial 
activation67. Furthermore, serial measurement of soluble ICAM-I 
concentrations in multiple trauma patients revealed elevated early and late 
soluble ICAM-I concentrations, with a very good correlation with the MOF-
score68. In addition, multiple peaks of IL-8 appeared to be associated with the 
gradual increase of soluble ICAM-I concentrations and development of 
MODS68 . 
The above mentioned data provide evidence for an important role of 
endothelial damage in the development of MODS. The relevance of the 
subsequent permeability changes will be discussed in the following section. 
3.3.2 Measurement of permeability changes 
Techniques to measure permeability changes include static measurements 
of the prevailing lung water content and kinetic methods to determine the 
rate or distribution of solute movement. Static measurements, that can only 
be used experimentally or post-mortem, include the determination of tissue 
wet/dry weight ratio and efferent lymph analysis69, 70. Clinically, chest X ray, 
magnetic resonance imaging (MRI) or positron emission tomography (PET)-
scan have been used, but these methods have a low reliability and accuracy. 
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Dynamic studies may be performed by double indicator or scintigraphic 
techniques. The double indicator technique is based on the detection and 
distribution of diffusable and non-diffusable indicators71. This method has 
shown to correlate well with morphologic and physiologic criteria of 
pulmonary tissue edema72. Scintigraphic methods use radiolabelled proteins 
(i.e. albumin, transferrin or non-specific IgG) that pass the endothelium, when 
leaky, and accumulate in the interstit ium73 '76. The single isotope technique 
compares tissue distribution with the blood pool activity, while the double 
isotope technique compares tissue distribution with radiolabelled 
erythrocytes, which remain in the vascular compartment76. Both techniques 
are of limited value if blood flow is disturbed due to micro-or macro-vascular 
thrombosis. 
' " i nd ium labeled non-specific polyclonal immunoglobulin G (" ' In-IgG) 
scanning has been originally proposed to detect and localize various types of 
focal infection77, 78. However, this technique also showed activity in certain 
malignant tumors77 . Both non-specific factors and specific Fc-receptor binding 
have been proposed to be important in the accumulation of ' ' ' In-IgG in 
infectious foci . However, recent data have shown a striking similarity 
between the biodistribution of ' ' 'In-IgG and ' ' 'in-human serum albumin 
(HSA), after induction of a staphylococcal abscess, suggesting that 
accumulation of ' ' ' In-IgG in inflammatory foci is not mediated by specific Fc-
receptor binding of the IgG part, but more by an increased vascular 
permeability and a subsequent local macromolecular entrapment of the 
1
 ' ' indium molecule in the tissues81' 82. Furthermore, in neutropenic rats and 
patients, In-IgG scanning was able to localize focal infection, supporting the 
hypothesis that specific Fc-receptor binding is not an important factor . 
Hence, ' ' ' In-IgG scintigraphy appears not to detect localisations of infection 
but the concurrent vascular permeability changes observed in inflammatory 
reactions. Since then, ' ' 'ln-lgG scintigraphy has also been shown to detect 
localisations of inflammatory reactions in reflex sympathetic dystrophy and in 
inflammatory bowel disease84, 85. Thus, ' ' ' In-IgG scintigraphy, might be useful 
to assess the concurrent permeability changes in various organs in MODS. 
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3.3.3 Permeability changes and the development of SIRS, 
ARDS or MODS 
Experimental data have shown generalized permeability changes after local 
infection, infusion of endotoxin or live bacteria, or after trauma. After 
hindlimb intramuscular injection with live £. coli or S. aureus in rats, a 
generalized increased vascular permeability in the muscle, liver, spleen, kidneys 
and bone marrow, measured with ' ' 'in-lgG-scanning, was detected81, 82. 
Endotoxin infusion has been shown to produce extravasation of proteins in 
liver and lung tissue, as measured with the double isotope technique, using 
In labeled transferrin and 99mTc labeled erythrocytes86. An increased 
transvascular albumin flux, as measured by the distribution of l 3 , l -albumin, has 
been reported in lungs, spleen, liver and abdomen after infusion of £. coli in a 
porcine septic shock model . Others have confirmed these results in a model 
of TNF and E.coli induced multiple organ damage, by using l25 l-albumin. In 
these models, increased accumulation of l25 l-albumin was observed in the 
adrenals, heart and liver, which correlated well with the histopathological 
findings . Specific acute lung injury induced by oleic acid has been shown to 
dramatically increase pulmonary 99mTc-albumin flux88. Intraperitoneal zymosan 
administration in rats, induces an early (24 hours after zymosan challenge) 
generalized increased endothelial permeability, measured by using l 3 l l -HSA, 
l25 l-HSA and 5 lCr-labeled EDTA, in a dose dependent fashion89. Shortly after 
zymosan challenge, wet:dry weight ratios of lung, liver, kidneys, spleen and 61 
bowel were decreased together with a concomitant increased lung 
permeability index90. 
Clinical studies on permeability changes have been performed mainly on 
ARDS patients. Using the double indicator technique, extravascular lung water 
content (EVLW) was increased shortly after trauma91. This was confirmed by 
others, who showed that in polytrauma patients with thoracic injury, EVLW 
measurement demonstrates a biphasic pattern with an early rise, a subsequent 
trend to normal and a late rise after 7 days, the latter indicating the 
development of MODS . Still, others have observed a continuous rise of 
EVLW after multiple trauma, especially in non-survivors93. 
Gamma scintigraphic analysis of the pulmonary 99mTc-albumin flux revealed 
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a significantly higher flux in patients with ARDS9 4. Furthermore, using the 
same technique, transvascular albumin flux displayed a return t o normal values 
when ARDS subsided9 4 9 5 Serial assessment of the accumulation of ' l 3 l n -
transferrm in a patient developing ARDS demonstrated an increased 
accumulation of the radionuclide, which antedated the observed radiological 
changes96 Multiple trauma patients displayed an early increase of pulmonary 
permeability as measured by 9 9 mTc-albumm flux, that even persisted I month 
after trauma Comparisons were made with patients after total hip 
replacement, who displayed a much lower Tc-albumin flux9 
During the development of SIRS, an increased first hour clearance of i.v 
injected radiolabelled albumin has been detected, suggesting an increased 
transvascular protein flux . SIRS developing after multiple trauma, was 
associated with a continuous rise in EVLW, while non-SIRS patients displayed a 
normalization of this parameter9 8. Pulmonary vascular permeability, as 
measured by transvascular 9 9 mTc-albumm flux, has been shown to be 
increased in patients developing ARDS, when compared with normal controls 
or patients with congestive heart failure. Furthermore, a significantly increased 
albumin flux was related to increased length of ventilatory support and ICU 
admission9 9. Using the double isotope technique, ARDS and MODS appeared 
to be associated with a generalized increase in lung microvascular 
permeability, rather than a localized increase in permeability as seen in direct 
lung injuries 
62 Thus, evidence is accumulating that endothelial damage with subsequent 
increased vascular permeability is an important event in the development of 
SIRS, ARDS and MODS. Assessment of the distribution and time pattern of 
permeability changes in various organs, and establishing a relationship with 
organ damage could provide supporting evidence that a generalized 
inflammatory response with subsequent generalized permeability changes plays 
an important role in the development of MODS. 
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3.4 M A C R O P H A G E S 
3.4.1 General aspects of macrophage function 
As already described by Metchnikoff and Ashhoff, macrophage activation is 
an important phenomenon in normal host defense by exerting microbial 
killing, antigen presentation, immune regulation and tissue repair 1 0 1 , . Upon 
stimulation, macrophages release a large variety of immunoregulatory 
products, some of which are pro-inflammatory (oxygen radicals, complement 
factors, PAF, IL-1, IL-6, IL-8, TNF), others being anti-inflammatory (IL-10, 
PGE2), immunosuppressive (IL-2) or procoagulatory (PCA) 1 0 3 . 
Evidence is emerging, that the activated macrophage has a pivotal role in the 
development of MODS. An excessive and uncontrolled activation of 
macrophages after an injurious event could lead to an excessive and 
dysregulated production of inflammatory mediators, with subsequent 
activation of other cascade systems and generation of a detrimental 
generalized inflammatory response leading to M O D S 1 0 4 . In an inflammatory 
response, PMN's have been shown to induce tissue injury. However, 
macrophages appear to be important regulators of this response, or to 
describe it more virtuoso: "lymphocytes play the music, but macrophages call 
the tune" l 0 5 . Hence it is not surprising that MODS has been characterized as 
the result of "mad macrophages and angry neutrophils" . In this perspective, 
limiting macrophage hyperactivity could thus attenuate or prevent the 
development of MODS. 
General aspects of macrophages and their activation, secretory products 
and specific subpopulations (alveolar, liver, spleen and peritoneal 
macrophages) will be discussed in search of their propensity to induce SIRS, 
ARDS and MODS. 
Origin and kinetics 
Macrophages are the definitive and irreversible differentiated cells of the 
mononuclear phagocyte system (MPS) which comprises bone marrow 
precursors, blood monocytes and resident macrophages1 0 6. The bone marrow 
contains a pool of various cells with different maturity i.e. monoblasts, 
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promonocytes, monocytes, as well as resident macrophages. Colony 
stimulating factors induce a differentiation from a progenitor cell to a mature 
monocyte, via the monoblast and promonocyte, in a transit time of 
approximately six days . Once liberated in the bloodstream, monocytes are 
distributed over a circulating and a marginating pool, with a species dependent 
distribution. In mice, 40% of the monocytes are circulating, while 60% belong 
t o the marginating p o o l 1 0 8 . Under steady state conditions, monocytes have an 
intravascular half-life of 17.4 hours with an average transit time of 25 hours 1 0 9 . 
From this vascular compartment, monocytes migrate by diapedesis through 
the endothelium t o the extravascular tissue, and are subsequently converted 
by specific tissue paracrine factors, t o tissue macrophages. Kinetic studies have 
shown that, under steady state conditions in mice, about 70% of the 
monocytes become hepatic macrophages, 15% pulmonary macrophages and 
7% peritoneal macrophages. The mean life span is 4 days for hepatic 
macrophages, 6 days for spleen and lung macrophages and 15 days for 
peritoneal macrophages . In humans, however, the life span is believed to be 
months for most macrophages. The final fate of resident macrophages is cell 
death (apoptosis) in the local lymph nodes for most macrophages, while 
alveolar macrophages (AM) are partly eliminated via the air 1 0 9 . From a kinetic 
point of view, monocytopoietic cells migrate through 3 compartments: bone 
marrow, blood and tissues. Until recently it was hypothesized that monocytes 
would not divide after leaving the bone marrow compartment, but recently it 
was demonstrated that the tissue macrophage population is maintained by an 
influx from monocytes and by local division of immature mononuclear 
phagocytes as w e l l ' l 0 . 
During acute inflammation, the kinetics as described above change with an 
increased production of monocytopoietic cells in the bone marrow and a 
decrease in time remaining in the bone marrow and blood compartments . 
Resting "resident macrophages" will become "elicited" when triggered and by 
continuous stimulation "activated ", with concomitant changes in morphology, 
function and receptor status . This conversion is effectuated by the release 
of endogenous cytokines like lymphocyte derived IFN1 ' 2 and GM-CSF1 '3, 
macrophage derived TNF 1 ' 4 , or by exogenous stimuli like endotoxin 1 0 7 . 
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Actions of the activated macrophage 
Activated macrophages exert many essential protective functions in host 
defense and the immune response by107: 
• Phagocytosis of invading noxious agents or cells 
• Antigen presentation to lymphocytes 
• Release of various regulatory factors 
Phagocytosis 
Essential in host defense is the diapedesis across the endothelial barrier 
and migration to locations of injury or invasion of microorganisms . After 
the influx of neutrophils into inflammatory sites, macrophages are attracted by 
chemotactic factors from other inflammatory cells, bacterial components, the 
Fc portion of immune complexes, complement cleavage products or 
arachidonic acid metabolites' '5. After recognition, microorganisms, noxious 
agents or injured tissue will be phagocytosed and killed by a respiratory burst 
in phagolysosomes with the concomitant release of hydrolytic enzymes and 
toxic reactive oxygen and nitrogen intermediates · 
Antigen presentation 
Materials processed by macrophages are presented to lymphocytes in 
conjunction with Class II major histocompatibility complex antigens (HLA-DR) 
on the cell surface"7 . The interaction of T-lymphocytes with HLA-DR , IL-1 
and IFN induces a proliferation of T-lymphocytes and antibody formation 
Regulatory function 
Macrophages exert an important regulatory function of the immune res-
ponse by the secretion of various immunoregulatory substances. These 
numerous products (about 100) have been cataloged by Nathan and include 
cytokines (i.e. IL-1, IL-6, IL-8, IL-10, TNF, interferons), neopterin, growth 
factors (i.e. GM-CSF and G-CSF), complement products, coagulation factors, 
hydrolytic enzymes, enzyme inhibitors, arachidonic-, reactive oxygen- and 
nitrogen-metabolites103. All these products influence in some way aspects of 
the immunological system like the inflammatory response' '9, hemostasis120, 
hematopoiesis121 and wound healing122 A full description of the abundant 
functions is beyond the scope of this thesis, so the focus will be directed at 
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those macrophage products that have been related t o the development of 
SIRS, ARDS and MODS. 
General aspects of studies on macrophage secretory products 
Macrophages exert an important regulatory function on the inflammatory 
response by secreting various mediators, such as cytokines. Cytokines are 
small proteins, which display many biological activities in host defense such as 
the regulation of the inflammatory response, antimicrobial function, wound 
healing, myelostimulation and mobilization of substrate stores. Since 
macrophages are the most important producers of cytokines, indirect 
evidence of an excessive or dysregulated macrophage activation during the 
development of SIRS, ARDS and MODS has been obtained from the 
involvement of cytokines in these processes. 
From a pathophysiological point of view, cytokines could be involved in 
SIRS, ARDS and MODS. Indeed, endothelial damage, neutrophil adherence and 
extravasation are processes encountered in these syndromes, that are 
mediated by cytokines. An exaggerated or prolonged secretion of cytokines 
might be detrimental for the host, inducing an excessive inflammatory res­
ponse, subsequently leading t o SIRS, ARDS or MODS. The involvement of 
cytokines in the development of SIRS, ARDS and MODS has been suggested 
because of the following observations: 
• Administration of some cytokines (TNF, IL-1) in healthy humans produces 
a clinical substrate closely resembling SIRS. 
• Elevated concentrations of cytokines have been correlated with the 
development of and poor outcome of SIRS, ARDS and MODS. 
• Anti-cytokine strategies in experimental models of SIRS, ARDS and MODS, 
and preliminary results f rom some clinical studies, have demonstrated an 
improvement of clinical parameters or, even more important, survival. 
To understand studies concerning the relationship between cytokine 
release and the development of SIRS and MODS, some general aspects of 
cytokines are important to consider • ' l 5 : 
• Cytokines are produced by nearly every cell in a specific pattern for every 
cytokine. 
• Cytokines are released mainly in response to an external noxious stimulus 
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Production of cytokines at various sites may be different depending on the 
location of the injurious stimulus 
Cytokines have biological effects through cell to cell interactions, acting as 
important paracrine mediators Circulating cytokine concentrations do not 
necessarily reflect local concentrations So, tissue concentrations of 
cytokines possibly are biologically more significant than circulating 
concentrations, which may only be the spill over of local production 
Circulating cytokines have a very short half life (minutes), have a temporal 
pattern of release and can thus be only temporarily present in the 
circulation Hence, we have t o realize that measurements of circulating 
cytokine concentrations are just random indications and do not necessarily 
reflect the highest or lowest concentration 
Cytokines are pleiotrophic ι e exert multiple biological effects and different 
cytokines can exert the same biological effect 
Cytokines act synergistically or antagonistically with other cytokines and 
inflammatory mediators The post-injury cascade of cytokines appears to 
be triggered and amplified in a complex interdependent matter 
Cytokines primarily are regulators of the inflammatory response, which is 
indispensable for normal host defense Disease could be the result of an 
excessive inflammatory response, with a concomitant excessive release of 
cytokines This would be the rationale for limiting the cytokine response 
On the other hand, the increased release of cytokines may still be 
inappropriate Finally, the balance of pro-inflammatory versus anti- 67 
inflammatory cytokines may be disturbed, resulting in an excessive 
inflammatory response and/or m immune depression with decreased 
resistance against infection In this perspective, supporting or modulating 
the cytokine response would be more appropriate in preventing disease 
The role of cytokines as causative mediators in disease have been derived 
from the effects of specific blockades rather than from studies on 
circulating concentrations 
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3.4.2 Macrophage products and the development of SIRS, 
ARDS or MODS 
In this section macrophage related cytokines and products will be 
discussed which have been implied in the development of SIRS, ARDS and 
MODS. 
T u m o r Necrosis Factor 
TNF is a 17 kDa polypeptide which is mainly produced by monocytes and 
macrophages, but also by lymphocytes, neutrophils, endothelial cells and mast 
cells123. Its synthesis can be elicited by various stimuli such as viruses, fungi 
and protozoans, but bacterial endotoxin is the most potent physiological 
stimulus. Furthermore, TNF production can be enhanced by various 
inflammatory mediators like C5a, lipoxygenase products, IL-1, IFN. Its 
production can be down-regulated by IL-10, glucocorticoids, pentoxifylline, 
PAF- antagonists and cyclooxygenase products124. TNF interacts with two 
specific surface receptors, with molecular masses of 55 and 75 kDa, which are 
present on almost every cell125. In addition, soluble TNF receptors bind and 
inhibit TNF, regulating the TNF response126. Under physiological conditions 
TNF exerts its immuno-stimulatory actions as an endogenous pyrogen, 
enhancing the activation, margination and extravasation of neutrophils and 
promoting the maturation and activation of macrophages. In addition to its 
68 immunological properties, TNF exerts various metabolic functions. It 
redistributes protein and fat synthesis from the periphery towards the liver, 
causing peripheral wasting. TNF is anabolic for hepatocytes, it enhances the 
production of acute phase proteins and preserves hepatic cell mass. 
Furthermore, TNF activates the coagulation system and has an important role 
in wound healing127, '28 . Intravenous administration of LPS and bacteria to 
rats, rabbits, baboons and human volunteers results in an early rise in serum 
TNF with peak concentrations occurring after 90-120 minutes and a return to 
the baseline within 3-4 hours. The serum half-life is very short: 5-20 
129 
minutes . 
The possible involvement of TNF in the pathogenesis of SIRS / ARDS and 
MODS has been proposed because of three lines of observations. 
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Systemic infusion of human recombinant TNF into experimental animals 
induces a systemic inflammatory response with ARDS-like changes in the 
lung, systemic hemorrhage, edema and inflammatory cell infiltration in 
almost every organ very similar to clinical changes observed in patients 
with SIRS, ARDS and MODS1 3 0 m Infusion with endotoxin resulted a high 
initial TNF peak followed by a rise m IL-1, IL-6 and IL-8 In the cecal ligation 
and punction (CLP) model, which represents a model of septic peritonitis, 
TNF production was much lower and did not follow such a clear 
pattern132 In an experimental model of MODS, the pattern of TNF 
concentrations was quite similar to the progression of the clinical illness133 
Elevated TNF concentrations have been demonstrated in patients 
developing septic shock However, concentrations were much lower when 
compared with the concentrations seen after endotoxin administration and 
show large mterstudy variation and its correlation with a poor outcome or 
the development of ARDS/MODS was variable128 l 3 2 In addition, studies 
using a bioassay for TNF (measuring biologically active TNF), reported 
elevated TNF-concentrations in only a minority of septic patients, m 
contrast to studies measuring TNF by immunoassays Immunoassays 
may detect both free TNF and complexes of TNF and its soluble 
receptors A recent prospective study, however, showed that the 
presence of biologically active TNF was the only independent predictor of 
mortality in critically ill patients136 Furthermore, a positive correlation 
between outcome and elevated concentrations of soluble TNF receptors 
or a decrease in cell surface TNF receptor values has been 
demonstrated137 Very interesting is the observation of an association 
between a homozygous genomic polymorphism within the TNF locus on 
chromosome 6 and higher concentrations of TNF and poor outcome138 
The most convincing evidence has been obtained by the protective effects 
of TNF-blockmg strategies in mice, rabbits and baboons prior to the 
challenge with LPS or live bacteria l 3 9 Recently, it has been shown that 
administration of monoclonal anti-TNF antibodies to primates after the 
challenge with lethal S aureus bacteremia, could prevent mortality and 
attenuate the IL-6 response and multiple organ damage140 However, it 
appears that anti-TNF antibody has divergent efficacy in different models 
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since administration of monoclonal anti-TNF could not prevent mortality in 
models of Ρ aeruginosa or Klebsiella pneumoniae bacteremia, and fungal 
sepsis141, l 4 2 . Furthermore, in models of peritonitis or abdominal sepsis, 
not anti-TNF, but low dose TNF was effective in reducing mortality · l 4 4 . 
The latter could be explained by the fact that TNF is essential in host 
defense in peritonitis models or by the fact that a non lethal dose of TNF 
prior to LPS challenge can induce tolerance t o LPS145. In a model of multi­
ple organ failure, administration of monoclonal anti-TNF antibodies was 
able to reduce TNF and IL-6 concentrations and early (5 day) mortality 
from 63% to I 1.6% . A phase I study reported an improvement of 
hemodynamic parameters and no adverse reactions after administration of 
murine monoclonal anti-TNF antibody to 14 septic patients1 4 7. To date, 
two prospective randomized clinical trials have been performed with 
monoclonal anti-TNF treatment, which could not demonstrate a positive 
effect on outcome or the development of septic shock . Early reports 
indicate that soluble TNF receptor treatment could prevent the 
development of experimental sepsis However, a randomized double-
blind placebo-controlled trial in patients with septic shock did not reduce 
mortality, and higher dosages appeared to be associated with an increased 
mortal ity 1 4 9 . 
Interleukin-I 
70 IL-1 comprises 2 polypeptides, IL-1 α and IL-1 β Both are predominantly 
produced by tissue macrophages and monocytes and to a lesser extent by a 
variety of other cells like endothelial cells, В lymphocytes and neutrophils . 
IL-1 α is bioactive and exists mainly as a membrane bound form, thus acting as 
a local paracrine cytokine. IL-1 β is the circulating soluble form, thus detectable 
in the serum, but does not appear to be very bioactive1 2 8. Like TNF, the 
circulating half life of IL-1 β is very short 6-10 minutes1 5 1. Both proteins can 
bind to a surface IL-1 receptor. Furthermore, a soluble IL-1 receptor 
antagonist (IL-Ira), binds to the IL-1 receptor with equal avidity as IL-1 and 
appears to be a natural regulator of the IL-1 response. In fact, during 
experimental endotoxemia, the concentration of IL-Ira is a 100-fold greater 
than the IL-1 concentration1 5 2 Significantly higher plasma IL-Ira 
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concentrations have been found in patients with meningococcal septic shock 
than in patient with meningococcal meningitis alone 1 5 3 . Others, however, have 
shown that plasma IL-1 ra concentrations were elevated in patients with severe 
sepsis, but did not correlate with outcome 1 5 4 . After an endotoxin challenge 
IL-1 serum concentrations reach their peak after approximately 180 minutes. 
IL-Ira concentrations are peaking 1-2 hours later and are 100 fold higher1 5 5 
IL-1 stimulates T-cell proliferation and it causes an increase of the number and 
immaturity of circulating neutrophils and monocytes by a direct action on the 
bone marrow via stimulation of the production of GM-CSF and CSF-1 . 
Local release of IL-1 contributes, as a chemotactic factor, t o the recruitment 
of inflammatory cells t o the site of injury, acting in concert with TNF t o induce 
this inflammatory response1 5 2. Furthermore, IL-1 release stimulates 
endothelial procoagulant activity, thus acting as a prothrombotic mediator and 
acts, like TNF and IL-6, as a endogenous pyrogen, and as an important inducer 
of the acute phase response1 5 6 Injection of IL-1 induces an inflammatory 
response with hypotension, tachycardia, leucopenia and neutrophil 
accumulation in various tissues. In this respect, IL-1 has an important 
synergism with other cytokines, since IL-1 potentiates the effects of TNF, IL-6 
and IL-81 5 6 , l 5 7 . IL-1 release is promoted by endotoxin, TNF, IFN and by IL-1 
itself and inhibited by corticosteroids and PGE2 1 5 8. 
Probably because IL-1 acts merely as a local paracrine pro-inflammatory 
cytokine, a variable correlation between IL-1 concentrations and the severity 
or mortality of SIRS, ARDS or MODS has been demonstrated 1 5 6 . In addition, η \ 
recent data have shown that the presence of nonspecific ¡mmunoactivity in 
sera may confound IL-1 and other cytokine assays of human biologic material 
resulting in false positive serum activity159. Elevated IL-1 concentrations have 
not been uniformly detected in patients with sepsis and septic shock and no 
convincing independent association has been found with outcome156. A per-
sistent elevation over time of IL-1 concentrations in plasma and 
bronchoalveolar lavage fluid appears to be related to outcome in patients 
developing ARDS160, ' 6 I . After multiple trauma, IL-1 concentrations were 
barely elevated shortly after injury, while a convincing relationship with the 
development of ARDS and MODS could not be established10, l 62. 
A more convincing support for the potential importance of increased 
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production of IL-1 in the development of SIRS and MODS, is derived from 
experimental data with IL-1 blocking strategies. In animal models with live 
E.coli or endotoxin infusion, IL-Ira has been shown to improve survival and to 
decrease the septic response139. After intratracheal administration of live 
E.coli and/or endotoxin, IL-Ira administration reduced the accumulation of 
neutrophils into the lungs . Even more important and in contrast with other 
anti-cytokine strategies, administration of IL-1 ra even after endotoxin 
challenge improved survival164. In a large placebo controlled clinical trial in 893 
patients with SIRS or sepsis, no significant efficacy was demonstrated. 
However, a post intention analysis showed that in patients with a more than 
24% predicted risk of dying as entry criterion, mortality was significantly 
reduced1 6 5. 
Recently antibodies to IL-1 surface receptors have been shown to protect 
against endotoxin lethality. To date, no data have been available on studies 
with this antibody in models of sepsis or MODS 1 3 9 . 
Other experimental data, however, support the fact that IL-1 has an 
important role in augmenting host defense against injury. Low dose 
administration of recombinant IL-1 α and β has been shown experimentally to 
be protective against lethal doses of LPS, severe infection, and peritonitis or 
abdominal sepsis166. 
lnterleukin-6 
72 IL-6 is a 21 kDa glycoprotein produced by a variety of cells, such as 
fibroblasts, endothelial cells, monocytes/macrophages, T-cell lines and mast 
cells 6 . IL-6 has a receptor, which is present on T-cells, monocytes and 
macrophages. Signal transduction to the cell occurs via the protein gp 130 
which forms a complex together with the IL-6 receptor 1 6 8 . IL-6 is not 
produced in steady state situations but its production is induced by LPS, IL-1 
and IL-3, TNF or GM-CSF169. IL-6 exerts multiple biological activities 
comprising the induction of the acute phase response (together with IL-1 and 
TNF), B-cell differentiation with the production of immunoglobms, T-cell 
activation via IL-2 and the hematopoiesis of granulocytic and monocytic cell 
lines (synergistic with GM-CSF and M-CSF and IL-3)156· l 7 0 . Furthermore, IL-6 
suppresses the production of TNF and I L - 1 l 5 6 . In contrast with IL-1 and TNF, 
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IL-6 appears to be a regulatory cytokine, rather than a mediator resulting in 
tissue injury, since experimental studies show that IL-6 administration causes 
fever but no acute toxic effects unless it is given in conjunction with TNF1 7 1 . 
After an intravenous bolus of endotoxin in human volunteers, IL-6 can be 
detected within 60 minutes in serum. However, IL-6 peaked after TNF and IL-
I, suggesting an upregulation of IL-6 by TNF and I L - 1 , 7 2 . This is in line with 
studies performed with TNF-antibodies and IL-Ira in bacteremic baboons, 
showing that IL-6 production was attenuated173. Hence, IL-6 appears to be a 
secondary cytokine in the inflammatory cascade174. Recent studies have shown 
that IL-6 can augment PMNs priming for oxidative burst, by delaying PMN 
apoptosis, resulting in a larger population of surviving PMNs, with a greater 
collective potential to facilitate PMN-mediated tissue injury175. 
Although IL-6 is an integral part of the cytokine cascade, its individual role 
in the pathophysiology of sepsis remains unclear. In experimental endotoxemia 
in baboons, monoclonal anti-IL-6 antibodies, did neither affect the 
development of an inflammatory response nor outcome. Only endotoxm-
mduced activation of coagulation was attenuated176. Clinical studies have 
almost uniformly shown that IL-6 is detected shortly after the onset of septic 
shock and that high IL-6 concentrations correlate with high TNF 
concentrations, and poor outcome10 ' IS4 l 7 7 1 7 9 . Furthermore, the 
development of ARDS/MODS or poor outcome appeared to be related more 
to the persistence of high concentrations of IL-6 than peak concentrations10, 
l60
·
 l 80
. In addition, IL-6 concentrations were closely correlated with the 73 
APACHE II score . As shown in study with multiple trauma patients, IL-6 
production seems to be more closely associated to soft tissue m|ury than 
other cytokines10 l81. 
lnterleukin-8 
IL-8, or neutrophil activating peptide, is a cytokine, which has gained recent 
attention. It is produced by macrophages, PMNs, endothelial cells and a variety 
of mesothehal cells in response to TNF and IL -1 l 8 2 . IL-8 is a potent 
chemoattractant as well as an activator of PMNs, by an upregulation of 
adhesion molecules and a stimulation of the respiratory burst156 
Furthermore, it increases endothelial permeability independent of PMN and 
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has been shown t o be angiogenetic1 8 3. 
IL-8 has been associated with the development of ARDS and MODS. It has 
been coined as the major PMN chemotactic factor in the lung and 
¡mmunocytochemistry suggests that the alveolar macrophage is the primary 
source of IL-8 in the lung184, l8S. In patients with ARDS, high and persistent 
systemic and bronchoalveolar lavage fluid (BAL) IL-8 concentrations have been 
associated with high PMN counts, lung injury and outcome161, l 85. 
Furthermore, experimental blockade of IL-8 by anti-IL-8 antibodies was shown 
to be protective against acute lung injury186. Recently it has been 
demonstrated that prolonged elevations of IL-8 concentrations are associated 
with the development of MODS68 . 
Interleukin 10 
Besides the wide range of pro-inflammatory cytokines which have been 
associated with the development of MODS, recent attention has been 
directed to antiinflammatory cytokines, such as IL-4 and IL-10. This section 
will focus on IL-10 because this antiinflammatory cytokine has been best 
studied. IL-10 is a 35 kDa protein that is produced by subpopulations of T-
helper cells, B-cells and macrophages187. It is a potent in vitro inhibitor of 
proinflammatory monocyte- and macrophage derived cytokines, such as TNF, 
IL-1, IL-6 and IFN l 8 8 . Inhibition of IL-10 by monoclonal antibodies resulted in 
increased levels of TNF and IL-6187. Furthermore, IL-10 has been shown to 
stimulate the IL-Ira production by monocytes189. High IL-10 concentrations 
have been documented, with concurrent high concentrations of pro-
inflammatory cytokines during septic shock, when compared with other 
critically ill patients190. Furthermore, IL-10 concentrations correlated 
significantly with APACHE II scores190. During sepsis higher concentrations of 
IL-10 have been observed in patients with shock than without shock191. After 
multiple trauma, IL-10 was associated with the development of sepsis192. From 
these data it can be hypothesized that IL-10 is an indirect marker of high local 
synthesis of proinflammatory cytokines. Furthermore, they suggest that IL-10 
is part of the normal feedback control mechanism during the excessive 
inflammatory response in septic shock. Moreover, it shows that this feedback 
mechanism is still unable to dampen the increased production of pro-
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inflammatory cytokines. Probably the high mortality of patients with severe 
sepsis may result from imbalances between proinflammatory and 
antiinflammatory host mediators1 9 3. Administration of IL-10 has been shown 
t o protect mice from lethal endotoxemia1 9 4. IL-10 thus has the potential for 
immunointervention strategies in order to reduce the excessive inflammatory 
response leading to MODS. On the other hand, by deactivation of 
macrophages, it has massive cellular immunosuppressive properties, which 
may theoretically augment susceptibility to the invasion of microorganisms1 9 5. 
Further studies are required to determine whether or not IL-10 can attenuate 
the development of MODS. 
Interferon-γ 
IFN is secreted by activated T-lymphocytes and natural killer cells which 
are triggered by microbial antigens or mediators like IL-1 and IL-2. In-vivo 
baseline production is very low and serum half-life of IFN is approximately 30 
minutes1 9 6 , l 9 7 . IFN was originally identified because of its antiviral activities 
but its main function appears to be the activation of macrophages, increasing 
the respiratory burst activity of monocytes and resident macrophages198. 
Furthermore it enhances the production of IL-1, TNF and complement factors 
and reduces macrophage PGE2 production. In fact, IFN synergizes with TNF, 
IL-1, GM-CSF and LPS. In addition IFN induces the expression of HLA-DR 
genes on the surface of macrophages, monocytes and endothelial cells1 5 8. 
IFN has little acute toxicity. Evidence for an important role in sepsis has 
been obtained by the reduction of TNF concentrations and prevention of 
mortality in experimental endotoxic shock, by treatment with monoclonal 
anti-IFN ant ibody 1 9 9 · 2 0 0 . This observation has been confirmed by others, who 
demonstrated that pre-treatment of rabbits with IFN before an endotoxin 
challenge resulted in an increased sensitivity to endotoxin, with decreased 
cardiac output and white blood cell counts and increased pulmonary 
permeability . Moreover, monoclonal anti-IFN antibody was protective in a 
murine model of E.coli peritonitis . On the other hand, other experimental 
data suggest an attenuation of the hemorrhage-induced immunosuppression 
and a decreased susceptibility to sepsis after administration of IFN in a 
combined hemorrhage-Cecal Ligation and Puncture model in mice . Clinical 
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studies on trauma patients have confirmed the presence of a posttraumatic 
immunosuppression correlating with a decreased IFN production by blood 
monocytes 
Granulocyte Macrophage Colony Stimulating Factor 
GM-CSF is a glycoprotein produced mainly by activated T-cells, but also by 
fibroblasts, macrophages and endothelial cells Its production is induced by LPS 
and IL-2205 206 A receptor for GM-CSF is present on granulocyte- and 
macrophage progenitor cells in the bone marrow as well as on mature cells in 
these cell lines207 GM-CSF regulates the production and differentiation of 
neutrophil and monocyte cell lines from their precursors in the bone marrow 
In addition, it prolongs the life span of mature cells by suppressing 
apoptosis208 On PMNs, GM-CSF has various effects such as increasing their 
phagocytic capacity and prime them for a more sensitive response to other 
chemoattractants Moreover, GM-CSF itself is chemotactic for neutrophils209 
GM-CSF has been shown to restore host defense in a bacteremic model in 
neutropenic mice210 Actually, in humans GM-CSF is most often used to 
restore granulocytopenia during chemotherapeutic regimens, neutropenic 
fever and myelodysplasia syndromes21 ' Experimental data have shown a 
favorable effect in septic models Administration of human recombinant GM-
CSF before challenge in transfusion-burn and transfusion-CLP experiments 
could reduce mortality and bacterial translocation212 In the CLP model in 
76 rats, post-challenge administration of GM-CSF reduced mortality213 
Only case reports have been described on the use of GM-CSF in the 
human setting Recombinant human GM-CSF was given to an ICU-patient with 
polytrauma and life-threatening agranulocytosis and sepsis Clinically, mature 
granulocytes reappeared and the patient recovered without any serious side 
effects due to this therapy However, another study reported a severe 
septic like syndrome during therapy with rhGM-CSF for a malignancy215 In an 
experimental model of CLP and burn injury, GM-CSF improved survival and 
restored burn-induced IL-2 and T-cell depression216 In another study with the 
CLP model, GM-CSF improved myelopoiesis and host defense and survival in 
fulminant intra-abdominal CLP-mduced sepsis in rats217 Further experimental 
and human studies however, are needed to evaluate the definitive role and 
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mechanisms of GM-CSF in the development and treatment of SIRS and 
MODS. 
Neopter in 
D-erythro-neopterm (neopterin) is not a cytokine but the relative inactive 
metabolite derived from guanosinetriphosphate breakdown. Macrophages are 
the principal producers of neopterin, especially after activation by endotoxin 
or IFN218. Hence, neopterin concentrations reflect the overall activation of 
macrophages of the host219 Neopterin is cleared from the circulation by renal 
excretion and measured concentrations should thus be related to renal 
function220 
Elevated serum concentrations of neopterin have been measured in 
patients with sepsis, multiple trauma and burns' ' 29 57 22 l _225 . Neopterin 
concentrations correlated well with the MOF-score and fatal outcome in 
patients with MODS and sepsis" 57· 225 Roumen et al studied the neopterin/ 
creatinine ratio in patients with severe blunt trauma and observed initially no 
difference between patients with and without MODS However after one 
week patients developing MODS showed higher ratio's, suggesting an ongoing 
activation of macrophages in patients developing MODS29 . 
3.4.3 M a c r o p h a g e subpopulat ions and t h e d e v e l o p m e n t o f 
S IRS , A R D S o r M O D S 
In the previous section attention was focused on products of the activated 
macrophage. In this section various macrophage subpopulations will be 
discussed in relation with a possible involvement in the pathophysiology of 
SIRS, ARDS or MODS 
Alveolar macrophages 
From a pathophysiological point of view, initial attention has focused on the 
detrimental effects of activated PMNs in the development of ARDS and 
MODS . However, since several reports have shown that ARDS can develop 
in neutropenic patients245"247, and as experimental neutrophil depletion does 
not prevent ARDS248"250, the role of neutrophils has been questioned and 
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other pulmonary inflammatory cells, i.e. alveolar macrophage (AMs), have 
received increasing interest. 
The AM has an important role in removing antigens from the lung by non-
specific phagocytosis and antigen-presentation251. Furthermore, they transport 
particles to the lung associated lymph nodes and are important regulators of 
the pulmonary immune response252, 253. AMs appear to down regulate the 
pulmonary inflammatory immune response254. Selective elimination of AMs 
results in a decreased antigen processing capacity and a strongly enhanced 
pulmonary immune response, possibly by abrogating suppressive factors like 
PGE2 secreted by AMs255 , 256. Under normal circumstances, resident AMs 
have been shown to be less efficient in antigen presentation , IL-1 release, and 
stimulation of PMNs than monocytes . So, AMs appear to adapt to the large 
burden of inhaled inflammatory stimuli by regulating the release of 
inflammatory mediators. Recently, high concentrations of heat shock protein 
72 mRNA in AMs in patients at risk for ARDS have been demonstrated, 
suggesting an increased protective mechanism of the AM against injury258. 
However, under pathological circumstances like SIRS, AMs appear to be 
less adapted, and release large numbers of inflammatory mediators, which 
could result in the development of ARDS and MODS2 5 9 . Experimental data 
have shown that after parenteral administration of endotoxin, an ARDS-like 
picture develops within several hours, with pulmonary edema and congestion 
of inflammatory cells260. In these models, an increased number of pulmonary 
macrophages, with a concomitant activation has been demonstrated by the 
increased production of oxygen intermediates and neutrophil Chemotaxis 
262
. However, a significant difference in the endotoxin clearance exists bet-
ween species, so data from these experiments should be extrapolated 
cautiously263. The fractional distribution of AMs in bronchoalveolar lavage fluid 
from polytraumatized ARDS patients demonstrates an early decrease in the 
number of AMs, with a subsequent increase during the days that ARDS 
develops. PMNs depict a complete different pattern, with a dramatical initial 
increase followed by a decrease . In both survivors and non-survivors, 
increased numbers of AMs were found during the development of ARDS. 
However, a sustained high number of AMs correlated with a decreased risk of 
death, suggesting a beneficial effect of AMs in the resolution of ARDS265. 
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Quantification of the number of macrophages does not indicate the 
functional activity of AMs. Experimental data on the functional aspects of AMs, 
have revealed that after the induction of abdominal sepsis by CLP in rats, a 
gradual increase of AM activation occurs as measured by an enhanced 
generation of toxic oxygen intermediates and lysosomal enzymes 6 6 . Others 
however, have demonstrated that murine CLP elevated serum cytokines 
together with little innate or inducable AM cytokine production, while 
peritoneal macrophages demonstrated an increased cytokine production . In 
patients with ARDS, increased concentrations of IL-1, IL-6, IL-8 and TNF in 
bronchoalveolar lavage fluids (BAL) have been found in comparison with 
patients without ARDS 1 6 1 ' l 8 S 2 6 8- 2 6 9 . Persistent high concentrations of 
cytokines were associated with poor outcome 1 6 1 . Furthermore, an increased 
expression of TNF-mRNA of AMs appears t o be a constant feature in patients 
with ARDS 2 7 0 . Since AMs in sepsis have been shown to be able to produce 
much more TNF than for example peripheral blood monocytes or liver 
macrophages2 7 1 , 2 7 2 and thus appear to be principal producers of TNF, these 
data indicate that AMs might play a pivotal role in the development of 
ARDS2 5 9. Immunocytochemistry studies showed that the AM was the principal 
source of cytokine production . Since increased concentrations of various 
cytokines are present in BAL of patients with ARDS, a common, proximal 
activation mechanism has been proposed. Indeed, recent studies have shown 
an increased activation of the nuclear transcriptional regulatory factor NF-
kappa В in AMs from patients with ARDS. Since NF-kappa В binding sequences 
are present in the enhancer/promoter sequences of various proinflammatory 
cytokines, activation of NF-kappa В may contribute to the increased 
expression of cytokines in the lung in the setting of established ARDS 2 7 3 . 
Kupffer Cells 
Kupffer cell (KCs) are the resident macrophages of the liver. They make up 
80-90% of the body's content of resident macrophages2 7 4. KCs are derived 
from the bone marrow via the circulating monocytes, as shown by studies on 
patients with liver and bone marrow transplantation . Population expansion 
results from local К С replication, whereas the remaining growth results from 
extra-hepatic recruitment from the bone marrow 2 7 6 . It has been suggested 
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that products from the Gl-tract are important to maintain the К С population, 
since decreased numbers of KCs have been demonstrated in germ free ani­
mals and following a portocaval shunting2 7 7 2 7 8 KCs have a unique position 
adjacent t o hepatocytes, lining the hepatic sinusoids and are thus directly 
exposed to inflammatory mediators circulating in the portal and systemic 
blood flow A t this site they play a key role in host defense by the clearance of 
(gut-derived) microorganisms and endotoxin Indeed, gut derived endotoxin 
produces an increase in the number of KCs, with a concomitant increased 
rate of phagocytosis and secretion of biological active substances important 
for normal host defense2 7 6 2 7 9 In this respect, KCs exhibit a higher in vitro 
phagocytic capacity than peritoneal macrophages2 8 0 During experimental 
bacteremia, a close bacterial adherence to KCs has been demonstrated In 
addition, the extent of К С adherence correlated with survival, suggesting an 
important role of KCs in normal host defense against overwhelming systemic 
bacteremia2 8 1 After m-vivo LPS administration, an increased ex-vivo cytokine 
production of KCs has been demonstrated, with an early TNF peak followed 
by an IL-6 peak and a rise in IL-1 product ion 2 8 2 The response of KCs appears 
to be biphasic, with an initially increased phagocytosis and a subsequent down-
regulation of respiratory burst (probably t o protect hepatocytes from damage 
by potential toxic mediators) However, this down-regulation can readily be 
enhanced by agents like interferon Furthermore, it appears that small 
dosages of LPS are needed to keep KCs down-regulated, since pretreatment 
with a very small dose of LPS protected animals from otherwise lethal 
endotoxin challenge 
The experimental induction of a septic challenge induced К С activation, 
with a concomitant increased release of inflammatory cytokines and an 
increased expression of tissue cytokine mRNA and adhesion molecules2 8 5"2 8 8 
Hence, it has been hypothesized that an excessive activation of KCs, with a 
subsequent release of inflammatory mediators induces a generalized 
inflammatory response leading to M O D S 1 0 4 Indeed, post-mortem 
immunohistochemistry studies on liver from MODS patients, shows a general 
activation of KCs 2 8 9 
Activated KCs have been shown t o modulate hepatocytes on a local 
concentrations and have profound systemic effects Since KCs are located 
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adjacent to hepatocytes, it appears from experimental data that KCs are able 
to alter the metabolism of hepatocytes2 7 4. Recent in the CLP model, suggest 
that hepatocellular acute phase gene expression is closely correlated with local 
paracrine TNF production by KCs, rather than with systemic TNF 
concentrations2 9 0. During sepsis, inflammatory stimuli are potent inducers of 
К С secretory activity, which subsequently alter hepatocyte function by nitric 
oxide dependent mechanisms to induce the production of acute phase 
proteins and hepatocellular dysfunction2 9 1 2 9 2 . In an ex-vivo hepatocyte-KC 
co-culture system, several aspects of hepatocyte-KC interaction have been 
studied. First it has been shown that LPS-activated KCs induce, by their 
secretory products, a biphasic response of hepatocyte protein synthesis 
showing an increase after low dose endotoxin and a decrease after higher 
dosages of endotoxin 2 7 4 . Furthermore, it was shown that splenectomy and 
germ-free status attenuated this endotoxm-mduced response of the 
hepatocyte-KC co-culture system 2 6 S . This suggests that a loss of priming 
factors from the gut and the spleen results in a decreased К С sensitivity to 
LPS. Priming factors from the Gl-tract that have been shown to be responsible 
are endotoxin and gram negative bacterial overgrowth 2 7 4 . 
Soluble factors influence КС responsiveness to endotoxin in different ways. 
Inhibition of К С responsiveness was achieved by PGE2 and Transforming 
Growth factor-beta (TGF-ß) IL-1 did not alter КС responsiveness and IFN, 
IL-2 and TNF increased the responsiveness of KCs2 9 3 2 9 5 However, a 
combination of cytokines produced the highest depression of К С 
responsiveness293 The origin of these cytokines has not been determined yet. 
Since the liver is on the crossroads of the systemic and portal circulation both 
pathways can deliver those factors. The portal route seems very important 
since deviation of the portal blood reduces the number of KCs 2 7 7 . In this 
perspective, an important observation is that recent data have shown that the 
gut also is a cytokme-generating organ 2 9 6 2 9 7 Recently it has been shown that 
sepsis-induced К С hyporesponsiveness to LPS is mediated by an increase in 
К С apoptosis2 9 8. 
К С activation does not only influence its local environment, but also 
modulates systemic responses. КС activation has been shown to increase the 
procoagulant activity, explaining the microvascular thrombosis often seen in 
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M O D S 2 9 9 Furthermore, it has been demonstrated that К С activation 
decreases the delayed type hypersensitivity reaction and increases formation 
of staphylococcal abscesses This immunosuppression could be attenuated by 
ablation of macrophages by carrageenan3 0 0 In the CLP model, blockade of К С 
phagocytic activity by gadolinium chloride results in reduced К С activation and 
a decreased immunosuppression, but in a higher mortal i ty 2 4 3 An explanation 
for this phenomenon was found in an m-vitro study, which demonstrated 
remarkable differences between KCs and AMs after stimulation with LPS 
While KCs exhibit a limited rise in IL-6 and TNF, AMs showed a dramatic rise 
in TNF production and a sustained rise in IL-6 This correlated with the 
limited production by AMs of immunosuppressive PGE2 It was hypothesized 
from this study that ARDS could be the result of failing KCs, resulting in a spill 
of endotoxin to the lung 2 7 2 3 0 1 Further support for this hypothesis has been 
obtained from gadolinium chloride induced blockade of К С phagocytic activity 
in LPS challenged rats Gadolinium chloride administration induced a decrease 
of microvascular perfusion failure, serum TNF and IL-6 concentrations, liver 
function disturbances and mortality CI2MBP-hposome induced elimination 
of KCs achieved an almost complete reduction of LPS-mduced IL-1, IL-6, IL-10, 
and IL-12 mRNA production in the liver TNF mRNA was reduced by 50-75%, 
providing evidence for a cytokine generating role of KCs in the l iver3 0 3 
Spleen macrophages 
82 The mam functions of the spleen are antigen-clearance and the generation 
of immune responses t o circulating antigens In the splenic tissue, T- and B-
cells, dendritic cells and macrophages interact with each other t o regulate the 
hosts immune response Splenic macrophage (SMs) are located in the white 
and red pulp and marginal zone Spleen B-cells meet the antigen m the 
marginal zone, migrate and present the antigen to T-cells in the periartenolar 
lymphocyte sheath (PALS)3 0 4 SMs are involved in the inductive phase of 
antibody response to particulate thymus-dependent antigens and cytotoxic T-
lymphocyte responses and binding of microorganisms3 0 5 Furthermore SMs 
have an enormous secretory capacity by releasing a large variety of 
inflammatory mediators 3 0 6 
Studies on the role of SMs in the development of sepsis and MODS are 
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sparse and only experimental. The abrogation of splenic function by 
splenectomy is rather rigorous and does not allow for assessing SM function 
alone. However, results from splenectomy studies have shown that soluble 
factors released by the spleen (probably by SMs) have a profound impact on 
other macrophage subpopulations Splenectomy alters the КС response t o 
LPS307 and the phagocytic activity of A M s 3 0 8 Furthermore, splenectomy 
impairs killing capacity and nitric oxide release of peritoneal macrophages, 
with enhancing the susceptibility to abdominal sepsis 
Administration of LPS is a strong inductor of TNF and PGE2 release by 
SMs, with a concomitant immunosuppression, especially of T-lymphocyte 
proliferation This T-lymphocyte proliferation is probably mediated by a PGE2 
induced suppression of IL-2 release3 1 0 3 I ' High peaks of tissue TNF and 
subsequent IL-6 mRNA expression in SM were observed after the induction of 
Gram-negative sepsis by infusion of live E coli306 Tissue injury by hemorrhage 
induces changes in SM function, like a decreased SM proliferation, a defective 
antigen presentation and decreased ex-vivo release of IL-1, IL-2 and IL-6, while 
TNF and PGE2 release was enhanced3 1 2 These changes correlated with an 
enhanced susceptibility to CLP-mduced sepsis and an improved survival by 
inhibiting PGE2 release In SMs, CLP induced sepsis produces a signifi­
cant suppression of the innate and stimulated ex-vivo production of IL-1, IL-6 
and TNF However PGE2 release was markedly enhanced, suggesting an 
important role of SMs in posttraumatic and septic immunosuppression287 3 I 5 
Since these data were obtained from endotoxm-intolerant СЗН/HeN mice, 83 
others showed that SMs from endotoxm-tolerant СЗН/HeJ had a higher 
stimulated IL-1 release and antigen presentation. Since СЗН/HeJ mice have a 
better survival post-CLP, it was concluded that the improved survival was due 
to either a supranormal response of SM in СЗН/HeJ mice or an inadequate 
response of SMs in СЗН/HeN mice 3 1 6 Portocaval shunting restored 
hemorrhage-induced SM proliferation inhibition and antigen presentation, 
suggesting that gut-derived mediators induce this SM dysfunction317 
After burn sepsis, a significantly increased release of IL-1, IL-6 and TNF by 
SMs, has been demonstrated Attenuation of this response by a combined 
treatment with mdomethacm and IL-1 β correlated with an improved survival, 
suggesting that negative modulation of SM hyperreactivity is beneficial with 
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regard t o the development of subsequent sepsis3 1 8 LPS-induced IL-1, IL-6, IL-
12 and IL-1 ra mRNA production was reduced in the spleen by selective 
elimination of SMs3 0 3 This shows that SMs are principal producers of cytokines 
in the spleen It remains to be established whether SM activation is beneficial 
or detrimental to the development of SIRS, ARDS or MODS 
Peritoneal macrophages 
The peritoneal cavity contains a large number of cells, 60-90 % of these 
cells being peritoneal macrophage (PMs) 3 I 9 During an inflammatory reaction, 
the number of PMs increases dramatically, largely by newly recruited 
monocytes, but also from local macrophage proliferation " 32° 3 2 1 , especially 
from the omental milky spots, in which homing of precursor cells has been 
demonstrated 3 2 2 Next to their functions in host defense, PMs also are impor­
tant immunoregulators For example, elimination of PMs resulted in an 
enhanced immune reaction t o intraperitoneal^ administered antigen in the 
draining lymph nodes3 2 3 
Human data on the role of PMs in the development of SIRS and MODS are 
sparse, and most are derived from studies on patients with Continuous 
Ambulatory Peritoneal Dialysis (CAPD)-pentonitis, providing a human model 
for bacterial peritonitis, with easy access t o PMs On the other hand, it has 
been disputed to be a good model, since CAPD produces a low grade 
peritoneal inflammation3 2 4 CAPD-pentonitis has been shown to be associated 
with an increased number of PMs, with phenotypical characteristics quite 
similar to normal inflammatory macrophages During CAPD-pentonitis, 
stimulated PMs show an elevated TNF, IL-1, PAF and PGE2 production 
capacity, while immune functions like Fc receptor expression were 
decreased The incidence of CAPD-pentonitis appears to be related t o 
the decrease in immune functions of PMs3 3 0 
Studies trying to correlate PM activation with the development of SIRS and 
MODS are only experimental Experiments performed with the CLP-, and the 
zymosan induced generalized inflammation (ZIGI)-model will be discussed, 
because these are slowly progressive models with a temporal (hypo- and 
hyperdynamic) course, resembling the clinical situation of patients developing 
MODS Intoxication models with the ι ρ injection of certain agents or LPS, 
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which are numerous, will not be discussed because they do not reflect a 
clinical situation. 
CLP induces a 3-fold increase of PMs, within 24 hours. Cytokine patterns in 
the serum were correlated to the ex-vivo cytokine production of PMs. Serum 
concentrations revealed an early TNF- and a subsequent IL-6 peak. The innate 
capacity of PMs to produce TNF, IL-6 and IL-1 was already elevated the first 
hour post-CLP. LPS stimulation revealed a suppressed IL-1 and IL-6 
production capacity and only a late suppression of TNF production. Since AM 
did not exert high innate cytokine production, it was concluded that PMs are 
major contributors to serum cytokine concentrations in this setting267. The 
mechanism proposed for this late macrophage dysfunction was a markedly 
increased PM apoptosis . Furthermore, it was demonstrated that these 
results were independent of endotoxin tolerance . Others have 
demonstrated steadily increasing tissue mRNA expression of TNF and IL-1 on 
post-CLP PMs, while antigen presenting activity, as measured by la antigen 
(MHC class II for the mouse) mRNA expression, decreased dramatically · 
. Thus it appears that during sepsis a functional shift occurs from antigen 
presentation activity to secretory functions of PMs312. An increased 
susceptibility to a septic challenge by CLP has been described by hemorrhage 
induced changes in PM characteristics. Whi le ex-vivo stimulated TNF and IL-1 
concentrations were not elevated, antigen presentation and phagocytic activity 
(diminished Fc and C3b receptor positivity) were decreased332,333. So remote 
tissue injury can change PM functional activity in sepsis. 
A recent study in a model of zymosan-induced MODS, showed that serum 
TNF concentrations were triphasic (an early and late peak), IL-6 
concentrations were only elevated the first days, and IL-1 " ' concentrations 
were only slightly elevated. Both the innate and stimulated PM cytokine 
production were suppressed during the first hours post-zymosan. However, 
while IL-1 and IL-6 production capacity remained suppressed, TNF production 
capacity was restored during the development of MODS133 . TNF release by 
PMs is strongly augmented by prestimulation with zymosan, which explains 
why PMs ¡η the late phase have an increased reprogrammed production 
capacity for T N F 3 3 4 . These result are in contrast with the late PM 
hyporesponsiveness observed in the CLP model, emphasizing the notion that 
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certain mechanisms are model dependent267. Hence, these data demonstrate a 
specific pattern in PM cytokine production during the development of MODS. 
The striking similarity between the severity of the clinical illness and PM 
production capacity of TNF suggest an important pathophysiological role of 
PMs in the development of MODS in this model. Further support for this 
hypothesis was established by the strongly increased cytotoxic activity and 
production of reactive oxygen and nitrogen intermediates by the PM during 
the evolvement of MODS in this model335. 
3.4.4 E l im ina t ion of m a c r o p h a g e s 
Most studies examining the role of macrophages in-vivo have focused on 
studying the release and blockade of various products. An alternative method 
of investigating the involvement of functional aspects of macrophages in 
various in-vivo processes is to evaluate the effect of macrophage elimination. 
Methods that have been employed include asbestos or silica336, dextran 
sulfate337, carrageenan338, ricin339, gadolinium chloride340, transforming 
growth factor-ß , anti-mononuclear serum , strontium 89 and whole 
body irradiation . However, no single method accomplishes a complete and 
selective blockade of all macrophage functions of a subpopulation of 
macrophages. Gadolinium chloride only achieves a blockade of macrophage 
phagocytic activity340. Moreover, such procedures may also affect other 
inflammatory cells or stimulate the non-depleted macrophages. For example, 
in a malaria model, silica administration induced the production of cytokines 
such as IL-6, while other methods of macrophage elimination did not . 
Carrageenan pretreatment enhanced LPS-induced TNF production and 
mortality . This might explain the conflicting results on the effects of various 
methods of macrophage elimination in experimental models. 
Liposome mediated macrophage suicide technique 
A selective and complete elimination of macrophages can be achieved by 
the "liposome mediated macrophage suicide technique". In this approach, 
dichloromethylene-bisphosphonate (Figure I, CI2MBP or clodronate) is 
delivered intracellular^ by a liposome carrier345,346(Figure 2 ) . 
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Figure I 
Chemical structure of dichloromethylene-bisphosphonate (CI2MBP) 
Bisphosphonates are effective inhibitors of osteoclastic bone resorption due 
to a binding to hydroxyapatite and a direct inhibition of osteoclasts3 4 7. Free 
CI2MBP has an extremely short half life and is not ingested by macrophages . 
Liposomes are spheres consisting of concentric phospholipid bilayers 
separated by aqueous solution. In the process of their formation they entrap 
the aqueous solution (with for example CI2MBP) in their bilayers3 4 8. 
Figure 2 
Liposomes are artificially prepared spheres, consisting of concentric 
phophohpid bilayers separated by aqueous compartments. They form, 
when phopholipds e.g. phophatidylchohne molecules, are confronted 
with water. Part of the aqueous solution together with hydrophylic 
molecules as СЦМВР (black squares) that are disolved in it, will be 
encapsulated during the formation of the liposomes. 
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Liposomes can be unilamellar or multilamellar and can be prepared from 
different phospholipids like phosphatidylcholine and cholesterol. By varying the 
charge of liposomes, delivery to certain macrophages can be differentiated. 
Macrophages in general and peritoneal macrophages in particular appear to 
prefer negatively charged liposomes . The cholesterol content may influence 
their uptake by certain 
macrophages350 , while macrophage uptake can also be enhanced by 
incorporation of mannose in their bilayers348. Using liposomes as carriers, 
CljMBP can be delivered intracellularly to macrophages since the natural fate 
of liposomes is phagocytosis by cells of the mononuclear phagocyte system351. 
Figure 3 
Liposomes with entrapped CI^MBP (solid squares) are ingested via 
endocytosis. The resulting vacuoles separate from the outer membrane 
surface of the cell and these phagosomes fuse with lysosomes (L) 
containing phopholipases (solid circles). The phospholipases disrupt the 
bilayers of the lipsomes and the drug is released in the cell.(N=nucleus, 
adapted with kind permission from N. van Rooijen) 
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Macrophages ingest the liposome encapsulated CI2MBP after which 
phosphohpases disrupt the phospholipid liposomal bilayer, with subsequent 
intracellular release of G2MBP, and in a destruction of the cell (Figure 3) In 
this respect, large multilamellar liposomes containing phosphatidylcholine and 
cholesterol have shown to be more efficient than their smaller unilamellar 
counterparts 3 4 5 3 5 2 Recent studies with radiolabelled CI2MBP, have shown 
that only one third of the original CI2MBP was still encapsulated by the time of 
ingestion by macrophages Three hours after ι ν injection no CI2MBP could be 
detected in the circulation 3 5 3 The exact mechanism of macrophage 
destruction by the intracellular delivery of CI2MBP remains to be elucidated 
However, there are indications that depletion of intracellular iron or the toxic 
effects of the t w o chlorine groups are involved 
Since a direct contact between liposomes and macrophages is mandatory 
for CljMBP-hposomes and since liposomes can not pass through the 
endothelial barrier, the route of CI2MBP-hposomes administration determines 
which macrophages are eliminated3 4 5 This provides a useful tool for 
selectively elimination of certain (sub)populations of tissue macrophages 
Intravenous injection of CI2MBP-hposome suspension results in the selective 
elimination of KCs and SMs within 2 days This elimination was confirmed by 
the absence of lysosomal acid-phosphatase activity as well as the incapacity of 
ingestion and accumulation of carbon particles , and by the physical 
absence of macrophages in ultrastructural studies Intratracheal 
administration of CI2MBP-hposome suspension eliminates AMs, but not 
interstitial macrophages in the lung within 3-5 hours 2 5 6 Intraperitoneal 
administration of two subsequent doses of CI2MBP-hposome suspension 
eliminates peritoneal, omental and to a lesser extent liver and spleen 
macrophages within 4 days3 2 3 3 5 8 Subcutaneous administration of CI2MBP-
liposome suspension targets the CI2MBP-hposomes to their draining lymph 
nodes, achieving a long lasting elimination of macrophages at that location 
within 5 days3 5 9 36° Orally administered distearoyl phosphatidylcholine 
CI2MBP-liposomes have been shown to eliminate macrophages (M-cells) in 
Peyer's patches3 6 1 Also, in-vitro macrophage cell lines may be manipulated 
with CI2MBP-hposomes3 5 5 3 6 2 _ 3 6 4 Furthermore, mtra-articular administration 
and direct injection in testicular tissue resulted in the elimination of synovial 
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lining phagocytic cells and testicular macrophages respectively · . 
Repopulation kinetics differ considerably between various macrophage 
subpopulations. Depending on the type of macrophage, SMs are repopulated 
after 7 days (red pulp macrophages) or more than 2 months (marginal zone 
macrophages). KCs repopulate after 7 days3 5 6. AMs repopulation starts after 5 
days and is complete after 18 days2 5 6. Intraperitoneal elimination of 
macrophages reveals repopulation of PMs after 7 days and macrophages of the 
omentum after 7-28 days3 5 8. Elimination of macrophages in lymph nodes is 
quite persistent since repopulation takes 5 months 3 6 7 . However, it should be 
noted that repopulation could be enhanced by stimulating the immune res­
ponse with Freund's adjuvant 3 5 8 , 3 6 7 . 
Concerning the use of CI2MBP-liposomes some critical remarks should be 
made. Control experiments generally use saline, sham treatment or no 
treatment, but the question has been raised whether or not empty liposomes 
should be used. Control animals should have normal non-manipulated 
macrophages. However, empty liposomes may temporarily block phagocytic 
activity of macrophages 3 6 8 , 3 6 9 , rendering them unfit for control experiments. 
CI2MBP-liposomes have not been proven t o influence other cells than those 
derived from the mononuclear cell line. PMNs are neither morphologically, 
nor functionally affected by CI2MBP-liposomes and only monocytes have been 
shown to be influenced ' . However, there are indications that non-
depleted macrophages demonstrate an increased activity as shown in the 
spleen and lung 3 5 2 . 
In conclusion, CI2MBP-liposome-mediated elimination of macrophages is 
very useful to examine the in-vivo role of certain macrophage populations in 
various murine experimental models. 
CI 2 MBP-liposomes in models of infection and inf lammation 
Experimental models studying infection and inflammation in combination 
with CI2MBP-liposome mediated elimination of macrophages have 
concentrated on the effects of LPS administration and microbial resistance. 
Elimination of KCs and SMs abrogated LPS induced symptoms but did not 
prevent lethality2 3 9. Others have confirmed an attenuation of thermogenesis 
and oxygen consumption after non-lethal doses of LPS . In addition 
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macrophage dependent thermogenesis was not linked t o IL-6 but to IL-1 
dependent mechanisms 3 7 1 , 3 7 2 . Suppression of endotoxin-induced К С priming 
after elimination of KCs in-vivo has also been shown 3 7 3 . Elimination of KCs 
and SMs achieves an almost complete reduction of LPS induced IL-1, IL-6, IL­
IO, and IL-12 mRNA production in the liver. TNF mRNA was reduced by 50-
75%. IL-1, IL-6, IL-12, IL-1 ra mRNA, but not IL-10 and TNFmRNA in the 
spleen were reduced 3 0 3 . These data show that KCs and SMs are the primary 
producers of those cytokines in these organs. Furthermore, elimination of 
KCs and SMs appears to decrease microbial resistance, since it has been 
shown to increase the susceptibility to disseminated candidiasis, Listeria 
monocytogenes, HSV-2 and malaria infections 2 4 0 " 2 4 2 . Elimination of AMs has 
been shown to increase the immune response to T-cell dependent antigens, 
while exhibiting no effect on T-cell independent ant igens 2 5 6 , 3 7 4 . Furthermore, 
it has been demonstrated that antigen presenting cells increased in number 
after elimination of AMs 2 5 5 . Others have shown an attenuation of the 
recruitment of PMNs and TNF release into the alveolar space after 
intratracheal administration of LPS by macrophage elimination . 
3.4.5 Arguments pro and contra limiting macrophage 
hyperreactivity in SIRS, A R D S or M O D S 
As substantiated by the numerous supporting arguments mentioned above, 
limiting macrophage hyperactivity could be beneficial in patients with an 9 | 
excessive generalized inflammatory response i.e. patients developing SIRS, 
ARDS or MODS. Indeed, anti-cytokine strategies have shown t o be very 
promising in experimental models. However, till now, application of those 
strategies in patients developing MODS has failed to demonstrate any 
beneficial effects1 3 9 . 
In contrast with this hypothesis, there are also indications that augmenting 
macrophage function could be beneficial in SIRS, ARDS or MODS. For 
example, the administration of cytokines has been shown to be protective in 
various models, supporting the fact that macrophage activation and the 
subsequent release of cytokines might have an important role in host defense 
against injurious stimuli. Administration of low dose TNF has been shown t o 
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be beneficial in models of peritonitis and endotoxic shock' 
Administration of low dose recombinant IL-1 α and β has been shown to be 
protective against lethal doses of LPS226 2 2 7 , severe infections2 2 8 2 2 9 and in 
models of peritonitis and abdominal sepsis2 2 7 23° 2 3 1 or burn sepsis232 
Augmenting host defense by the administration of poly-glucotnosyl-
glucopyranose (PGG)-glucan, a strong immunostimulator and potent 
macrophage stimulant, has been shown to increase the number of PMNs and 
macrophages, induce early IL-1 release, and improve survival in models of 
E coli induced peritonit is 2 3 3 2 3 5 and candidiasis236 Furthermore, two recent 
clinical double blind placebo controlled trials in patients undergoing major 
surgery or with multiple trauma, have shown that activation of macrophages 
with PGG-glucan reduced mortality, infectious complications, antibiotic 
requirements and length of ICU stay2 3 7 2 3 8 
Elimination of liver and splenic macrophages by liposome encapsulated 
clonodrate in a model of LPS induced mortality, decreased symptoms but did 
not decrease mortal i ty 2 3 9 Others have shown that eliminating KCs and SMs 
appears to decrease microbial resistance, since it increases susceptibility to 
disseminated candidiasis, Listeria monocytogenes, Herpes simplex virus-2 and 
malaria infections2 4 0 2 4 2 On the other hand, although blockade of Kupffer cell 
phagocytic activity by gadolinium chloride in the CLP model resulted in a 
restoration of CLP-mduced depression of systemic cell-mediated 
immunosuppression Mortality, however, was increased 
92 It appears from these data that macrophages have a variable regulatory 
action in the inflammatory response leading t o MODS Certain macrophage 
functions or populations are essential in host defense, while others can be 
detrimental to the host Hence, it has to be determined in the future, which 
macrophage functions or populations are essential and need to be stimulated, 
while others may be detrimental and might require modulation 
3.5 C O N C L U S I O N 
In conclusion, the data presented in this chapter provide an extensive 
support for a concomitant activation of various components of the 
inflammatory response such as the complement cascade, PMNs, endothelium 
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and macrophages during the development of MODS. The exact role of these 
mediators and cells in the development of MODS needs further clarification. 
Selective elimination or blockade of these mediators and cells in an 
experimental model for MODS could provide us more insight in their in-vivo 
role in MODS. 
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S~L.r,,£S 0\ T~iE Мсгоч Of MODS 
In order to address the questions posed ¡π the next chapter of this thesis, 
we applied the Zymosan Induced Generalized Inflammation (ZIGI) model in 
mice. In this chapter relevant aspects of zymosan and the ZIGI model will be 
discussed 
4.1 B I O C H E M I C A L C O M P O S I T I O N O F Z Y M O S A N 
Zymosan is a particulate cell wall product of the yeast Saccharomyces 
cerevisiae. It is constituted of polysaccharide chains of various molecular 
weight, containing, with some variations, 73% polysaccharides (mainly ß-glucan 
and ra-mannan), 15 % proteins, 7% lipids and inorganic components • . The 
preparation of zymosan was first described by Pillemer and the procedure 
involved boiling yeast in basic phosphate, digesting the proteins with trypsin 
and extraction with water and alcohol3. Zymosan is insoluble in water. The 
sterility of zymosan should be ascertained, and to inactivate eventual bacterial 
spores, irradiation is recommended before use when appropriate. Zymosan 
may also contain small amounts of endotoxin, which can not be demonstrated 
by Limulus assay, as zymosan itself causes a positive Limulus assay. Due to its 
non-homogeneous constitution, the biological activity of various batches of 
zymosan may vary. Using one batch per experimental set-up is therefore 
recommended. 
4.2 B I O L O G I C A L A C T I O N S OF Z Y M O S A N 
Pillemer's studies with zymosan4 led to the discovery of the alternative 
pathway of the complement system. Indeed, zymosan is a potent activator of 
the complement system, since challenging serum with zymosan in-vitro and in-
vivo at 37°C, leads to a decrease in serum-CH50 and the formation of C5a. 
The ΖI-antigen of guinea pigs, which is involved in the phagocytosis of 
zymosan by macrophages and is the complement receptor C 3 in this species, 
shows cross-reactivity with human CR3 5, indicating that this mechanism of 
complement activation was developed early during evolution. 
Zymosan is a very potent pro-inflammatory substance which is 
demonstrated by the following biological actions: 
Смдртрр 4 
ZIGI THE EXPÉRIMENTAI MODEL 
In-vitro and in-vivo ( intraperitoneal (IP), intrathoracic and/or intravenous 
(IV)) administration of zymosan leads to a strong activation of phagocytes, 
stimulating Chemotaxis and phagocytosis Zymosan induces an increase in 
PMN count, in PMN production of LTB4, TxB2 and oxygen radicals (oxidative 
burst), and induces the extracellular release of elastase, lactofernn and 
myeloperoxydase from PMNs6 Zymosan is commonly used for m-vitro testing 
of phagocytic activity 
Unopsonized zymosan is also a potent activator of macrophages After 
zymosan is phagocytosed, macrophages are stimulated to release lysosomal 
enzymes8, reactive oxygen metabolites, arachidonic acid9 and TNF1 0 The 
interaction between zymosan and macrophages appears to be mediated by 
three classes of cell surface receptors, namely the mannose/fucose receptor 
l2
, the ß-glucan receptor13 l 4 and the CR3 (CD I lb /CD 18) receptor15"17 
Furthermore, zymosan induces the proliferation of Kupffer cells in vivo , 
enhances PGE2 synthesis of rat mesangial cells and stimulates angiogenesis in 
the chick embryo yolk sac assay Zymosan induces also degranulation of mast-
cells with release of histamine Intraperitoneal administration produces a 
sustained release of TNF by peritoneal macrophages19 
4.3 E X P E R I M E N T A L USE O F Z Y M O S A N 
Zymosan activated plasma has been utilized in in-vivo experiments to 
induce ARDS in rabbits 2 I , and as an adjunctive stimulus in inducing trauma- ι 15 
tic shock in the baboon . Intravenous administration of zymosan in 
experimental animals causes a septic shock-like state2 3 2 4 IP inoculation in 
rats, when using a dose of 3 mg per 100 g body weight, induces a profound 
resistance to £ coli peritonitis, increasing phagocytosis and bacterial killing2 5 
Low dose IP zymosan (1-5 mg/100 g body weight) in rabbits increases 
circulating C5a and PGI 2 2 6 Similar doses administered IP in mice induce the 
extracellular release of phospholipase-A2 
4.4 Z I G I M O D E L 
High dose IP inoculation (100 mg/100 g body weight) in rats, mice and 
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rabbits causes an early SIRS-like hyperdynamic response with shock, fever, 
lethargy, ruffled fur, hemorrhagic fluid from the nose and conjunctivae, and 
diarrhea. In this phase, a score of changes have been documented, such as 
ARDS, the release of oxygen radicals28, 29, a severe drop in plasma, lung and 
liver anti-oxidant capacity as shown by low GSH-levels30, increased production 
of PAF and eicosanoids31,32, decreased PMN counts, increased plasma levels 
of TNF and IL-6,33"35, increased oxygen consumption36, bacterial translocation 
from the gut3 7 , 3 8 , and an early mortality of approximately 35%. After a 
recovery phase from day 3 to 6 after inoculation, during which the 
experimental animals behave rather normally, a late hypodynamic MODS 
phase sets in. This phase is characterized by a mortality of approximately 15%, 
severe ARDS, hypothermia, impaired liver function, lethargy, low oxygen 
consumption, lactacidemia, high PMN- and platelet counts36, increased plasma 
levels é& TNF , and peritoneal macrophage cytotoxic capacity and 
production of reactive oxygen and nitrogen intermediates together with a 
decreased anti-oxidant capacity in the lung concurrent with a mononuclear 
cell invasion39"41 . Histopathological changes in various organs indicate a 
gradual development to a generalized inflammatory response with tissue 
injury36 42, 43. Shortly after zymosan challenge, an increased lung permeability 
index and myeloperoxydase activity, and decreased wet:dry weight ratios of 
lung, liver, spleen, kidney and bowel have been demonstrated34. Others 
confirmed this early increased endothelial permeability in various organs . 
I | 6 Recently is has been demonstrated that during the evolution of MODS 
wet:dry weight ratios of lung, liver, spleen and kidneys were decreased, 
indicating a generalized tissue edema42. All these changes appear to be 
independent of the presence of bacteria or endotoxin36, 4 5 , 4 6 . 
Hence, this model provides an experimental setting for bacteria- and 
endotoxin-independent development of MODS, due to a generalized 
inflammatory response and has been coined as the ZIGI-model3 6 , 4 ·4 6 . The 
ZIGI-model has been introduced by Goris et al. and validated by various other 
groups34 ,36 , 43. The major importance of this model is that it is of a non-
bacterial origin and that it is one of the few chronic experimental models for 
MODS. Most other experimental models are acute models with an end point 
of minutes or maximally 2-5 days47"50. Furthermore, most of these models are 
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Figure I 
Schematic representation of the Zymosan Induced Generalized 
Inflammation (ZIGI) model. 
intoxication models using a single bolus injection of LPS or bacteria. In our 
critically ill patients LPS or bacteria are not released as a high dose bolus, but 
in a temporal low dose pattern. While these models are very suitable for 
revealing pathophysiological mechanisms, they do not represent a clinical 
situation. For this reason, studies that involve the direct intravascular infusion 
of bacteria or LPS should be interpreted cautiously, especially with respect t o 
outcome 4 8 . For example, anti-TNF therapy has been shown to reduce 
mortality in models of intravascular infusion of bacteria or endotoxin, 
however it could not prevent mortality in a model of bacterial peritonit is5 1. 
Since it requires at least 5 to 7 days after the initial event to fully develop 
MODS in our critically ill patients, chronic models are more likely t o be of 
clinical relevance5 2. To date, there are only t w o chronic models i.e. the Cecal 
Ligation and Puncture (CLP)-model and the ZIGI-model. In the CLP-model, 
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the cecum is ligated through a midline laparotomy, and punctured with needles 
in various sizes, depending on the severity of the insult5 0. Animals in the first 
24 hours are referred t o have "early sepsis", with a hyperdynamic circulatory 
response. After this period the animals are referred t o have "late sepsis" with 
a hypodynamic circulatory response. Mortality depends on the size of the 
needle, and varies between 40-100 %. The CLP model represents the 
consequences of a slowly progressive bacterial peritonitis, but is not a model 
for MODS per se. To date, the ZIGI model is the only long term experimental 
animal model of MODS 3 6 . 
4.5 C O N C L U S I O N 
Zymosan is a potent in-vitro and in-vivo activator of multiple pro­
inflammatory activities. In-vitro it is widely used to stimulate phagocytes. 
Depending on its dosage, zymosan may be utilized experimentally in-vivo to 
increase the resistance to infection, or to induce a generalized inflammatory 
response with shock, ARDS and MODS, providing us with a unique model to 
study MODS (ZIGI-model). 
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ST4DILS ON THE MOWR Of MODS 
The aim of this thesis is to elucidate the m-vivo causative role of various 
inflammatory mediators and cells in an experimental model for MODS We 
were focused on the endothelium (i.e. permeability changes), complement 
system and macrophages. To delineate the concurrent endothelial damage 
during the development of MODS, scintigraphic methods were used to assess 
permeability changes To study the relationship between complement and 
macrophage activation and the evolution of SIRS, ARDS and MODS, genetic 
deficiencies and elimination methods of those mediators and cells were 
applied The following questions were addressed in the experimental studies 
I Does endothelial damage, as measured by permeability changes using 
scintigraphic methods (ι e. " 'ind-IgG scanning), occur in various organs 
(hart, muscle, lung, liver, spleen, ileum, colon and MLN) in our MODS 
model.' Is there a temporal pattern and do permeability changes have a 
relationship with subsequent organ damage' 
2. Does activation of the complement system, especially factor C5a, play a 
pivotal role in the development of MODS? Can we prevent or attenuate 
the clinical syndrome, organ damage or mortality by using genetically C5-
deficient animals in our model for MODS? 
Macrophages have an important biological protective function in host defense 
However, it has been hypothesized that excessive activation of macrophages 
can be detrimental and could result in the development of MODS In our ZIGI 
model three aspects are important: 
• A hyperdynamic (SIRS) early phase with a high mortality 
• Early bacterial translocation during the early phase. 
• A late hypodynamic (MODS) phase with concurrent mortality and organ 
damage independent from bacteria 
Hence, in this model we are able to study Ф е connections between bacterial 
translocation, SIRS and the development of MODS In this context the 
following questions were posed: 
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3 Does CI2MBP-hposome mediated elimination of Kupffer cells and splenic 
macrophages prevent or attenuate the early inflammatory response in this 
model ' 
Would the observations change when bacterial overgrowth was induced' 
Does CI2MBP-liposome mediated elimination of certain subpopulations of 
macrophages (ι e Kupffer cells, alveolar, splenic and peritoneal 
macrophages) before and after zymosan challenge affect the late 
hypodynamic MODS phase' 
4 Because bacterial translocation is an early phenomenon in this model and 
normal host defense could theoretically be impaired by macrophage 
elimination, the following questions were asked 
• What are the effects of macrophage elimination on the concurrent 
bacterial translocation and spread of bacteria' 
• Would the observations change when bacterial overgrowth was 
induced' 
• H o w do these phenomena relate to the development of MODS' 
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CHAPTER 5 
MODS and Endothelial Permeability 
Organ damage is preceded by changes in protein extravasation in an 
experimental model of the Multiple Organ Dysfunction Syndrome. 
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6.1 ABSTRACT 
Objective: to determine the serial evolution of vascular permeability as measured by 
protein extravasation in various organs during the development of zymosan induced 
multiple organ dysfunction syndrome (MODS). W e evaluated the biodistribution of 
' ' ' indium labeled nonspecific polyclonal immunoglobulin G (' ' 4n-lgG). 
Materials and Methods: on days 2, 5, 8 and 12 after intraperitoneal challenge with I 
mg/g zymosan, mice were sacrificed. Heart, liver, spleen, kidneys and the mesenteric 
lymph node complex and tissue samples of muscle, ileum and colon were dissected 
free and weighed. 24 h before sacrifice 10 pg IgG labeled with 2 MBq ' ' ' in was 
injected ¡.v. Relative organ weights (ROW) , wet to dry weight ratio's (WDR) and a 
permeability index (PI) were calculated 
Results. R O W increased gradually until day 12. W D R also increased gradually in most 
organs Lung W D R , however, initially increased with a subsequent return to normal. 
Splenic W D R did not change over time. Liver, spleen, ileum and colon PI were the 
highest on day 2, fol lowed by a decrease towards normal. Lung PI showed a triphasic 
course with peak values at days 2 and 12. Mesenteric lymph node complex-PI was 
continuously elevated. 
Conclusion: W D R (tissue edema) and PI (protein extravasation) have different courses 
in various organs. Most organs displayed an early increase in PI, followed by a late 
decrease, while R O W (organ damage) was still increasing. It appears that organ 
damage is preceded by an increased protein extravasation. 
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6.2 I N T R O D U C T I O N 
Inflammation is defined as a localized protective response elicited by injury 
or destruction of tissues, which serves to destroy, dilute, or sequester both 
the injurious agent and the injured tissues'. Teleologically, local inflammation is 
an adequate response, however, an excessive generalized inflammatory res-
ponse can have detrimental consequences for the host. Because patients with 
the multiple organ dysfunction syndrome (MODS) display typical 
characteristics of inflammation i.e. rubor (generalized vasodilatation), calor 
(fever), tumor (generalized edema) and functio laesa (organ dysfunction), it has 
been hypothesized that MODS results from the "hor ror autotoxicus" of an 
autodestructive generalized inflammatory response . 
One of the main targets of an inflammatory response is the vascular 
endothelium, which under normal circumstances maintains a homeostatic 
equilibrium of fluid shifts between the tissue and intravascular compartments4. 
An inflammatory response however, induces migration, adherence, activation 
and infiltration of polymorphonuclear granulocytes (PMN), which release 
oxygen radicals and proteases injuring endothelial cells5. Subsequently these 
interactions between endothelial and inflammatory cells induce profound 
structural and functional changes in the barrier function of the vascular 
endothelium resulting in a capillary leakage syndrome and subsequent tissue 
edema4. 
Most clinical studies on endothelial permeability in critically ill patients have 129 
focused on lung vascular permeability changes in relation to the development 
of the adult respiratory distress syndrome (ARDS)6"9 .Only a few have 
demonstrated a generalized altered permeability in sepsis10. Permeability 
changes in other organs have been investigated in experimental sepsis or 
shock models' '" '5 . Postmortem studies suggest that such permeability changes 
also occur in patients with MODS. Their organs reveal signs of generalized 
endothelial damage such as overall increased organ wet weights and 
morphological evidence of a systemic inflammatory response with pronounced 
PMN and monocytic invasion. The organs also demonstrate diffuse 
microvascular damage with concurrent severe interstitial protein rich edema 
and cell necrosis in the lungs, liver, spleen, kidneys and heart16, '7. However, 
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to date, a direct measurement of vascular permeability in relation to the 
development of MODS has not been reported 
We have established an experimental model in which zymosan induced 
generalized inflammation, leads to M O D S 1 8 2 I An intraperitoneal zymosan 
challenge induces an early hyperdynamic response with concurrent bacterial 
translocation and gut-derived septicemia, and a late bacteria independent 
hypodynamic MODS phase with a generalized inflammatory response and 
organ dysfunction2 2 2 3 To determine changes in permeability during the 
development of MODS in this model we studied the serial evolution of 
extravasation of ' ' ' indium labeled non-specific polyclonal immunoglobulin G 
(' ' Ίη-lgG) as a function of time after zymosan challenge 
1
 ' Ίη-lgG scintigraphy was originally introduced to detect and localize 
various types of focal infection2 4 2 5 However, recent data have shown that 
accumulation of ' ' Ίη-lgG in inflammatory foci is not mediated by specific Fc-
receptor binding of the IgG part, but more by a nonspecific increased vascular 
permeability and a subsequent local macromolecular entrapment of the ' " i n 
molecule in the tissues2 6 2 7 Furthermore, IgG as a protein has the advantage 
of a low accumulation in noninflamed tissues compared to other proteins, 
resulting in high target-to-nontarget ratios 2 7 ' ' ' Ιη-lgG shows no efflux from a 
focus, but accumulates over a period of up to a week This occurs due to 
dissociation of the ' " i n from the IgG with a subsequent retention of " In in a 
focus (especially in the first 48 hours) while part of the deposited IgG is 
I 30 washed o u t 2 8 2 9 Because the ' " i n and not the IgG itself is measured, the 
uptake in a focus reflects the influx of protein only 2 8 The radioactivity 
measured therefore indicates the degree of inflammatory activity caused by an 
increased extravasation of large proteins Moreover, ' ' Ίη-lgG scintigraphy has 
been shown to be a useful marker of inflammation in a wide variety of diseases 
in clinical practice3 0 
6.3 M A T E R I A L S A N D M E T H O D S 
A n i m a l s 
Specific pathogen free male inbred C57BI/6 mice (Charles Rivers, Wiga, 
Germany) of 6-8 weeks old were adapted to handling in their cages for 7 days 
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before the start of the actual experiment. Throughout the experiment, all 
mice had free access t o water acidified with hydrochloric acid to a pH of 3. 
They were fed with standard mice laboratory chow (RMH-GS pellets, Hope 
Farms, Woerden, The Netherlands) irradiated at 10 kGy. Room temperature 
was kept constant at 2 Г С and a 12 hour lighting cycle was maintained. The 
experiments were approved by the Animal Ethics Review Committee of the 
Medical Faculty, University of Nijmegen. 
Zymosan 
Zymosan A ( Sigma Chemicals, St. Louis, MO) was γ-irradiated with 5 kGy 
and suspended (2.5 g/100 ml) by high frequency vibration in liquid paraffin (60-
80 mPa, European pharmacopea PA.S.68.81 CP84602I) for 60 min at 40°C. 
The suspension was sterilized at I00°C for 80 min.. Before use, the sus­
pension was warmed t o 40°C and vibrated at high frequency for 15 min. 
Sterility was verified by aerobic incubation on a blood-agar medium for 2 days. 
The zymosan suspension was administered in a dose of I mg of zymosan 
suspended in 0.04 ml of paraffin per gram of body weight. 
Indium-1 I 1-lgG 
Bicyclic diethylenetriaminpentaacetic anhydride (bicyclic DTPA) was 
conjugated t o human nonspecific polyclonal immunoglobulin G (Sandoglobulin, 
Sandoz AG, Nürnberg, Germany) according to the method of Hnatowich et 
al. . Two to three DTPA ligands were coupled to one IgG molecule. The 
purified DTPA-conjugated IgG was diluted to 2 mg/ml with 0.15 M acetate (pH 
= 6.5) and sterilized by membrane filtration. Aliquots of 0.5 ml of the I 3 | 
conjugate were radiolabeled with ' " i n (Indium chloride, Mallinckrodt Medical, 
Petten, The Netherlands) via citrate transchelation. Radiochemical purity was 
determined by instant thin layer chromatography (ITLC) on Gelman ITLC-SG 
strips (Gelman Laboratories, Ann Arbor, Ml) with 0.1 M citrate (pH = 5) as 
solvent. Labeling efficacy was higher than 95%. 
Experimental design 
One hundred and eighty mice were randomly assigned to five groups: 
control animals (n=20) and experimental animals scheduled for sacrifice on 
day 2 (n=40), day 5 (n=40), day 8 (n=40) and day 12 (n=40) after the zymosan 
injection on day 0. Control animals did not receive an injection at all and were 
sacrificed on day 0. Body weight and rectal temperature were measured daily. 
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Clinical condition with possible symptoms such as loss of hemorrhagic fluid 
from the nose, conjunctiva and mouth, lethargy, anorexia, hyperventilation, 
ruffled fur and loss of liquid stools and mortality were monitored. 24 h before 
sacrifice, all mice received an intravenous injection of 10 pg IgG labeled with 2 
MBq ' " i n . On the day of sacrifice the mice were anesthetized, bled by ocular 
extraction and killed by cervical dislocation. Subsequently, heart, liver, spleen, 
kidneys and the mesenteric lymph node complex (MLN) were dissected free. 
Tissue samples of muscle, ileum and colon were collected and weighed 
Relative organ weights (ROW) of heart, lungs, liver, spleen and kidneys were 
calculated using the formula: R O W = (wet organ weight/ body weight) χ 
100%. The activity of the blood, organs and tissue samples were measured in a 
shielded well type gamma counter. To correct for radioactive decay and to 
permit calculation of the uptake of the radiopharmaceuticals in each organ as 
fraction of the injected dose, aliquots of the respective doses were counted 
simultaneously. After these measurements tissue samples and organs were 
vacuum dried for 48 hours to determine the dry weight The measured 
activity in tissues was calculated as percentage of the injected dose per dry 
weight (%ID/g) Blood %ID/g was expressed per wet weight The applied ' ' ' ln-
IgG scintigraphy is a single isotope technique and harbors the theoretical 
disadvantage of biasing background activity of the blood To eliminate this 
interference in our study, however, we have completely exsanguinated the 
animals Furthermore, we measured all tissue activity in relation to the blood 
activity as the permeability index (PI) t o eliminate differences in blood activity 
PI was calculated using the formula: PI = %ID per gram tissue / %ID per gram 
blood. Wet weight to dry weight ratios (WDR) were calculated to determine 
the extent of tissue edema. 
Statistical analysis 
All values are expressed as mean ± SEM Comparisons were made between 
treatment groups and the control group. The nonparametric Kruskal-Wallis 
and Wilcoxon t w o sample tests were used for statistical analysis To correct 
for the fact that multiple comparisons were made with one control group, a 
level of significance of occ= 2 a / к was used, where к is the total number of 
comparisons Thus, with α = 0.05, differences between each of the four 
treatment groups and the control group (figs 2 and 3) were considered signifi-
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cant at ρ (a c ) < 0.025. 
6.4 RESULTS 
Zymosan challenge induced a typical triphasic illness. In the acute phase 
(days 0-4) the mice were lethargic and anorectic, hyperventilated, had diarrhea 
and showed hemorrhagic discharge from the nose and conjunctivae. As 
depicted in Fig. I, both body weight and body temperature declined 
dramatically in this phase. After 2 days the condition of the surviving mice 
improved as demonstrated by an increase in temperature and body weight. 
However, after 7 days clinical condition started to deteriorate progressively 
with the mice becoming more lethargic, dyspneic and again losing hemorrhagic 
fluid from the nose and conjunctivae. This deterioration was illustrated by the 
decrease in temperature and body weight Mortality was 40% (16 of 40) in the 
day 2 group, 42 5% ( 17 of 40) in the day 5 group, 17.5% (7 of 40) in the day 8 
group and 50% (20 of 40) in the day 12 group 
Inspection of the organs 2 days after zymosan challenge showed little 
abnormalities except a hyperemic aspect of the lungs and an extensive 
distention of the digestive tract with a hyperemic peritoneum After 12 days 
the lungs were extremely hyperemic with hemorrhagic spots and frequently 
hemorrhagic infarction. The abdomen demonstrated a fibroplastic peritonitis 
with massive adhesions but without any abscesses Most organs were 
macroscopically enlarged. After 5 and 8 days the latter changes were also 
present but less pronounced. 
As shown in Fig. 2, although no significant changes were found in heart and 
kidney relative weight, R O W of lungs, liver and spleen increased gradually 
from day 2 until day 12. Earlier experiments have shown a close relationship 
between the increase in R O W and microscopic organ damage22 
Changes in protein extravasation expressed as the PI in all organs are 
shown in Fig ЗА. When compared with control values, PI was increased 
significantly on days 5, 8 and 12 in the muscle, on days 5 and 8 in the heart, on 
days 2 and 5 in the spleen, and on all days in the lungs, liver, ileum, colon and 
MLN The PI did not change in the kidney. When focusing on the time course 
of PI during the development of MODS, lung PI showed a typical triphasic 
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Figure I 
Cumulative body temperature and body weight of all surviving mice 
until their respective day of sacrifice calculated as the percentage 
change when compared to day 0. Open ardes indicate control mice, solid 
ardes indicate mice challenged with zymosan . Data are expressed as 
mean ± SEM. Comparisons were made with control values on the same 
day: *: p<0.05, **:p<0 0 l . 
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Figure 2 
ROW at 2, 5, 8 and 12 days after zymosan injection ROW was 
calculated using the formula (organ weight/body weight)xlOO% Data 
are expressed as mean ± SEM Comparisons were made with the 
control group л : p<0 01 
course. Liver, spleen, ileum and colon PI demonstrated the highest activity on 
day 2, followed by a gradual decrease towards normal values. Muscle PI was 
the highest on day 5, with a gradual decrease towards normal 
values thereafter. The PI in the MLN was constantly elevated after zymosan 
injection, and in the kidneys PI was hardly changed. 
The course of W D R is shown in Fig. 3B. Although not all changes were 
statistically significant at all time points, most organs demonstrated a gradual 
increase in WDR. However, the lungs and spleen showed a different pattern. 
Lung W D R showed an initial rise in the early phase, with a maximum on day 5 
and returning to normal in the late phase. Spleen W D R appeared not to 
change over time. 
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Figure 3 
( A ) PI of different organs at 2, 5, 8 and 12 days after zymosan challenge. 
Tissue PI was calculated as fol lows: percentage of the injected dose per 
gram tissue dry weight / percentage of the injected dose per gram blood 
wet weight. ( B ) Tissue W D R of different organs at 2, 5, 8 and 12 days 
after zymosan challenge. Data are expressed as mean ± SEM. 
Comparisons were made w i t h the contro l group: *: p<0.025, **: 
p < 0 . 0 l . 
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6.5 D I S C U S S I O N 
An important finding from the present study was that in most organs the 
highest PI was measured in the early hyperdynamic phase 2 days after zymosan 
challenge and that lung, liver and splenic organ damage as measured by the 
ROW was preceded by an increased protein extravasation. Furthermore, 
while these organs demonstrated a decreasing PI on the subsequent days, 
organ damage was still increasing. These data suggest that an initial increase in 
protein extravasation, observed the first days after zymosan challenge, 
precedes late organ damage. This is in line with a clinical study in which the 
pulmonary accumulation of ' l3 ln-transferrm anticipated the observed 
radiological changes in a patient developing ARDS32. On the other hand, the 
development of the systemic inflammatory response syndrome (SIRS) has been 
associated with a continuous rise in extravascular lung water content (EVLW) 
and pulmonary vascular permeability, as measured by transvascular 99mTc 
labeled albumin flux, while non-SIRS patients displayed a decrease9,33. We 
cannot conclude from the present study, however, whether there is a causal 
relationship between organ damage and changes in protein extravasation. As 
serial measurements were not performed in the same animal, we are cautious 
of drawing conclusions from the course of PI over time. Sequential organ 
damage was not studied on a histological basis extensively as earlier studies 
have demonstrated a gradually increasing infiltration of inflammatory cells, 
interstitial and cellular edema, and cell injury in almost every organ, closely 
correlating with ROW 1 9 22. Furthermore, postmortem studies in patients with 
MODS have shown that organ weights correlated well with organ damage16 
17
 Hence, the relationship between R O W (as far as available) and PI was 
studied, to evaluate the relationship of organ damage and PI. 
Other experimental studies have shown an increased generalized 
permeability m models after local infection, infusion of endotoxin or live 
bacteria or sepsis. A generalized increased protein extravasation in the 
muscle, liver, spleen, kidneys and bone marrow, measured with In-lgG-
scmtigraphy, was reported shortly after hindhmb intramuscular injection with 
live Escherichia coli or Staphylococcus aureus in rats26 27. Endotoxin infusion in 
sheep and pigs has been shown to induce a transvascular albumin flux in lungs, 
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spleen, liver and abdomen, as measured with double isotope techniques 
Lymph flow studies m sheep have demonstrated evidence of an increased 
pulmonary and peripheral microvascular permeability in a model of abdominal 
sepsis34 35 Histological studies in the cecal ligation and puncture (CLP) model 
in sheep, which is a model of chronic abdominal sepsis, have demonstrated an 
intracellular and high-protein intercellular edema, as well as patchy cell injury 
in the lungs, myocardium, striated muscle, liver and pancreas All those 
studies, however, document only early changes in models which only 
represent the early hyperdynamic response observed in sepsis They do not 
examine the hypodynamic response seen in patients with MODS Direct 
clinical evidence on permeability changes during the development of MODS 
has only been obtained in the lung Using the double isotope technique, 
MODS appeared to be associated with a generalized increase in lung 
microvascular permeability, rather than a localized increased permeability as 
seen in direct lung m|ury38 Permeability changes in other organs have only 
been suggested by the demonstration of generalized protein rich edema 
In this respect, the data of the present study are interesting because they 
demonstrate permeability changes as measured by protein extravasation and 
tissue edema in both the early hyperdynamic and the late hypodynamic res-
ponse in a model that closely resembles the clinical syndrome of MODS2 
The data of colon and ileum protein extravasation are remarkable, because 
the observed early rise followed by a decrease in protein extravasation 
138 coincides with an increased bacterial translocation reported in the early phase 
of this model23 and the absence of bacterial translocation in the late phase of 
this model22 This correlates well with the particular sensitivity of the 
endothelium of the gut to ischemia-reperfusion in|ury, leading to an increased 
permeability and failure of intestinal barrier function39 
An interesting phenomenon in this study is the different course of W D R 
and PI In the early phase, most organs show a concomitant increase in W D R 
and PI, which is in line with data from studies in the CLP mode l " This is not 
remarkable, because the early phase of our model is a hyperdynamic phase, 
similar to the response observed in the CLP model22 4 0 Such a pattern was 
not found in the spleen, because PI showed the most pronounced rise in the 
early phase in this organ, whereas W D R did not change at all So, it appears 
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that tissue edema formation is not an important phenomenon in the spleen 
and that the observed changes in PI could be the result of other mechanisms 
such as immunological entrapment of the IgG-part of the ' ' ' In-IgG in the 
spleen, or because there is actually no real endothelial barrier in the splenic 
sinusoids 
The late MODS phase shows a different pattern in various organs 
Although the PI decreases or remains unchanged in heart, liver, ileum, colon 
and kidney, the W D R is still increasing This suggests that mechanisms other 
than an increased vascular permeability are responsible for the observed 
increase in tissue edema From this perspective it is important to realize that 
tissue edema is the result of a transvascular fluid and protein flux over the 
endothelial membrane which is governed by Starling forces hydrostatic 
pressure, colloid osmotic pressure and properties of the microvascular barrier 
(protein permeability)4 ' The relative importance of each of these factors can 
vary to have the same result The observed phenomenon of a decreasing PI, 
while W D R is increasing could thus be explained by a predominant influence 
of Starling forces over permeability factors Furthermore, because fluid shifts 
(WDR) depend both on endothelial permeability and the exposed surface 
area, it could be hypothesized that the occurrence of microvascular 
thrombosis, which is often observed in organs of MODS patients, could 
explain these discordant results of PI and W D R 3 3 Because scintigraphic 
techniques depend on an intact circulation, measurements theoretically can be 
biased by perfusion deficits due to micro- and macrovascular thrombosis The 
lungs demonstrate a completely different pattern, with a decrease in tissue 
edema and an increase in PI In this respect PI is underestimated, because 
histopathologic data reveal areas of hemorrhagic infarction, leading to a 
decreased number of perfused capillaries which are not accessible for 
intravenously injected ' ' ' In-IgG Our data show a remarkable similarity in 
histopathologic data of lung tissue of patients developing ARDS, with an early 
exudative phase of edema and hemorrhage (high PI, high W D R ) evolving 
through a proliferative cellular phase of organization and repair (high PI, low 
WDR) to a late fibrotic phase Because the animals were killed after 12 days, 
the latter phase may not yet be reached in our experiment4 2 Furthermore the 
triphasic pattern of lung PI was comparable with clinical data of EVLW 
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measurements in polytrauma patients with thoracic trauma, in which a late 
rise of EVLW after 7 days indicated the development of MODS 4 3 . The sharp 
decline in spleen PI could be explained by the observed histologic exhaustion 
of lymphoid tissue2 2, resulting in less entrapment of the IgG-part of the In-
IgG in the spleen or the earlier mentioned sinusoid structure of this organ. 
These observations are in line with the disappointing clinical efficacy of ' In-
IgG-scintigraphy in detecting infectious foci in the spleen . 
One could argue that in general, changes in protein extravasation do not 
really reflect organ damage and organ dysfunction, because a typical triphasic 
pattern of PI, corresponding with the clinical course, as depicted by the course 
of body temperature and body weight, was only observed in the lung. On the 
other hand, a strikingly similar course between permeability changes and organ 
damage is observed in histopathologic data of lung tissue of patients 
developing ARDS4 2. Furthermore, a clinical study of patients with ARDS 
suggested a close relationship between organ damage and increased vascular 
permeability, because changes in protein extravasation measured with the 
double isotope technique correlated remarkably well with lung function . 
However an important phenomenon, the observed altered protein 
extravasation did not correlate with another important process in an 
inflammatory response namely PMN extravasation. However, the latter 
process is an active transendothelial migration regulated by chemotactic 
factors and thus less dependent from static physical properties as the 
140 permeability of the endothelial barrier 4 6 . 
In conclusion, we have shown that changes in protein extravasation have a 
specific course in this model of MODS. In most organs an early increase in 
microvascular protein extravasation is followed by a decrease, while organ 
damage is still increasing and the animals develop a late hypodynamic MODS 
phase. Tissue edema, as measured by WDR, and vascular permeability chan­
ges, as measured by PI, are phenomena with a different time course in various 
organs. Thus, it appears that organ damage is preceded by an increased 
protein extravasation in the early hyperdynamic phase of this model. Whether 
this constitutes a true causal relationship still remains to be proven 
unequivocally. Conceptually, the phenomena observed in this study 
correspond well with the hypothesis that MODS is the result of a generalized 
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inflammatory response, with concurrent endothelial damage and consequently 
an increased vascular permeability, leading t o an increased protein 
extravasation. 
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CHAPTER 6 
MODS and the Complement System 
Deficiency of complement factor C5 reduces early mortality but does not prevent 
organ damage in an animal model of Multiple Organ Dysfunction Syndrome. 
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7.1 ABSTRACT 
Objective To evaluate the role of complement factor C5 in a model of zymosan-
mduced multiple organ dysfunction syndrome 
Materials and Methods Twenty five C5-deficient B2D10/Old and 25 C5-sufficient 
B 2 D I 0 / N e w mice received on day 0 an intraperitoneal injection with zymosan 
suspended in paraffin in a dose of I mg/g body weight Between days 0 and 12, 
biological parameters (temperature, body weight and clinical condition) were 
measured daily and mortality was monitored Clinical condition was assessed as a 
symptom score by blindly grading the degree of lethargy, conjunctivitis, diarrhea, and 
ruffled fur of each mouse on a 2-point scale (maximum score of 4) On day 12 all 
surviving mice were sacrificed and relative organ weights of lungs, liver, spleen and 
kidneys Relative organ weight was defined as (organ weight/body weight) χ 100% 
were calculated 
Results Zymosan administration induced a typical triphasic illness Deterioration of 
the clinical condit ion, as indicated by the symptom score, and the decrease in 
temperature and body weight in the acute phase were all significantly less severe in 
C5-deficient mice (all ρ < 0 005) In the late phase, no differences could be noticed in 
the courses of these biological parameters Overall mortal i ty was 2 (8%) of 25 in C5-
deficient mice and 8 (32%) of 25 in C5-sufficient mice (p=0 049), a difference that was 
mainly due t o a difference in the acute phase Organ damage, assessed as the relative 
organ weights, did not show any statistical differences for any organ between both 
strains 
Conclusions Complement factor C5 appears t o play an important role in the acute 
hyperdynamic septic response in this model However, deficiency of C5 could not 
prevent organ damage in the late multiple organ dysfunction syndrome phase This 
finding suggests that other factors must be more important in the development of the 
inflammatory response leading to multiple organ dysfunction syndrome 
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7.2 I N T R O D U C T I O N 
Despite advances in intensive care treatment, multiple organ dysfunction 
syndrome (MODS) and the adult respiratory distress syndrome (ARDS) still 
remain the most common causes of death of patients admitted to a surgical 
intensive care unit after major abdominal surgery, acute pancreatitis or severe 
trauma'. It has been hypothesized that MODS and ARDS could be the result 
of a generalized excessive autodestructive inflammatory response . Since the 
complement system is an important initiator and mediator in the inflammatory 
response3 an excessive activation of the complement system has been 
implicated in the pathogenesis of MODS and ARDS4"7. 
The complement system consists of at least 25 plasma proteins, formed by 
the liver and macrophages4, 8"10. Two pathways of complement activation 
currently are recognized: the classical pathway which is activated by antigen-
antibody complexes , and the alternative pathway which is activated by 
foreign material and tissue injury12. Both pathways converge at the breakdown 
of C3, the subsequent cleavage of C5, and the activation of the final common 
pathway3,4. C5 is divided enzymatically into C5a and C5b. C5a is both an 
anaphylatoxin and a chemotactic agent. The latter function is probably the 
most important since C5a is rapidly converted into C5a desarginine (des Arg) 
with concomitant loss of its anaphylatoxic activity. Its chemotactic activity 
stimulates activation, aggregation and adherence of polymorphonuclear 
granulocytes to the endothelium with subsequent degranulation and release of 
oxygen radicals , vasoactive substances and a variety of proteinases which can 
cause endothelial damage • l4 , ' 5 , resulting in generalized edema. The 
chemotactic activity of C5a and C5a des Arg is specifically enhanced by Gc-
globulin and is inactivated by chemotactic factor inactivator16, '7 . Pro-
inflammatory cells possess a receptor for C5a18. In addition to many 
inflammatory functions, C5a also has immunoregulatory activities. For 
example, C5a induces the release of interleukin (IL)-6 by stimulated 
monocytes19 and stimulates the production of IL-1 after binding to 
macrophages19, 22. 
C5b will participate together with C6, C7, C8 and C9 in the formation of 
the terminal complement complex. The terminal complement complex exists 
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in two analogous forms. One form exists in a fluid phase in combination with 
the S-protein: this complex is non-lytic, can be detected m plasma and 
inflammatory fluids1 9 2 2"2 4. The other form is the membrane attack complex, 
which can cause cell-lysis by penetrating lipid membranes such as the 
endothelium . Excessive complement activation can thus result in a 
generalized endothelial damage with a subsequent generalized permeability 
edema and organ injury1 3. 
We have developed a model of MODS in which an intraperitoneal injection 
of zymosan suspended in paraffin leads to a generalized inflammatory response 
and histopathological changes closely resembling the clinical entity of MODS 2 6 . 
This model has been validated in our lab and by others 2 7 " 3 0 Zymosan is a 
particulate cell wall product of the yeast Saccharomyces cerev/s/oe , containing, 
with some variations, 73% polysaccharides (mainly ß-glucan and a-mannan), 15 
% proteins, 7% lipids and inorganic components . Classically, zymosan has 
been identified as a potent activator of the alternative complement pathway32 
Unopsonized zymosan also stimulates macrophages to the release of various 
inflammatory mediators33. The interaction between zymosan and macrophages 
appears to be mediated by three classes of cell surface receptors, namely, the 
mannose/fucose receptor34, the ß-glucan receptor35 , and the CR3 (CD I I b/ 
CD 18) receptor36 
In this model, interruption of complement activation could theoretically 
lead to an attenuation of the inflammatory response which leads to the 
development of MODS. In order to test this hypothesis we utilized C5-
deficient mice in this model to evaluate the role of C5 in the development of 
MODS. 
7.3 MATERIALS A N D M E T H O D S 
Z y m o s a n 
Zymosan A (Sigma Chemicals, St. Louis, MO) was irradiated with 5 kGy 
and suspended (2 5 g/100 mL) by high frequency vibration in liquid paraffin, 
during 60 mms at 40°C This suspension was sterilized by incubation in a 
waterbath at I00°C for 80 mins. Sterility was confirmed by aerobic incubation 
on blood-agar plates for two days at 37°C Before utilization, the zymosan was 
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warmed t o 40°C and vibrated in a high frequency waterbath for 15 mm. 
Animals 
BI0D2/Old.Sn and В10D2/New.Sn mice were obtained from Jackson 
Laboratories (Bar Harbor, ME) and from Harlan Olac Limited (Bicester, UK), 
respectively. BI0D2/Old.Sn mice are congenitally C5-deficient by a deletion 
mutation on chromosome 2 3 7. The BI0D2/New.Sn mouse is the coisogenetic 
twin of the BI0D2/Old.Sn mouse, but without the mutation on chromosome 
2 3 7 . C5-deficiency in BI0D2/Old.Sn mice was shown to be accompanied by an 
almost complete absence of hemolytic complement activity . Only male mice 
were used, because female mice were reported not t o be consistent in their 
C5 concentrations3 9. Throughout the experiment, all mice were allowed free 
access t o water acidified with hydrochloric acid to pH of 3 and were fed 
standard laboratory chow (RMH-GS pellets, Hope Farms, Woerden, The 
Netherlands) irradiated at 10 kGy. Room temperature was kept constant at 
2 I ° C and a 12-hr lighting cycle was maintained The experiments were 
approved by the Animal Care Committee of the Medical Faculty of Ni|megen 
Experimental design 
Twenty five C5-deficient (BI0D2/Old.Sn.), 14 wks old and weighing 19-32 
g, and 25 control mice (BI0D2/New.Sn.), 12 wks old and weighing 22-29g, 
were adapted to handling 2 wks before t o the start of the experiment On day 
0 of the experiment, all mice received an aseptic intraperitoneal injection of 
zymosan in a dose of I mg/g body weight. Between days 0 and 12, body 
temperature, body weight and clinical condition were measured and 
monitored daily. Clinical condition was assessed as a symptom score by 
grading the severity of conjunctivitis, diarrhea, ruffled fur and lethargy in a 
blinded fashion on a 2-pomt scale (0 = none, I = present; minimum = 0, 
maximum = 4). Mortality rate was monitored daily. On day 12, all surviving 
mice were anaesthetized with aether and bled by retro-ocular puncture. The 
abdomen was opened using a sterile technique and samples of the peritoneal 
fluid were collected for aerobic and anaerobic culture on blood-agar plates for 
2 days at 37°C. Subsequently, lungs with trachea, spleen, liver and kidneys 
were inspected, dissected free and weighed. 
Relative organ weights were calculated using the formula: (organ weight/body 
weight) χ 100% In mice that died prematurely before day 12, no anaerobic 
CHAPTER 7 
STUDIES ON THE MOTOR OF MODS 
cultures were performed from the peritoneal fluid because post-mortem 
anaerobic overgrowth could be expected. 
Statistical analysis 
Statistical analysis of biological parameters (body-temperature, body-weight 
and symptom score) was performed using the distribution-free curve analysis 
according to Koziol et al.4 0. Since the zymosan-induced illness is characterized 
by distinct phases, comparisons were made both for the acute phase (days 0 
to 4) and the late phase (days 8 to 12). Relative organ weights were compared 
using the distribution-free Wilcoxon's two sample test. Non-continuous data 
(mortality rate) were analyzed using Fischer's exact test. Differences between 
groups were considered t o be statistically significant when ρ < 0.05. 
7.4 R E S U L T S 
Biological Measurements 
Intraperitoneal administration of zymosan induced a typical triphasic clinical 
illness, depicted in Fig. I as the course of the symptom scores. In the acute 
phase (days 0 to 4), the mice became lethargic, anorectic, hyperventilated, lost 
hemorrhagic fluid from the nose and conjunctivae, and had diarrhea. 
According t o the symptom score, C5-deficient animals displayed significantly 
less severe (p < 0.0001) symptoms than C5-sufficient mice. After 3 days the 
condition of the surviving mice improved: they became more active, showed 
no signs of conjunctivitis or diarrhea, and their fur was only slightly ruffled. 
Recovery of C5-deficient mice appeared to be quicker. However, after 8 days, 
the clinical condition of the mice deteriorated progressively. They became 
more lethargic and started t o lose hemorrhagic fluids from the nostrils and 
conjunctivae. C5-deficient mice deteriorated significantly slower (p < 0.0001) 
than their C5 sufficient controls. 
Fig. I shows that body-temperature declined dramatically in C5-sufficient mice 
the first day after zymosan injection. C5-deficient mice, however, showed little 
(p < 0.001) decrease in temperature. After a recovery phase, temperature 
decreased again in the late phase. A t this time no significant differences were 
noticed between both groups. 
The course of body weight was also triphasic as shown in Fig. I. Body-weight 
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Figure I 
A) Clinical condition of the surviving mice assessed as the symptom score by 
grading the seventy of con|unctivitis, diarrhea, ruffled fur and lethargy in a blinded 
fashion on a 2-point scale (0=none, l=present, minimum=0, maximum =4) Com­
plement factor C5 deficient mice showed significantly less symptoms in the acute 
and late phase B) Body temperature of the surviving mice calculated as the 
percentage change when compared to day 0 In contrast with complement factor 
C5 sufficient controls, complement factor C5-deficient mice did significantly show a 
smaller decrease in temperature m the early phase No significant differences were 
noticed in the late phase C) Body weight of the surviving mice calculated as the 
percentage change when compared to day 0 Recovery in the early phase was 
significantly better in the complement factor C5-deficient mice No significant 
differences were noticed in the late phase D) Survival rate after in|ection of 
zymosan on day 0 Overall mortality was significantly lower (p = 0 049, Fischer's 
exact test) in complement factor C5-deficient mice, mainly due to a difference in 
the acute phase In all graphs solid ardes indicate complement factor C5 sufficient 
controls and the open ardes indicate complement factor C5 deficient mice Values 
in graphs A through С are expressed as mean ± SEM 
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decreased in the acute phase. Recovery in C5-deficient mice was significantly 
better (p < 0.0001) than in the C5-sufficient controls. After this recovery 
phase, body weight declined again in both groups with a less serious decline in 
C5-deficient mice. However, this difference did not reach statistical 
significance (p = 0.0552) . 
Survival Rates 
Survival rates for both groups are depicted in Fig I. In the acute phase, 
seven C5-sufficient mice died vs. one C5-deficient mouse. N o mice died in the 
recovery phase and in the late phase one mouse died in each group. Overall 
52 
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R E L A T I V E O R G A N W E I G H T S 
Ί 
Γ Ί CS deficient 
Η Controls 
ЛШ 
Lung Liver Spleen Kidney 
Organs 
Figure 2 
Relative organ weights 12 days after zymosan i n a c t i o n . Relative organ 
weights were calculated using the formula: (organ weight/body weight) 
χ 100%. Black bars indicate complement factor C5 sufficient controls; 
grey bars, complement factor C5 deficient mice. N o significant 
differences were noticed in organ damage of the surviving mice 
(Wi lcoxon's t w o sample test). Organ weights are expressed as percen­
tage of body weight. Data are expressed as mean ± SEM. 
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mortality was 8 % (two of 25) in C5-defic'ient mice and 32% (8 of 25) in C5-
sufficient controls (p = 0.049), due mainly to the difference observed in the 
acute phase. 
Macroscopy and Relative Organ Weights 
After samples of the peritoneal fluid had been taken for anaerobic and 
aerobic bacterial cultures, the organs were dissected free and inspected. The 
organs of the mice that died in the acute phase showed little abnormalities. 
The lungs were hyperemic and in the abdomen no or few adhesions were 
found. No differences were noticed between both groups. The lungs of mice 
that died in the late phase or that were killed on day 12 were extremely 
hyperemic, with hemorrhagic spots, and occasionally extensive hemorrhagic 
infarction. The abdomen showed signs of an extensive fibroplastic peritonitis 
with massive adhesions. Although the C5-sufficient control mice showed the 
most extensive macroscopic abnormalities, no significant differences were 
found with the C5-deficient mice (data not shown). Organ damage of the 
surviving mice, assessed as the increase in relative organ weights of lungs, liver, 
spleen and kidneys is depicted in Fig. 2. No significant differences were found 
between both strains. 
Bacteriology 
All cultures of the peritoneal fluid of the surviving mice were sterile, 
thereby indicating the absence of bacterial peritonitis. 
7.5 D I S C U S S I O N 
Both clinical and experimental data have suggested a relationship between 
activation of the complement system and the pathogenesis of septic shock, 
ARDS and MODS. During septic shock, most clinical studies have shown an 
activation cf C5a. However, data are conflicting when C5a is correlated to 
prognosis. Successful treatment of septic shock was associated with a 
normalization of the C5a/C5a des Arg ratio and terminal complement com-
plex concentrations, but not of C5a concentrations25, 4 I . Other studies could 
not confirm that the severity or mortality of sepsis is correlated with a per-
sistent rise of C5a concentrations42, 43. On the other hand, a strong 
correlation was found between elevated plasma concentrations of C5a and the 
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development of ARDS , while C5a concentrations correlated with the 
severity of pulmonary failure4 5. It also has been demonstrated that C5a is 
increased in bronchoalveolar lavage fluid in patients developing ARDS, with a 
normalization after ARDS had resolved1 6. Chemotactic factor inactivator, 
which decreases C5a-directed neutrophil Chemotaxis, has been shown to be 
markedly elevated in ARDS bronchoalveolar lavage fluid. However, 
chemotactic factor inactivator-functional activity was markedly decreased, 
suggesting that patients with ARDS are functionally deficient in chemotactic 
factor inactivator with a subsequent increased ability of C5a to attract 
neutrophils4 6. Plasma terminal complement complex concentrations have been 
shown to be increased t w o days before to the onset of ARDS in septic 
patients and to be decreased immediately after resolution, suggesting that 
terminal complement complex formation could be a good predictor of 
ARDS4 7. Other studies could not confirm a relationship between C5a or 
terminal complement complex formation and the development of ARDS or 
mortality from ARDS4 3 - 4 8 , 4 9 . Only a few studies have been conducted into 
the possible relationship between complement activation and the development 
of MODS. Heideman and Hugli5 reported a possible correlation between high 
concentrations of C3a and C4a, but not of C5a, with the development of 
MODS. Nuytinck et al.6 showed a good correlation between the multiple 
organ failure score and early C l q , C3, C3 pro activator and C4 
concentrations, but not with C5a concentrations. Roumen et 
al.50demonstrated recently in patients with severe blunt trauma that an early 
increase in C3a and terminal complement complex concentrations, were 
associated with the development of MODS. However, only C3a/C3 ratios 
early after trauma, and not terminal complement complex concentrations, 
were associated with mortality. 
In most clinical studies it is difficult to interpret measured concentrations 
of C5a, since C5a, and to a lesser extent, C5a des Arg, are relatively unstable 
molecules and concentrations of C5a or C5a des Arg do not always reflect the 
level of C5a activation. C5a is rapidly cleared from the circulation and 
converted to C5a des Arg by serum carboxypeptidase. Furthermore, C5a des 
Arg is rapidly bound and removed from plasma by neutrophils5 1. The 
conflicting results concerning the correlation between septic shock, ARDS and 
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MODS, and the activation of C5a might be explained by this observation. 
In order to find a possible causal relationship between complement 
activation and the development of septic shock, ARDS and MODS, 
experiments have been performed with complement depletion and, more 
specifically, C5-depletion by using C5-deficient animals or using antibodies 
against C5a. In a porcine endotoxic shock model52, complement depletion 
with Naja haje cobra venom factor significantly improved cardiac index and 
visceral perfusion. In another porcine model53 using a continuous infusion with 
Pseudomonas aeruginosa, complement depletion resulted in less pulmonary 
failure. In a septic primate model with infusion of Escherichia coli , treatment 
before and during infusion with anti-C5a-antibodies resulted in a reduction of 
mortality, an attenuation of ARDS and decreases in the systemic 
manifestations of sepsis. Peak C5a concentrations were decreased and no 
significant differences were seen in C3a or C4a concentrations . These 
experiments were confirmed by others in an endotoxic rat model in which 
anti-C5a-antibodies attenuated the hypotensive and vascular permeability 
changes after endotoxin-induced shock. C5-deficient BI0D2/new mice showed 
less septic lung injury and early mortality in the cecal ligation and puncture 
model, although total mortality was equal to that in C5-sufficient BI0D2/old 
mice37. In another study57, it was demonstrated that C5-deficient mice were 
protected from tumor necrosis factor-endotoxin-induced mortality, shock, 
hypothermia, hemoconcentration and bowel injury. The latter study also 
showed the importance of C5 since C3-deficient mice were not protected. 
The present study shows that C5-deficient mice displayed an attenuated 
response in the acute hyperdynamic septic phase, as measured by the 
reduction in the symptom score, hypothermia and decrease in body weight. 
Overall mortality was reduced, but this reduction was mainly due to a 
decrease in the acute phase. This finding suggests that C5a might be an impor-
tant mediator in the acute hyperdynamic septic response in this model. This 
conclusion is in agreement with the above mentioned clinical studies in which 
a possible relationship is suggested between C5a activation and septic shock. It 
is also in line with the reported attenuation of the acute response in 
experimental studies with cecal ligation and puncture and TNF- or endotoxin-
induced sepsis. It has been suggested that C5a modulates the endotoxin-
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triggered TNF response. Endotoxin administration in C5-deficient mice 
resulted in markedly lower serum TNF-activity when compared to C5-
sufficient mice 5 8 . Since TNF production has been documented in the acute 
phase of our model and pre treatment with anti-TNF antibodies could 
attenuate the acute response59, the attenuation seen in C5-deficient mice 
could be TNF-mediated However, late organ damage as measured by the 
relative organ weights, was not reduced, suggesting that C5a might not be an 
important mediator in the late hypodynamic phase of this model. This finding 
is in agreement with the few clinical studies in which no relationship could be 
found between C5a activation and MODS 5 6. It is also in line with the studies 
done in the cecal ligation and puncture model where overall mortality did not 
decrease despite a decrease in acute mortality . 
Since zymosan is also an important stimulator of macrophages , we 
hypothesize that activation of C5a is not the decisive factor associated with 
the development of MODS in this model and that other factors such as 
macrophage activation may be more important in this respect Clinical 
indications, suggesting the importance of macrophage activation, are the 
association between neoptenn concentrations and a poor outcome in sepsis 
and multiple trauma patients6 0 6 I Neoptenn is a stable inactive end product 
of macrophage metabolism and a marker of macrophage activity A recent 
study has shown that early after severe blunt trauma, neopterin/creatmine 
ratios were not significantly higher in patients developing MODS. However, 
from 8 days after trauma, these ratios were significantly higher in those 
patients. This finding suggests that a late activation of macrophages is 
associated with the development of MODS. In the TNF-endotoxin-model, C5 
deficient mice were protected from TNF-endotoxm-effects. However, when 
the TNF dose was increased no protection occurred, suggesting that high 
doses of TNF act independent of the complement system . This finding 
shows that experimentally, other, more potent factors could be implicated in 
the pathogenesis of MODS. Further support for this hypothesis comes from 
the fact that in our model mortality could be reduced by elimination of liver 
and splenic macrophages with liposome encapsulated dichloro-methylene-
diphosphonate prior to zymosan administration, suggesting that macrophage 
activation is also an important mediator6 2 
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We thus conclude that C5 deficiency attenuates the acute hyperdynamic 
response, but does not prevent organ damage in a model of zymosan induced 
generalized inflammation. Thus, C5a is not the only factor involved in the late 
inflammatory response leading to MODS. 
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Macrophage eimination increases bacterial translocation and gut-origin septicemia but 
attenuates symptoms and mortality in an model of systemic inflammation. 
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8.1 ABSTRACT 
Objective Both an uncontrolled activation of macrophages and the loss of intestinal 
barrier function have been implicated in the development of adult resiratory distress 
syndrome and multiple organ dysfunction syndrome The central question tested in 
this study was whether dichloromethylene-bisphosphonate (Cl^MBP) liposome-
mediated ehmantion of hepatic and splenic macrophages would influence zymosan 
induced bacterial translocation and the zymosan-mduced generalized inflammatory 
response. 
Materials and Methods Macrophage elimination was accomplished by intravenous 
injection of 200 μ I CI^MBP-hposome suspension C o n t r o l mice received an 
intravenous injection wi th 200μΙ phosphate buffered saline T w o days later the animals 
were challenged intraper i toneal^ wi th zymosan suspended in paraffin over a dose 
response curve (0 1, 0 5 or 1.0 mg/g body weight) Twenty four hours after zymosan 
challenge, signs of systemic stress were determined, and bacterial translocation to the 
mesenteric lymph node, liver, spleen and blood was measured A separate mortality 
study was performed wi th a dose of 1.0 mg/g zymosan suspension 
Results The incidence of systemic spread of bacteria was significantly increased in the 
macrophage depleted mice Although systemic bacterial translocation was promoted 
by macrophage elimination, systemic toxic response was significantly decreased in all 
macrophage-depleted groups (p < 0 01) The 12 day mortal i ty was 0% in the 
macrophage-depleted groups and 27% in the control group (p = 0.05) 
Conclusions The lethal and toxic effects of zymosan appear t o be related more t o the 
excessive activation of macrophages than to the systemic spread of bacteria 
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8.2 I N T R O D U C T I O N 
Both an uncontrolled inflammatory response1 and the loss of intestinal 
barrier function leading to gut-origin septic states2 have been clinically 
implicated in the development of adult respiratory dustress syndrome and 
multiple organ dysfunction syndrome (MODS) The experimental and clinical 
evidence supporting the macrophage and gut hypotheses of MODS have been 
recently reviewed3 Briefly, in the macrophage- or inflammatory-mediated 
model of MODS, the trigger that initiates the cascade of events leading to 
organ failure is the excessive and uncontrolled production and release of 
cytokines and other immunoinflammatory products By contrast, in the gut 
hypothesis of MODS, the loss of intestinal barrier function results in the 
translocation of bacteria and/or endotoxin from the gut to systemic organs 
and tissue, where they initiate, exacerbate, or perpetuate a systemic 
inflammatory response The ability of gut-derived portal and systemic bacteria 
and endotoxin to activate Kuppfer cells and other tissue macrophage 
populations has been well documented experimentally Thus, there appears 
to be considerable physiologic overlap between the two hypotheses, since the 
mediators that ultimately lead to organ in)ury m both hypotheses are similar 
Conceptually, macrophage elimination could disrupt the sequence of events 
leading to organ m|ury by dampening the inflammatory signal However, 
because macrophages are involved in wound healing, antibacterial host 
defenses, and the metabolic response, impaired macrophage function can also | 53 
have deleterious consequences Consequently, it would be of interest to 
examine what influence macrophage elimination might have in a model of 
generalized inflammation associated with bacterial translocation To 
accomplish this goal, we utilized the "liposome mediated macrophage suicide 
technique" to deplete mice of splenic and hepatic macrophages6 before 
challenge with the inflammatory agent, zymosan7 This was chosen as the 
inflammatory agent, because it induces a generalized inflammatory response 
that is associated with bacterial translocation8, signs of sepsis9 and the 
development of a syndrome similar to MODS7 
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8.3 M A T E R I A L S A N D M E T H O D S 
A n i m a l s 
Ninety specific pathogen-free male mice (ICR, Harlan Breeding 
Laboratories, Prattsville.AL) weighing 21 t o 25 g were used in these 
experiments. The mice were housed in autoclaved polystyrene cages under 
barrier-sustained conditions with controlled temperature (22 °C), humidity, 
and lighting (12-hour light-dark cycles) They were fed standard laboratory 
chow (Diet 5001, Ralston Purina, St. Louis, MO) and acidified water (0.001 N 
HCl) ad libitum. The mice were maintained according to the recommendations 
of the National Institutes of Health Guide for Care and Use of Laboratory 
Animals, and the experiments were approved by the Louisiana State 
University-Medical Center, Shreveport, Animal Care Committee 
Z y m o s a n 
The zymosan suspension was prepared as previously described1 0. The 
zymosan (Sigma Chemical Co., St. Louis, Missouri, U.S.A.) was irradiated with 
5 kGy and suspended by high frequency vibration in 100 ml of liquid paraffin 
(European Pharmacopea PA.S.68.81 CP84602I) This suspension was sterilized 
by incubation in a water bath at 100 °C for 80 minutes The concentration of 
the zymosan in the paraffin suspensions varied based on the dose administered 
t o ensure that each animal received the same volume t o each animal group 
(approximately ImL/ammal)· 2.5 mg/mL for the 0.1 mg/g dose, 12 5 mg/mL for 
the 0.5 mg/g dose and 25 mg/mL for the I 0 mg/g dose. Before use, the 
zymosan suspension was warmed t o 40 °C and vibrated at high frequency for 
15 minutes. Sterility was verified by incubation on blood-agar culture plates. 
The zymosan suspension was administered intraperitoneal^/, depending on the 
treatment group, m doses of 0.1 mg, 0.5 mg or I 0 mg of zymosan per gram 
body weight 
C I 2 M B P - L i p o s o m e s 
Multilamellar liposomes were composed of phosphatidylcholine and choles­
terol (molar ratio 64) and contained dichloromethylene-bisphosphonate 
(CL2MBP) dissolved in phosphate buffered saline (PBS, 0.25 g/mL). They were 
prepared as described previously6. In brief, 86 mg phosphatidylcholine and 8 
mg cholesterol (Sigma Chemical Co, St Louis, Missouri) were dissolved in 10 
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ml chloroform, and a lipid film was produced by low vacuum rotary 
evaporation, which was dissolved in 10 ml СЦМВР. The suspension was kept 
at room temperature for 2 hours, after which it was sonicated for 3 minutes 
in a water bath sonicator at 20 °C and again kept for 2 hours at 37 °C. The 
CI_2MBP-liposome suspension was then diluted in 100 ml PBS and 
centrifugated at 100,000 χ g for 30 minutes t o remove free СЦМВР, after 
which the CI_2MBP-liposomes were resuspended in 4 ml PBS. СЦМВР was a 
kind gift of Boehringer Mannheim (Mannheim, Germany). 
Testing for bacterial translocation 
The mice were killed by cervical dislocation. After cleaning the skin with 
75% alcohol, the thorax was opened using sterile instruments and 
approximately 0.5 mL of blood was withdrawn by heart puncture and cultured 
aerobically for 24 hours at 37 °C in 50 mL of brain heart infusion solution. A 
specimen of the lungs was removed, weighed and placed in grinding tubes 
(Tri-R instruments, Rockville center, NY) containing sterile PBS. Subsequently, 
an incision was made through the skin and peritoneum of the abdomen. Using 
sterile technique, the mesenteric lymph node complex (MLN), spleen, liver 
and the cecum were removed, weighed and placed in grinding tubes. The 
organs were then homogenized and aliquots (0.1 mL) of the homogenate were 
plated directly and after serial dilutions onto blood-agar to detect total 
aerobic and facultative aerobic bacteria and onto MacConkey's agar to detect 
gram-negative enteric bacilli. The plates were incubated aerobically for 24 
hours at 37 °C. The number of viable bacteria was determined as the number 
of colony-forming units per gram of tissue. 
Experimental protocol 
To examine whether or not macrophage elimination could influence 
zymosan-induced bacterial translocation and toxicity, three doses of zymosan 
were tested. Before the zymosan challenge, the mice were randomly assigned 
t o a macrophage-nondepleted "control" group and a macrophage-depleted 
group (n=8 in each group). The macrophage-depleted groups received 200μΙ 
of the CLjMBP-liposome suspension and the macrophage-nondepleted groups 
200μΙ of PBS by tail vein injection. Eighty-four hours later, the animals received 
an intraperitoneal injection of the zymosan suspension at a dosage of either 
0.1 mg/g, 0.5 mg/g or 1.0 mg/g. Twenty-four hours after the zymosan injection, 
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signs of systemic toxicity were determined and the organs were tested for 
bacterial translocation Systemic toxicity was graded in a blinded fashion and 
assessed by recording the extent of Conjunctivitis, ruffled fur, lethargy and 
diarrhea using a five-points scale (0 = none, I = minimal, 2 = moderate, 3 = 
severe and 4 = extensive). 
An additional t w o control groups of six animals were tested t o verify that 
neither the paraffin vehicle, the PBS nor the СЦМВР-liposome suspension 
alone induced bacterial translocation or systemic toxicity. One group received 
200 μΙ of PBS and the second group received the CL2MBP-liposome sus­
pension intravenously followed 2 days later by an intraperitoneal injection of 
the paraffin vehicle (0.04 mL/g) that did not contain zymosan. 
Lastly, the mortality rate was assessed in t w o separate groups of control and 
macrophage-depleted mice (η=Ι5 per group) challenged with a dose of 1.0 
mg/g of zymosan. These animals were followed for 12 days 
Histology 
To determine whether or not macrophage elimination altered the 
zymosan-induced intestinal mucosal in|ury, the ileums from at least three mice 
per group were analyzed by light microscopy. The specimens were recovered 
after death and fixed by luminal perfusion and immersion in 2% 
paraformaldehyde, 2% glutaraldehyde in 0.1 mol/L phospate buffer at pH 7.4 
overnight at 4°C. The tissue was then dehydrated t o 95% ethanol and 
embedded in methyl methacrylate (JB-4, polysciences, Warrington, PA). 
Semithin sections of 2-3 μιπ were cut on glass knives and stained with 1% 
toluidine blue 
To verify that the macrophages had been successfully eliminated by the 
time of zymosan administration, specimens of the spleens were removed and 
cryostat sections of 8-μΓπ thickness were cut. The sections were stained for 
acid phosphatase activity Acid phosphatase activity was demonstrated by 
incubation with naphtol biphosphate and para-rosaniline for 30-45 minutes at 
37 °C. 
Statistical analysis 
Continuous data were analyzed by analysis of variance (ANOVA) Bet-
ween-group significance levels were assessed by using the 
Student-Newman-Keuls post-hoc test Data on bacterial levels were log 
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transformated before analysis. Discontinuous data were evaluated by using the 
Fischer exact test when the smallest number in a comparison was smaller then 
or equal t o 5. In all other cases, the chi-square test with a continuity 
correction was used. When ρ < 0.05, the difference was considered signifi­
cant. 
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Figure Ι 
Splenic tissue sections stained for acid phosphatase 48 hours after 
pretreatment, (χ 100). (A) PBS pretreated mouse spleen in which 
macrophages are present throughout the tissue. (B) CL2MBP-containing 
liposome-pretreated mouse spleen in which most macrophages are 
eliminated. Some macrophages in the white pulp remained. Scale bar = 
100 pm. 
Macrophage elimination was successfully achieved by the injection of 
liposomes containing СЦМВР, as reflected by the absence of acid phosphatase 
activity in the splenic tissues of the СЦМВР-treated mice (Fig. I). 
Neither the paraffin vehicle nor the CI_2MBP-liposome suspension 
promoted bacterial translocation in the absence of a zymosan challenge (Table 
I) or induced signs of systemic toxicity (data not shown). By contrast, 
bacterial translocation occurred in the mice receiving zymosan in a dose-
dependent fashion (Table I), with more systemic spread being observed in the 
animals receiving 0.5mg/g or 1.0 mg/g than the animals receiving 0.1 mg/g of 
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Table I. INFLUENCE OF MACROPHAGE DEPLETION ON THE INCIDENCE OF 
BACTERIAL TRANSLOCATON AND CECAL POPULATION LEVELS 
G r o u p 
Paraffin 
Controls 
M 0 depleted 
Zymosan 0.1 mg/g 
Controls 
M 0 depleted 
Zymosan 0.5 mg/g 
Controls 
M 0 depleted 
Zymosan 1-0 mg/g 
Controls 
M 0 depleted 
Bac te r ia l 
N t r a n s l o c a t i o n t o M L N (%) 
12 
M 
8 
0/6 (0) 
_o/6 $i 
6/12 (50) 
0/11 (0)* 
7/8 (88)11 
6/8 (75)11 
Sys temic bac te r ia l t r a n s l o c a t i o n 
( l i ver /sp leen/ lung/b lood) (%) 
0/24 (0) 
0/24 (0) 
Ceca l p o p u l a t i o n levels 
( l og C F U / g ) 
1/48 (2) 
4/44 (9) 
A e r o b e s 
5.14 ±0.05 
5 07 ±0.15 
6.95 ± 0.44/ 
6.26 ± 0 . 2 1 / 
Gram-nega t i ves 
4.20 ± 0.25 
4.13 ± 0 16 
6.77 ± 0.48/ 
5.65 ± 0.25 ƒ 
10/32 (3I)H 
19/32 (59)H* 
10.25+ 0.IO§ 
9 I 8 ± 0 . 4 0 § 
9.27 ± 0.43§ 
9 69 ± 0.35§ 
zymosan dosegroup /=p<0.05 and 
sher's exact or A N O V A with Student-
I0.I8±0.II§ 
9.00 ± 0.47§ 
9I7±0.43§ 
9.60 ± 0.33§ 
8 7/8 (88)Ц 11/32 (34)1) 
8 8/8 (ІОО)Ц 23/32 (72)Hf 
M 0 = macrophage. + =p<0.05 and f = p < 0 0 l control versus macrophage depleted group of same 
§=p<0.0l zymosan versus paraffin.. Ц - р < 0 0 1 zymosan 1.0 mg/g or 05 mg/g versus 0.1 mg/g (F 
Newman-Keuls post-hoc). 
zymosan. 
The incidence of bacterial translocation to the MLN was similar between 
the macrophage-depleted and -nondepleted groups. However, 
macrophage depletion was associated with a significantly higher incidence of 
the systemic spread of bacteria after challenge with the higher two doses of 
zymosan (Table I). This was especially true for the lung (Table 2). 
The indigenous bacterial flora, as reflected in the cecal population levels, 
was clearly increased by zymosan administration (Table I). The cecal bacterial 
population levels were not higher in the macrophage-depleted groups than the 
comparable nondepleted groups after zymosan challenge. Thus, the increase in 
the systemic spread of translocating bacteria observed after macrophage 
depletion does not appear t o be related to changes in cecal bacterial 
population levels (Table I). 
By contrast with the incidence of bacterial translocation, the magnitude of 
bacterial translocation to the MLN and the systemic organs, expressed as the 
number of colony-forming units of total aerobic bacteria (includes gram-
negative enteric and gram-positive facultative aerobes), was similar between 
the macrophage-depleted and -nondepleted groups (Table 3). This was also 
true when the magnitude of only gram-negative enteric bacterial translocation 
was quantified (data not shown). 
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Table 2. DISTRIBUTION OF THE INCIDENCE OF SYSTEMIC 
BACTERIAL TRANSLOCATION AMONG THE TESTED ORGANS 
Group Liver 
Zymosan 0.5 mg/g 
Controls 37.5 
M0 depleted 75 
Zymosan 1.0 mg/g 
Controls 50 
M0 depleted 87.5 
Spleen 
50 
50 
50 
62.5 
Lung 
25 
100* 
25 
87.5+ 
Blood 
12.5 
12.5 
12.5 
50 
M0= macrophage. Values are percentages; *=p<0.05 and f=p<0.0l control versus macrophage depleted group 
of same zymosan dosegroup using Fisher's exact test on the actual numbers. 
Zymosan-induced mucosal injury appeared to occur in a dose-dependent 
fashion and ranged from slight villous tip edema at the lowest zymosan dose to 
almost complete disruption of the mucosal architecture at the highest dose 
(Fig. 2).Since the magnitude of histological damage to the terminal ileum was 
similar between the groups, the increased incidence of systemic bacterial 
translocation in the macrophage-depleted mice did not appear to be due to an 
increase in the extent of injury to the mucosal barrier. 
The administration of zymosan was associated with the development of 
signs of systemic toxicity that occurred in a dose-dependent fashion (Fig. 3). 
However, the macrophage-depleted mice receiving either 0.5 mg/g or 1.0 mg/g 
zymosan had lower symptom scores than did the macrophage-nondepleted 
animals receiving comparable doses of zymosan. In addition, the 12-day 169 
Table 3. INFLUENCE OF MACROPHAGE DEPLETION O N T H E 
M A G N I T U D E OF BACTERIAL T R A N S L O C A T I O N 
Group MLN Liver Spleen Lung 
Zymosan 0.5 mg/g 
Controls 
M0 depleted 
Zymosan 1.0 mg/g 
Controls 
M0 depleted 
M0= macrophage. Data 
there are no significant 
2.49 1 0.20 
3.04 ± 0.25 
3.34 ± 0.34 
2.77 ±0.17 
expressed as Log" 
differences. 
3.32 ± 0.52 
2.87 1 0.28 
3.87 ± 0.47 
3.0010.41 
3.0410.18 
3.0010.21 
4.25 + 0.41 
2.6910.13 
' CFU/g of aerobic bacteria in positive organs; 
2.8410.11 
3.1010.30 
4.72 1 0.56 
3.28 1 0.35 
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Figure 2 
Plastic sections of distal ileum 24 hours after zymosan administration 
stained with toluidin blue (x220). (A) Normal mucosa from a control 
mouse. (B) Administration of 0.1 mg/g of zymosan resulted in lifting of 
the villus tip epithelium. (C) A dose of 0.5 mg/g of zymosan 
administration caused more pronounced edema of the villus. (D) 
Administration of 1.0 mg/g of zymosan administration led to a complete 
disruption of the normal architecture of the mucosa. Scale bar = 100 
pm. 
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Points 
И -
— S Y M P T O M S C O R E S 
Controls 
S U R V I V A L -r 125 
% alive 
-100 
75 
- 50 
- 25 
0.1 mg/g 0.5 mg/g I 0 mg/g 
p<0.0l p<0.05 
Figure 3 
Symptom scores w e r e dose dependent and significantly lower in the 
macrophage-depleted mice when compared w i t h those in the c o n t r o l 
animals. Af ter 1.0 mg/g of zymosan suspension, 12-day survival rate was 
significantly better in the macrophage-depleted mice than that in the 
contro l mice. (Fisher's exact test on the actual numbers and A N O V A 
w i t h Student-Newman-Keuls post-hoc test). 
mortality rate after a 1.0-mg/g zymosan challenge was significantly lower in the 
macrophage-depleted than in the macrophage-nondepleted mice (Fig. 3). 
8.5 D I S C U S S I O N 
The central question being asked in this study was what effect elimination 
of splenic and hepatic macrophages would have in a systemic inflammatory 
model associated with bacterial translocation. To answer this question we 
used the CL2MBP-liposome mediated macrophage suicide technique6 to 
eliminate the hepatic and splenic macrophage populations. In this technique, 
liposomes are used as carriers for the СЦМВР because 
liposome-encapsulated СЦМВР is easily and preferentially ingested by 
macrophages. Once phagocytized, the liposomal bilayers are disrupted by 
17 
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lysosomal enzymes, resulting in the intracellular release of СЦМВР and the 
subsequent death of the macrophages Which macrophage populations will be 
eliminated depends on the route by which the CL2MBP-hposomes are 
administered1 '. Because liposomes cannot cross the endothelium or 
epithelium, only liver and splenic macrophages will be eliminated after an 
intravenous injection Macrophages in organs without sinusoids like the lung, 
mesenterial lymph nodes or lamina propria of the intestine will not be 
eliminated using the intravenous administration route After these populations 
of macrophages have been killed, the animal will remain macrophage depleted 
until these macrophage compartments are repopulated by bone marrow-
derived macrophages Repopulation requires at least 7 days in the liver and, 
depending on the macrophage subpopulation, 7 to 30 days in the spleen; 
therefore, this technique appears to be a suitable approach t o study the effects 
of macrophage depletion in vivo Zymosan, which is a cell wall preparation 
from the yeast Saccharomyces cerevisiae, was chosen as the inflammatory agent, 
since it induces a generalized inflammatory response that has been associated 
with dose-dependent bacterial translocation8 l 0 '3, signs of sepsis9 l 4 and 
the development of a syndrome similar to MODS 7 . 
The elimination of macrophages did not result in an attenuation of bacterial 
translocation; therefore, zymosan-induced bacterial translocation does not 
appear t o be mediated directly by macrophages or their products However, 
zymosan-induced toxicity, as measured by the symptom-scores and mortality, 
172 did appear t o be macrophage mediated. These results are consistent with 
earlier studies documenting that zymosan-induced bacterial translocation 
occurs in macrophage function deficient СЗН/HeJ-mice10, although mortality 
and morbidity is significantly less in these macrophage deficient compared to 
normal mice 1 5 . Thus, these results indicate that zymosan-induced toxicity and 
zymosan-induced bacterial translocation are independent phenomena 
and.therefore, probably mediated by different mechanisms. 
The exact reason why the incidence of systemic bacterial translocation was 
higher in the macrophage-depleted animals can not be determined from the 
results of this study However, the most likely explanation is that the 
translocating bacteria which reach the liver and spleen are more likely to 
survive when macrophages are absent than when they are present. 
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Furthermore, in the absence of hepatic and splenic macrophages, circulating 
endotoxin will not be efficiently cleared and endotoxemia has been 
documented to promote bacterial translocation even m macrophage-déficient 
mice16 
A major finding of this study was that elimination of hepatic and splenic 
macrophages significantly decreased the toxicity and mortality associated with 
the zymosan challenge, even though macrophage elimination potentiated the 
degree of bacterial translocation This observation indicates that the early 
deaths observed after zymosan challenge is related more to the activation of 
macrophages and the subsequent release of their products than to the 
translocating bacteria Thus, in essence, elimination of splenic and hepatic 
macrophages disassociated zymosan-mduced toxicity from zymosan-induced 
bacterial translocation This apparent disassociation between toxicity and the 
extent of bacterial translocation or infection was consistent with recent 
advances in our understanding of the biology of the septic response Until 
relatively recently, although it was believed that bacterial pathogens or their 
products, such as endotoxin, were directly responsible for the 
pathophysiologic manifestations of the septic response, it is now clear that this 
is not the case' l 7 l 8 Instead, it is the host's immunomflammatory response 
to the invading bacteria and their products (especially endotoxin) that are the 
direct mediators of the septic response In fact, one of the major conceptual 
advances of the last decade has been the realization that sepsis and infection 
are not synonymous and that the septic state can even occur in the absence of 
infection or bacteria7 '9 This realization explains why uninfected patients with 
major inflammatory diseases such as pancreatitis, and traumatized victims who 
have sustained severe tissue injuries that induce a major inflammatory res-
ponse a septic syndrome develops that may be clinically indistiguishable from 
uncontrolled infection1 2 l 9 20 
Understanding the relative contribution of infection or other inflammatory 
stimulants, such as zymosan, as distinct from their induced inflammatory 
response in the evolution of organ injury and death is of major potential 
importance For example, using the paradigm that the host is an innocent 
bystander who is being directly injured by invading bacteria, one potential goal 
of therapy would be to augment the host's inflammatory and immune respon-
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ses and thereby increase his ability to fight infection. By contrast, if the 
paradigm is modified to take into account that the host is being injured by an 
excessive or uncontrolled inflammatory response, the goal of treatment will 
include attempts to modulate the immunoinflammatory response and thereby 
limit toxicity In this context, the results of the present study indicate that 
selective elimination of hepatic and splenic macrophages can be beneficial in a 
model of systemic inflammation 
This disassociation between bacterial translocation and toxicity does not 
mean that bacterial translocation is not an important phenomenon, although in 
this model the systemic spread of bacteria does not appear to be related 
directly to mortality and morbidity rates For example, germ-free animals 
survived zymosan challenge better than did animals with a normal gut flora , as 
did cefoxitm-treated mice In these models, because elimination or control 
of the gut flora reduced the mortality rate, bacteria appear to be an important 
factor, but not the only factor, in the pathophysiology of zymosan-induced 
death. 
Elucidation of the mechanisms by which depletion of hepatic and splenic 
macrophages reduces mortality and morbidity will require further 
examination However, it is possible that by depleting these macrophages and, 
thereby, preventing the subsequent release of their products, the inflammatory 
and metabolic responses to zymosan as well as gut-derived bacteria and 
endotoxin were attenuated In addition, because posttraumatic 
174 immunosuppression has been attributed to dysfunctional macrophages21 
restoring this immunosuppression might be another mechanism by which 
elimination of macrophages could lead to an attenuation of the zymosan-
induced illness. Although this concept is consistent with studies demonstrating 
that elimination of alveolar or peritoneal macrophages is associated with an 
increase in local immune responsiveness22 23, it does not seem very likely 
since bacterial spread was increased in the macrophage-depleted groups 
However, it is not known what is the indirect effect of the СЦМВР-liposomes, 
that is, the effect mediated by dying macrophages It is possible that these 
dying macrophages release cytokines or other mediators that induce 
tolerance 2 4 2 5 Until experiments testing these and other possibilities are 
carried out, the explanation of why macrophage depletion improved survival 
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must remain speculative. Furthermore, these results should not 
unconditionally be extrapolated to other models or to humans. For example, 
although Kupffer cell blockade by gadolinium chloride in the cecal ligation and 
puncture (CLP) model results in an attenuation of the CLP-induced 
suppression of systemic cell-mediated immunity, mortality is also increased . 
Recently, it was shown that the intensity of bacterial translocation was 
significantly associated with mortality in a combined model of burn and blood 
transfusion27. 
In summary, this experiment showed that the observed early lethal and 
toxic effects of zymosan appear to be related more to the excessive activation 
of macrophages than to the systemic spread of bacteria. This correlates well 
with the clinical impression that the inflammatory response and not the 
systemic spread of bacteria determines outcome 
28 
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MODS, Macrophages and Bacterial 
Overgrowth 
The consequences of elimination of macrophages in a model of bacterial overgrowth 
and systemic inflammation. 
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9.1 ABSTRACT 
Objective: To evaluate whether dichloromethylene-bisphosphonate (CI-2MBP) -
liposome mediated elimination of liver and splenic macrophages (mo) would influence 
zymosan induced bacterial translocation (BT) and the zymosan induced generalized 
inflammatory response in a model in which BT to the MLN is already established (i.e. 
monoassociation wi th £ coli C25). 
Design: Randomized animal trial. 
Setting: Animal laboratory Louisiana State University Medical Center, Shreveport, LA, 
USA. 
Participants: Male outbred ICR mice. 
Interventions: Decontamination of the gut was accomplished by placing 0.9 mg penicillin 
G sodium and 2 mg streptomycin sulfate per ml in the drinking water. After 4 days 
the mice were monoassociated by adding E.coh CIS to their drinking water. 
Elimination of mo was accomplished by i.v. injection with C^MBP- l iposome sus-
pension. Control mice received an i.v. injection with phosphate buffered saline. Two 
days later the animals were challenged intraperi toneal^ with zymosan at a dose of 0.5 
or 1.0 mg/g body weight. 
Mam Outcome Measures: Symptom scores, BT to the mesenteric lymph node (MLN), 
liver, spleen, blood and cecal population levels were determined 24 and 48 hours 
after zymosan challenge. A separate mortality study was performed with a dose of 1.0 
mg/g zymosan suspension. 
Results: The incidence of systemic spread of bacteria was significantly increased in the 
macrophage depleted mice compared to the control mice, especially after 48 hours 
and the lower zymosan dose. Symptom scores were significantly decreased in the 
macrophage depleted groups. Early mortality after 48 hours was 0% in the 
macrophage depleted groups and 33 % in the control group (p=0.04), after 12 days 
mortality was 20% and 53 % respectively. 
Conclusions: In a model where intestinal bacterial population levels were increased and 
BT was already occurring, macrophage elimination decreased mortality and systemic 
signs of inflammation even though BT was increased. Thus, macrophage elimination 
disassociated zymosan induced BT f rom zymosan induced toxicity. 
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9.2 I N T R O D U C T I O N 
Despite improvements in the resuscitative and supportive management, the 
Multiple Organ Dysfunction Syndrome (MODS) remains the leading cause of 
death among surgical patients in the ICU ' 2 Since the concept of MODS was 
introduced some 20 years ago 3 our understanding of its pathophysiology has 
increased enormously Notwithstanding, we still do not know which events 
are the motors of this "horror autotoxicus" 4 For example, an excessive 
uncontrollable inflammatory response has been proposed to play a ma|or role 
in the pathogenesis of MODS even in the absence of bacteria or infection 5 
This concept is based on evidence that the excessive activation of 
macrophages induces a generalized dysregulated and excessive inflammatory 
response, leading to the development of the Systemic Inflammatory Response 
Syndrome (SIRS), Adult Respiratory Distress Syndrome (ARDS) or MODS 2 6 
7
 Furthermore, macrophage-denved cytokines administered to healthy 
volunteers produce a syndrome closely resembling SIRS 8 and increased 
levels of macrophage-denved products such as cytokines and neoptenn have 
been documented to be positively correlated with mortality and the 
development of MODS l 0 ' ' Lastly, anti-cytokine strategies have been shown 
to attenuate or prevent the development of SIRS and subsequent MODS in 
I ") 
various experimental models 
On the other hand, gut barrier failure leading to the passage of bacteria 
and endotoxin to mesenteric lymph nodes and other organs, a process termed 
bacterial translocation (BT), has been proposed to be the "motor " of MODS 
Both macrophage activation and gut barrier failure seem to be present in 
patients developing MODS, however their interrelationships remain poorly 
investigated14 
In the Zymosan Induced Generalized Inflammation model, intraperitoneal 
challenge with zymosan results in a typical triphasic illness which is 
characterized by a) an early hyperdynamic response associated with concur-
rent BT from the gut, b) a recovery phase and c) a late bacteria independent 
hypodynamic MODS-like phase associated with a generalized inflammatory 
response and organ dysfunction 5 l 5 Recently we have shown that 
elimination of liver and splenic macrophages, by liposomes containing 
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dichloromethylene-bisphosphonate (CI2MBP or clodronate) '6, before 
zymosan challenge induces an increase in systemic BT, yet zymosan induced 
symptoms and mortality were attenuated17. 
To further extend these earlier studies, we examined the effect of zymosan 
administration in macrophage-depleted and non-depleted mice 
monoassociated with Exoli CIS. This monoassociation results in a higher 
intestinal bacterial challenge with an already established BT to the MLN l8. 
The rationale for these studies is that intestinal bacterial overgrowth by 
potentially pathogenic bacteria has been documented in ICU patients ' 
putting these patients at increased risk of bacterial translocation 20. 
9.3 MATERIALS A N D M E T H O D S 
A n i m a l s 
Specific pathogen-free male outbred mice (ICR) weighing 25 to 34 g were 
used in these experiments. The mice were housed under barrier-sustained 
conditions in autoclaved polystyrene cages with stainless steel lids covered 
with individual filter tops and controlled temperature (22°C), humidity, and 
lighting (12-hour light dark cycles).They were maintained with standard 
laboratory food (Diet 5001, Ralston Purina Co., St. Louis, MO) and acidified 
water (0.001 N HCl) ad libitum. The mice were maintained in accordance with 
the recommendations of the National Research Council's Guide for Care and 
Use of Laboratory Animals and the experiments were approved by the 
Louisiana State University-Medical Center, Shreveport, Animal Care 
Committee. 
Z y m o s a n 
The Zymosan suspension was prepared as previously described 5. Zymosan 
(Sigma Chemical Co., St. Louis, Missouri, U.S.A.) was suspended by high 
frequency vibration in liquid paraffin (European pharmacopea PA.S.68.81 
CP84602I). This suspension was sterilized by incubation in a water bath at 
I00°C for 80 minutes. The concentration of the zymosan in the paraffin 
suspensions varied based on the dose administered in order to ensure that 
each animal received the same volume (approximately I ml/animal): 12.5 mg/ 
ml for the 0.5 mg/g dose and 25 mg/ml for the 1.0 mg/g dose. Before 
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utilization, the zymosan suspension was warmed t o 40°C and vibrated at high 
frequency for 15 minutes Sterility was verified by incubation on blood-agar 
culture plates The zymosan suspension was administered intraperitoneal^ 
depending on the treatment group in dosages of 0 5 mg or I 0 mg zymosan 
per gram body weight 
CI 2 MBP-Liposomes 
Multilamellar liposomes were composed of phosphatidylcholine and choles­
terol (molar ratio 6 I) and contained dichloromethylene-bisphosphonate 
(CljMBP) dissolved in phosphate buffered saline (PBS) (0 25 g/ml) They were 
prepared as previously described In brief, 86 mg phosphatidylcholine and 8 
mg cholesterol (Sigma Chemical Co , St Louis, Missouri, U S A ) were 
dissolved in 10 ml chloroform and, by low vacuum rotary evaporation, a lipid 
film was produced, which was dissolved in 10 ml CI2MBP The suspension was 
kept at room temperature for 2 hours, after which it was sonicated for 3 
minutes in a water bath sonicator at 20 C C and again kept for 2 hours at 37 
°C The CljMBP-hposome suspension was then diluted in 100 ml PBS and 
centrifuged at 100,000 g for 30 minutes to remove free CI2MBP, after which 
the CI2MBP-hposomes were resuspended in 4 ml PBS CI2MBP-hposome 
suspension was administered m a dose of 200 μΙ intravenously CI2MBP was 
kindly provided by Boehnnger Mannheim GmbH, Mannheim, Germany 
Antibiotic decontamination and monoassociation with E.coli C25 
All mice received 0 9 mg penicillin G sodium and 2 mg streptomycin sulfate 
per ml ad libitum in their drinking water in order to decontaminate their gut 
Decontamination was verified by a gram staining the feces E coli C25 was 
cultured overnight in brain heart infusion broth (Difco Laboratories, Detroit, 
Mich ) Four days after starting the antibiotic decontamination the mice were 
monoassociated by adding Ecoli CIS to fresh sterile drinking water The mice 
continued to receive streptomycin sulfate (2 mg/ml) in their drinking water 
throughout the whole experiment 
Testing for bacterial translocation 
The mice were killed by cervical dislocation After soaking the skin with 
75% alcohol the thorax was opened using sterile scissors and approximately 
0 5 cc of blood was withdrawn by heart puncture and incubated aerobically for 
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48 hours at 37°C in 50 cc of brain heart infusion solution (Difco Laboratories, 
Detroit , Mich ) containing streptomycin sulfate ( 2 mg/ml ) A specimen of the 
lungs was removed, weighed and placed in a grinding tube (Tri-R instruments, 
Rockville center, NY) containing sterile PBS Subsequently the abdomen was 
opened and using sterile technique the mesenteric lymph node complex 
(MLN), spleen, liver and lastly the cecum were removed, weighed and placed 
in grinding tubes containing sterile PBS The organs were then homogenized 
with Teflon grinders and aliquots of the homogenate were plated directly and 
after serial dilutions onto MacConkey's agar enriched with streptomycin 
sulfate ( 2 mg/ml ) The plates were incubated aerobically for 24 hours at 
37°C The numbers of viable E coli C25 were determined as the number of 
colony forming units (CFU) per gram of tissue 
Experimental design 
Seven days prior to the zymosan challenge all mice were antibiotically 
decontaminated and subsequently monoassociated with E coli С 25 four days 
later as described above Throughout the whole experiment the mice received 
streptomycin sulfate (2 mg/ml/) in their drinking water 
To examine whether or not macrophage depletion would influence 
zymosan induced ВТ and toxicity, t w o dosages of zymosan were tested Prior 
to zymosan challenge the mice were randomly assigned to a macrophage non-
depleted "control" group and a macrophage depleted group (n= 14 each 
group) The macrophage depleted groups received 200μΙ of the CI2MBP-
I 82 liposome suspension and the macrophage non-depleted groups 200μΙ of PBS 
by tail vein injection. Eighty-four hours later, the animals received an 
intraperitoneal injection of the zymosan suspension at a dosage of either 0 5 
mg/g or I 0 mg/g body weight To examine if there was a time relationship in 
the occurrence of systemic signs and ВТ, 24 and 48 hours after the zymosan 
injection, signs of systemic toxicity were determined and the organs were 
harvested for cultunng Systemic toxicity was graded in a blinded fashion and 
assessed by recording the extent of conjunctivitis, ruffled fur, lethargy and 
diarrhea using a five points scale (0 = none, I = minimal, 2 = moderate, 3 = 
severe and 4 = extensive) 
Additionally three control groups were tested t o verify that neither the 
paraffin vehicle nor PBS or CI2MBP-hposomes alone induced systemic ВТ or 
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toxicity. One group (n=8) received 200 μΙ PBS, the second group (n=8) 
received G2MBP-liposome suspension i.v. followed t w o days later by an 
intraperitoneal injection of the paraffin vehicle (0.04 ml/g body weight) that did 
not contain zymosan. The third group (n=5) received nothing at all and was 
only monoassociated. 
Lastly, mortality was assessed in two separate groups of control and 
macrophage depleted mice (η=Ι5 per group) challenged with 1.0 mg/g body 
weight zymosan. These animals were followed for 12 days. 
Histology 
To determine whether or not macrophage depletion altered the zymosan 
induced intestinal mucosal damage, the ilea from at least three mice per group 
were analyzed by light microscopy. The specimens were recovered after death 
and fixed by luminal perfusion and immersion in 2% paraformaldehyde, 2% 
glutaraldehyde in 0.1 M phosphate buffer at pH 7.4 overnight at 4°C. The 
tissue was then dehydrated t o 95% ethanol and embedded in methyl 
methacrylate (JB-4, polysciences, Inc., Warrington, PA). Semithin sections of 2-
3 μιτι were cut on glass knives and stained with 1% toluidine blue. 
To verify that the macrophages had been successfully eliminated by the 
time zymosan was administered, specimens of the spleen were dissected free 
and stained for acid phosphatase activity. Acid phosphatase activity was 
demonstrated by incubation with naphtol AS-BI phosphate and pararosaniline 
for 30-45 minutes at 37°C 
Statistical analysis 183 
Continuous data were analyzed by analysis of variance (ANOVA). Between 
group differences were assessed by using the Student-Newman-Keuls post-
hoc test. Data on bacterial levels were log transformed prior t o analysis. 
Discontinuous data were evaluated by using the Fisher's Exact or the Chi-
square test with continuity correction when appropriate. When ρ < 0.05 the 
difference was considered statistically significant. 
vs. 0.5 mg/g zymosan challenge (Fisher's exact / Chi-quare test or A N O V A 
with Student-Newman-Keuls post hoc when appropriate). 
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SYSTEMIC BACTERIAL TRANSLOCATION 
Points 15 
184 
Ц 24 hours Controls 
Ц 24 hours M 0 depleted 
| | 48 hours Controls 
Q 48 hours M 0 depleted 
0 5 rng/g Zymosan 0 mg/g Ζγρηοίλη 
Figure I 
Effects of macrophage elimination on the incidence of systemic ВТ 24 
and 48 hours after zymosan challenge (expressed as percent positive 
organs) and on symptom scores (expressed as mean points ± SEM). * 
p<0.05, •** p<0.0l c o n t r o l vs. macrophage depleted; # p<0.05, # # 
p<0.0 l 48 hours vs. 24 hours; ¥ p<0.05 1.0 mg/g vs. 0.5 mg/g zymosan 
challenge (Fisher's exact / Chi-square test or A N O V A wi th Student-
Newman-Keuls post hoc when appropriate). 
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9.4 RESULTS 
Macrophage elimination by CI2MBP-hposomes was confirmed by the 
absence of acid phosphatase activity in the splenic tissues of the G2MBP-
treated mice (data not shown) 
Decontamination was established since no microorganisms were seen in the 
Gram staining of fecal material after four days of the antibiotic regimen The 
subsequent monoassociation with Ecoli C25 was accomplished as shown by 
the high cecal population levels (10-12 log10 CFU/g) cultured on Streptomycin 
containing MacConkey's agar (Table I ) 
Monoassociation resulted in a 75-100% translocation rate to the MLN after 
24 and 48 hours in all groups (Table I) Neither monoassociation nor the 
paraffin vehicle or the CI2MBP-hposome suspension alone promoted systemic 
BT (which was defined as the recovery of viable bacteria in liver, spleen, lung 
and blood together) in the absence of a zymosan challenge (Table I) or 
induced signs of systemic toxicity (data not shown) In contrast, in the mice 
receiving zymosan systemic BT occurred in a high percentage and in a dose 
and time-dependent fashion (Table I and Figure I) Since neither zymosan 
administration nor macrophage depletion affected cecal bacterial population 
levels of E coli C25 (Table I), the changes seen in systemic BT cannot be 
explained by differences in cecal bacterial population levels 
After 24 hours, the systemic spread of bacteria was higher in the animals 
receiving I 0 mg/g of zymosan than the animals receiving 0 5 mg/g No signifi- | 85 
cant differences were noticed between the macrophage depleted and 
macrophage non-depleted groups 24 hours after receiving zymosan At 48 
hours, however, the incidence of systemic BT decreased by almost half of the 
24 hour rate in both zymosan control groups (from 33 9% to 18 3% at the 0 5 
mg/g dose and from 46 4% to 23 2% at the I 0 mg/g dose) The macrophage 
depleted animals however did not show this decrease in systemic BT and at 
the 0 5 mg/g dose an increase in the incidence of systemic BT was observed 
(from 30 to 44 2%) Systemic BT occurred to a greater extent in the livers and 
spleens rather than in the lungs and blood, although these differences were 
not statistically significant (Table 2) 
In contrast to the incidence of BT, the magnitude of BT to the systemic 
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Table I. INCIDENCE OF BACTERIAL TRANSLOCATON AND CECAL 
POPULATION LEVELS 
24 hours after zymosan challenge 
Group 
MA only 
M A+Paraffin 
Controls 
M 0 depleted 
MA+ Zymosan 0.5 
Controls 
M 0 depleted 
M A+Zymosan 1.0 
Controls 
M 0 depleted 
mg/g 
mg/g 
N 
5 
8 
8 
14 
14 
14 
14 
Bacter ia l Systemic bacter ia l t ranslocat ion 
t rans locat ion t o M L N ( l iver/spleen/lung/blood) 
(%) (%) 
5/5 (100) 0/20(0) 
8/8 000) 0/32 (0) 
7/8 (88) 0/32 (0) 
14/14 (88) 19/56 (34)t 
14/14 (75) 17/56 (30)t 
14/14 (100) 26/56 (46)t 
14/14 (100) 31/56 (55)tH 
Cecal populat ion 
levels 
(log1· CFU/g) 
1 
11.6 ±0.2 
1 1.1 ±0.4 
10.8 ±0.3 
1 I.I ±0.3 
11.3 ±0.3 
11.3+ 1.3 
l , . 0±0 .2 
48 hours after zymosan challenge 
Group 
Bacter ia l 
t rans locat ion t o M L N 
(%) 
M A+Zymosan 0.5 mg/g 
Controls 
M 0 depleted 
MA+Zymosan 1.0 mg/g 
Controls 
M 0 depleted 
¡5 
13 
14 
15 
Systemic bacter ia l t rans locat ion 
( l iver/spleen/lung/blood) (%) 
15/15 (100) 
12/13 (92) 
14/14 (100) 
15/15 (100) 
11/60 ( I8 ) t 
23/52 (44)t* 
13/56 (23)t# 
22/60 (37)t 
Cecal populat ion 
levels 
(log'» CFU/g) 
MA only 
M A+Paraffin 
Controls 
M 0 depleted 
5 
8 
8 
4/5 (80) 
7/8 (88) 
6/8 (75) 
0/20 (0) 
0/32 (0) 
0/32 (0) 
12.6 ±0.2 
12.1 ±0.2 
12.1 ±0.1 
11.6 ± 0.3 
12.0 ± 0 . 2 
I 2 .5±0 .2## 
I2 .2±0 .2## 
MA=monoassociated, M 0 = macrophage. *=p<0.0l control versus macrophage depleted; |=p<0.0 l zymosan versus 
paraffin; #=p<0.05 ,##=p<0.0l 48 hours versus 24 hours; Tl=p<0.05 1.0 mg/g versus 0.5 mg/g zymosan challenge. 
(Fisher's exact or ANOVA with Student-Newman-Keuls post-hoc when appropriate). 
organs (expressed as log10 CFU of bacteria in the positive organs/g) was 
similar between the macrophage depleted and non-depleted groups. (Table 3). 
Histological mucosal injury was similar in the macrophage-depleted and the 
control mice (data not shown). So, the increase in systemic BT did not appear 
to be due to an increase in the extent of injury to the mucosal barrier. 
As demonstrated by the symptom scores, the administration of zymosan 
was associated with the development of signs of systemic toxicity which 
occurred in a dose and time-dependent fashion (Figure 2). However, the 
CHAPTER 9 
/VI ODS, MACROPHAGES AND BACTERIAL OVERGROWTH 
Table 2. DISTRIBUTION OF THE INCIDENCE OF SYSTEMIC BACTERIAL 
TRANSLOCATION AMONG THE TESTED ORGANS 
Group Liver 
24 hours 48 hours 
Spleen 
24 hours 48 hours 
Lung 
24 hours 48 hours 
Blood 
24 hours 48 hours 
MA+Zymosan 0.5 mg/g 
Controls 
M 0 depleted 
M A+ Zymosan 1.0 mg/g 
Controls 
M 0 depleted 
M0= macrophage. Values 
36 
50 
64 
64 
are percentages. 
20 
54 
22 
55 
There are 
43 
36 
50 
72 
no significant 
20 
54 
36 
57 
differences 
29 
14 
36 
43 
20 
38 
21 
20 
29 
21 
36 
43 
13 
31 
14 
29 
macrophage-depleted mice that received either 0.5 mg/g or 1.0 mg/g zymosan 
had lower symptom scores after 24 hours than the control animals receiving a 
comparable dose of zymosan. 48 Hours after zymosan challenge, symptom 
scores were reduced when compared with 24 hours. This was true for both 
the macrophage non-depleted and the macrophage depleted groups. 
Macrophage depleted animals also had lower symptom scores after 48 hours 
and this was statistically significantly for the 0.5 mg/g dose. 
Additionally, the early survival rate (first 48 hours) after a 1.0 mg/g 
zymosan challenge was significantly higher in the macrophage-depleted than 
the macrophage non-depleted mice (100% vs. 67%). Overall 12 day survival 
rate was also higher in the macrophage depleted animals (80% vs. 47%) but 
this difference did not reach a level of statistical significance (Figure 3). 
Table 3. MAGNITUDE OF BACTERIAL TRANSLOCATION 
187 
Group Spleen Lung 
MA only 
MA+ Paraffin 
Controls 
M 0 depleted 
MA+Zymosan 0.5 mg 
Controls 
M 0 depleted 
MA+Zymosan 1,0 mg. 
Controls 
M0 depleted 
24 hours 48 hours 24 hours 
2T7 ± 0.6 1.9 ± 0.6 0.0 ± o".o ~ 
2.9 ± 0.2 
3.5 ± 0.7 
2.4 ± 0.4 
15 ± 0.7 
4.6 ± 0.3 
4.1 ±0.4 
4.010.3 
3.5 ± 0.3 
0.0 ± 0.0 
0.0 ± 0.0 
4.7 ± 0.9 
3.7 ± 0.8 
5.0 ± 0.4 4.4 ± 0.4 5.2 ± 0.5 
5.3 ± 0.4 4.710.4 4.8 ± 0.6 
MA=monoassociated; M0= macrophage. Data are expressed as I 
significant differences 
48 hours 
<M¡ ±0Л 
0.0 ± 0.0 
0.0 ± 0.0 
5.2 ± 0.7 
4.5 ± 0.7 
24 hours 
~0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
48 hours 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
5.1 ±0.8 
4.9± I.I 
5.7 ± 0.8 
5.2 ± 0.5 
4.7±I.O 6.1 ±0.4 6.1 ±0.5 
5.2 ±0.7 5.4 ± 0.5 5.4 ± 0.7 
g'° CFU E-Coli CIS in positive organs : 
24 hours 
~0.0±0.0 
0.0 ± 0.0 
0.0 ± 0.0 
5.3 ± 0.8 
6.0 ± I.I 
48 hours 
~ O 0 ± 0 . 0 ~ 
0.0 ± 0.0 
0.0 ± 0.0 
3.8 ± 0.3 
3.5 ± 0.4 
5.1 ± 0.4 
6.2 ± 0.5_ 
SEM. There 
3.8 ± 0.6 
4.3 ± 0.5 
are no 
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8 0 -
7 0 -
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ρ = 0.04 
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1 47% 1 
Overall ( 
80% 
12 days) 
" 
• 
D 
Controls 
M0 depleted 
188 
Figure 2 
Effects of macrophage elimination on survival rates after zymosan 
challenge. 48 hour survival was significantly better in the macrophage 
depleted mice when compared with the control mice. Overall survival 
was better in macrophage depleted but did not reach a level of 
statistical significance (Fisher's exact or Chi-square test when 
appropriate). 
9.5 DISCUSSION 
The main conclusion of the present study is that in a model in which cecal 
bacterial population levels of Exoli CIS were increased and BT to the MLN 
was occurring, zymosan induced toxicity, as measured by symptom scores and 
mortality, was reduced in macrophage-depleted mice even though systemic BT 
was increased. This is in accordance with our previous study in which we 
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documented that CI2MBP-liposome mediated elimination of liver and splenic 
macrophages increased the incidence of systemic BT but decreased morbidity 
and mortality in mice with a normal gut flora challenged with zymosan . In 
this previous study mortality and morbidity appeared t o be independent of the 
systemic spread of bacteria, providing evidence that macrophages are impor­
tant mediators of toxicity in this model. However, it is possible that these 
observed phenomena are model-dependent, since Callery et al. have shown 
that Kupffer cell blockade by Gadolinium Chloride increased mortality in the 
cecal ligation and puncture (CLP) model, which is a model of chronic sepsis . 
Additionally, Groeneveld et al. demonstrated that elimination of macrophages 
did not reduce mortality in animals challenged with intravenously injected LPS 
2 2
. So, it appears that in some models, in which bacteria or endotoxin play an 
important role, macrophage elimination is not beneficial and can even be 
detrimental. 
The E.co// CIS used in the current study is a streptomycin resistant 
bacterial strain that was originally isolated from the feces of a healthy human 
2 3
. Berg et al. have demonstrated that Exoli C25 monoassociation induces a 
consistent almost 100% translocation t o the MLN 2 4 and that a direct 
relationship exists between cecal population levels and the number of viable 
bacteria cultured from the MLN 2 S . In this E.coh monoassociation model 
bacteria rarely spread to other organs like the spleen, liver, lung or blood 
unless host immune defenses are impaired. The current study confirmed that 
monoassociation alone with Exoli C25 resulted in very high cecal bacterial 
population levels associated with an almost 100% translocation rate t o the 
MLN but no systemic spread of bacteria. Additional zymosan challenge 
however, induced a generalized inflammatory response, resulting in the 
systemic spread of bacteria in a dose-dependent fashion. 
It has been demonstrated that BT impairs systemic immunity 2 6 and 
activates tissue macrophages 2 7 and Kupffer cells in particular 2 8 . In this 
perspective, it was surprising that the Exoli C25 monoassociation did not 
increase the earlier described generalized inflammatory response response t o 
zymosan challenge in this model S' l s . So it appears that the immunological 
changes induced by BT itself are minor when compared t o the zymosan 
challenge. 
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Macrophage elimination did not change the spread of bacteria to the MLN. 
This could be due to the already high levels of BT to the MLN by 
monoassociation alone, but also because intravenously administered CI2MBP-
liposomes eliminate almost exclusively macrophages in liver and spleen and 
not in the intestinal wall or MLN l 6 
The time and dose dependency of zymosan challenge was studied, by 
evaluating systemic signs and BT at both 24 and 48 hours after zymosan 
challenge with 0.5 mg/g or 1.0 mg/g doses of zymosan. It was of interest that 
the symptom scores 24 hours after zymosan challenge significantly decreased 
in the macrophage depleted mice, while the incidence of systemic BT did not 
significantly change. Furthermore, at 48 hours systemic BT was twice as high in 
the macrophage-depleted mice as in the control mice, although the symptom 
scores continued to be lower in the macrophage-depleted mice. Thus, it 
appears that macrophage elimination decreases the clearance of bacteria. The 
main contribution to the increased incidence of systemic BT in the 
macrophage-depleted mice was due to an increase in BT to the liver and 
spleen, which were the organs that were selectively depleted of macrophages. 
Since macrophages in these organs play a fundamental role in the normal host 
defense against portal derived bacteria and endotoxin 29, it appears that the 
systemic signs and mortality in this experiment were determined more by the 
elimination of macrophages than by BT. This observation corresponds with 
the clinical impression that outcome is determined more by the host's 
inflammatory response than by the septicemia itself 30. 
As mentioned earlier, our data are in contrast to studies using the CLP 
model, in which Kupffer cell blockade was accomplished by injection with 
gadolinium chloride 2 I , since in this study macrophage blockade increased 
mortality. One explanation for these discordant results may be related to the 
differential effects of CI2MBP-liposomes versus Gadolinium chloride, that is, 
CljMBP-liposomes physically eliminate hepatic and splenic macrophages while 
Gadolinium chloride predominantly blocks phagocytic activity of Kupffer cells, 
leaving other macrophage functions relatively intact . In addition, a recent 
study has shown that Gadolinium chloride treatment induces a pronounced 
rise of serum cytokine concentrations, which theoretically can enhance the 
ongoing inflammatory response32. Furthermore, the ZIGI model is primarily 
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an inflammatory model while the CLP model is a slowly progressive septic 
model, in which an intact host defense against bacteria is probably very impor-
tant 5 33 Taken together, these results indicate that attenuating macrophage 
function can have detrimental effects in models that depend on the host's 
intact phagocytic activity, while macrophage depletion may be beneficial in 
inflammatory models Furthermore, recent clinical data have questioned the 
macrophage hypothesis of MODS because it was demonstrated that 
preventive activation of macrophages by PGG-glucan was beneficial in patients 
undergoing major surgery or multiple trauma 34 35 
We realize that we have not shown that macrophage elimination fully 
prevents mortality, nor did we examine the extent of organ damage in this 
model Nonetheless, survival was significantly better in the macrophage 
depleted group during the first 48 hours after zymosan challenge although this 
difference was somewhat lost after 12 days So it seems that macrophage 
elimination did not have an as profound effect on late phase mortality in this 
zymosan model Why macrophage elimination did not fully prevent mortality 
could be explained by the fact that intravenously m|ected Q2MBP-liposome 
suspension exclusively eliminates liver and splenic macrophages l 6, leaving 
other subpopulations of macrophages intact, whose activation could eventually 
lead to organ damage and mortality In addition, another explanation could be 
the repopulation of liver and splenic macrophages which could have occurred 
during the 12 days of this study In fact, it has been demonstrated that 
repopulation from the bone marrow requires 7 days for Kupffer cells and, 19 | 
depending on the type of macrophage, 7 days (red pulp macrophages) to 60 
days (marginal zone macrophages) for splenic macrophages 36 
Recent data suggest that the relationship between gut barrier failure 
function and MODS may be more complex than initially assumed Studies on 
the translocation of bacteria to the MLN using E coli -ß-galactosidase and 
electron microscopic evaluation, suggest that most of the bacteria that 
reached the MLN are already ingested and killed by macrophages 37 38 Thus, 
it can be argued whether or not we are measuring the total extent of BT by 
culturmg only viable bacteria Additionally, intestinal bacteria or endotoxin, do 
not necessarily need to reach the portal circulation to induce a systemic 
inflammatory state BT could induce a local intestinal inflammatory response 
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that leads t o the subsequent release of cytokines and other pro-inflammatory 
factors from the gut associated lymphatic tissues, which could sequentially 
activate macrophages in other tissues It has been shown that after 
hemorrhagic shock gut-derived cytokines can be liberated even in the absence 
of detectable bacteria or endotoxin in the portal circulation 3 9 Lastly, ВТ does 
not necessarily have to be the only determinant factor leading t o an 
inflammatory response, but could be one of many factors leading to MODS In 
support of this concept, a recent study in our ZIGI model suggests a temporal 
relationships between the inflammatory response and the occurrence of ВТ 
4 0
 Specifically, shortly after a zymosan challenge a first peak of TNF-a activity 
is observed, which could be due to the activation of macrophages by zymosan, 
while a second peak of TNF-a and IL-6 occurs, which coincides with the 
occurrence of bowel edema and BT In addition, while BT was decreasing in 
the late phase of the model, organ damage, TNF-a and IL-6 production were 
still ongoing 4 0 These results indicate that ВТ is a second insult in the cascade 
leading to MODS and occurs at a time when macrophages are still being 
activated by a self-perpetuating inflammatory response 
In conclusion, although the intestinal bacterial load was higher and ВТ 
already occurred to the MLN before zymosan administration in the E coli CIS 
monoassociated mice, macrophage elimination disassociated zymosan induced 
BT from zymosan induced toxicity Systemic spread of bacteria occurred but 
the spread of bacteria by itself appeared not to be the critical factor in 
zymosan induced toxicity Caution however must be exercised in 
extrapolating these result to other situations since sensitivity to bacteria and 
endotoxin differs between species Nonetheless, this study demonstrates that 
excessive activation of liver and splenic macrophages can promote or 
perpetuate the development of MODS Further studies are required to define 
the role of other macrophage subpopulations in the pathogenesis of MODS 
and whether or not macrophage elimination can prevent late organ damage in 
this zymosan model of systemic inflammation and MODS 
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10.1 ABSTRACT 
Objective To evaluate the role of specific macrophage subpopulations in the 
development of zymosan induced multiple organ dysfunction syndrome by selective 
elimination of liver, splenic, alveolar and peritoneal macrophages 
Design Randomized animal trial 
Setting Central animal laboratory at the University Hospital Ni|megen, Nijmegen, the 
Netherlands 
Animals Male C57BI/6 mice 
Interventions Elimination of macrophages was accomplished by administration of 
multilamellar liposomes that contained dichloromethylene-bisphosphonate (C^MBP) 
Intravenous, intratracheal, and intraperitoneal administrations induced an elimination 
of liver and splenic, alveolar macrophages and peritoneal and omental macrophages 
respectively Zymosan I mg/g was injected intraper i toneal^ at day 0 The liposomes 
that contained C ^ M B P were administered before and after zymosan challenge A t day 
12 all surviving mice were killed 
Main Outcome Measures The body weights, temperatures and mortality rates were 
monitored daily Relative organ weights (ROWs) were calculated from the lungs, liver, 
spleen and kidneys after the mice were killed 
Results The liposomes that contained C ^ M B P administered intravenously before or 
after zymosan challenge did not induce significant changes in body weight, 
temperature or mortality rate The R O W of the liver was significantly decreased in 
both treatment groups Elimination of liver and splenic macrophages after zymosan 
challenge induced an increased R O W of the lung and a decreased R O W of the liver 
The liposomes that contained C ^ M B P administered intratracheal^ before zymosan 
challenge completely prevented deaths The body weights, temperatures and R O W s 
of the mice were not changed The liposomes that contained C ^ M B P administered 
intraper i toneal^ did not change body weight, temperature o r R O W C^MBP-
liposomes IP before zymosan challenge increased mortal i ty f rom 50% to 90% 
Conclusions These data show that the elimination of specific macrophage 
subpopulations and the elimination on specific time points in this model has 
differential effects, indicating a differential role of specific macrophage subpopulations, 
either protective or detrimental, in the development of multiple organ dysfunction 
syndrome 
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10.2 I N T R O D U C T I O N 
In normal host defense mechanisms, an inflammatory response is 
teleologically beneficial and is meant t o protect the host against injurious 
events On the contrary, in pathological conditions (eg, the systemic 
inflammatory response syndrome (SIRS), the adult respiratory distress 
syndrome (ARDS) and the Multiple Organ Dysfunction Syndrome (MODS)), 
an excessive generalized inflammatory response may have detrimental effects 
on the host1 2 Macrophages play a pivotal role in normal host defense 
mechanisms because of their antimicrobial phagocytic activity, antigen 
presenting capacity and regulation of the inflammatory response by their 
secretion of various immunoregulatory substances3 However, evidence has 
been accumulating with regard to an excessive activation of macrophages that 
could induce a generalized dysregulated excessive inflammatory response, 
leading to the development of SIRS, ARDS or MODS 4 6 This hypothesis is 
supported by various observations First, administration of macrophage-
derived cytokines to healthy volunteers produces a syndrome that closely 
resembles SIRS7 8 Second, experimental and clinical data indicate a concur­
rent activation of macrophages during the development of SIRS, ARDS and 
MODS, as demonstrated by increased levels of macrophage-denved products 
(eg, tumor necrosis factor, mterleukin-l and neoptenn) with a positive 
correlation of elevated levels with the subsequent mortality rate9 l 0 Finally, 
anti-cytokme strategies have attenuated or prevented the development of SIRS 
and subsequent MODS in various experimental models' '"'3 
Several studies have been ascribed a special pathophysiological role t o 
specific macrophage subpopulations (eg, alveolar macrophages14 l s , Kupffer 
cells1 6 l 7 splenic macrophages18 l 9 and peritoneal macrophages20 2 I ) in these 
syndromes 
An alternative approach to study the respective causal role of macrophage 
subpopulations in the pathogenesis of MODS is by investigating the effects of 
selective elimination of these cells For this purpose, we used the "liposome 
mediated macrophage suicide technique' In this approach, 
dichloromethylene-bisphosphonate (CI2MBP or clodronate) is selectively 
delivered intracellular^ to macrophages by a liposome carrier, which results in 
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a destruction of the cell. Other cells are nor structurally nor functionally 
affected by this technique2 3. By varying the route of administration, liposomes 
can be targeted to eliminate macrophages in specific tissues22 
We have applied this technique in the Zymosan Induced Generalized 
Inflammation model. In rodents, intraperitoneal (IP) challenge with zymosan, a 
particulate cell wall product of the yeast Saccharomyces cerevisiae , induces a 
typical triphasic illness with an early hyperdynamic response with concurrent 
bacterial translocation from the gut and, after a recovery phase, a late bacteria 
independent hypodynamic MODS-like phase with a generalized inflammatory 
response and organ dysfunction • . 
Recently, we have shown that elimination of liver and splenic macrophages 
can abrogate the early hyperdynamic response in this model, despite an 
increased bacterial translocation2 6. The purpose of the present study is to 
determine the role of specific macrophage subpopulations (i.e. liver, spleen, 
alveolar or peritoneal macrophages) in the development of MODS by studying 
the consequences of selective elimination of those macrophage 
subpopulations, either prior to or after the challenge with zymosan, for the 
clinical syndrome and organ damage in the late phase of this model. 
10.3 M A T E R I A L S A N D M E T H O D S 
A n i m a l s 
Inbred, specific pathogen free, male C57BI/6 mice (Charles Rivers, Wiga, 
Germany) (age range 6-8 weeks) were adapted to handling in their cages for 7 
days prior to the start of the actual experiment. Throughout the experiment 
all mice had free access to water taht was acidified with hydrochloric acid (to 
pH 3) and to standard mice laboratory chow ( RMH-GS pellets, irradiated at 
10 kGy, Hope Farms, Woerden, the Netherlands). The room temperature was 
kept constant at 21 °C and a 12 hour lighting cycle was maintained. The 
experiments were approved by the Animal Ethics Committee of the Medical 
Faculty of the University of Nijmegen, Nijmegen, the Netherlands. 
Z y m o s a n 
Zymosan A ( Sigma Chemical Co., St. Louis, Missouri, U.S.A.), sterilized by 
use of γ-irradiation S kGy), was suspended (25 mg/ml) by high frequency 
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vibration in liquid paraffin (60-80 mPa, European pharmacopeia PA S 68 81 
CP84602I) The suspension was sterilized by incubation in a water bath at 
I00°C for 80 minutes One day before use, the suspension was heated to 
40°C and dispersed by high frequency vibration for 15 minutes Sterility was 
confirmed by culture on a blood-agar medium The zymosan suspension was 
administered IP in a dose of I mg/g of body weight 
Preparation of CI2MBP-Liposomes 
Multilamellar liposomes were composed of phosphatidylcholine and choles-
terol (molar ratio 6 I) and contained CI2MBP dissolved in phosphate buffered 
saline (PBS, 0 25 g/ml) They were prepared as described earlier22 In brief, 86 
mg phosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany) and 8 mg 
cholesterol (Sigma Chemical Co) were dissolved in 10 ml chloroform, and a 
lipid film was produced by low vacuum rotary evaporation Subsequently, 10 
ml of the CI2MBP solution was added and the suspension was left at room 
temperature for 2 hours, sonicated for 3 minutes at 20 °C and left for 2 hours 
at 37 °C The liposome suspension was then diluted in 100 ml PBS, centrifuged 
at 100,000g for 30 minutes to remove free CI2MBP, and resuspended in 4 ml 
PBS 
Elimination of macrophage subpopulations 
Elimination of Kupffer cells and splenic macrophages was achieved by an 
intravenous (IV) inaction of 200 μΙ of liposomes that contained CI2MBP in the 
tail vein, this method has been demonstrated previously to achieve an 
elimination of these macrophages within 2 days2 2 Alveolar macrophages were 199 
eliminated by administering CI2MBP- containing liposomes intratracheal^ 
(IT) The mice were fixed in an upright position under total anesthesia with 
30 μΙ of a mixture (ratio 4 3 7) of ketamme hydrochloride (100 mg/ml, A U V 
Cui|k, the Netherlands), xylazme hydrochloride (Rompun, Bayer, Leverkusen, 
Germany) and saline that was injected intramuscularly Using a nylon tube 
(diameter 0 46 mm) that was connected to a I-ml syringe fixed in a 
micromanipulator, 100 μΙ of the CI2MBP-conatmmg liposome suspension was 
administered through the glottis into the trachea It has been demonstrated by 
this method that alveolar, but not interstitial, macrophages are eliminated 
within 3-5 hours 2 7 Elimination of peritoneal macrophages was accomplished 
by administering 100 μΙ of CI2MBP-containmg liposomes IP, 2 times 
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successively . The latter method has been demonstrated to eliminate 
peritoneal, omental and to a lesser extent liver and splenic macrophages 
within 4 days28 
For each route of liposome administration, verification of macrophage 
elimination was performed on 3 animals and the results were compared with 
those for untreated mice. Elimination of macrophages in the liver and spleen 
was verified by analyzing acid phosphatase activity in 8-μηη cryostat tissue 
sections of liver and spleen 2 days after IV injection of CI2MBP- conatining 
liposomes. Acid phosphatase activity was demonstrated by incubation with 1% 
naphthol-AS-BI-phosphate and 4% hexazotized pararosaniline for 30 minutes 
at 37°C. Elimination of alveolar macrophages was verified by quantification of 
macrophages in the alveolar lavage fluid 2 days after IT administration of 
CI2MBP-containing liposomes. After the lungs were dissected free, alveolar 
lavage was performed 3 times with I ml of PBS that contained 0.38% citrate. 
After staining with trypan blue, cells were counted using a hemocytometer 
chamber (Bürker counter, Tamson Co, Zoetermeer, the Netherlands). 
Cytospin preparations confirmed that more than 95% of the alveolar cells 
were macrophages. Elimination of the peritoneal macrophages was verified by 
quantification of macrophages in the peritoneal lavage fluid. The liposomes 
that contained CI2MBP were administered IP at days -4 and - 1 . A t day 0, 
peritoneal lavage was performed with 4 ml of PBS that contained 0.38% 
citrate. Quantification of cells was performed as described previously. 
200 Exper imental design 
Three series of experiments were performed to assess the effects of 
macrophage elimination in the various tissues. Within each series, 3 groups of 
mice were used: a control group, that received only zymosan, and 2 
experimental groups that received the CljMBP-containing liposome sus-
pension either before or after administration of zymosan. 
Thus, 3 groups of 15 animals were used to study the effects of IV liposome 
administration. The experimental groups received liposomes either 2 days 
before or 4 days after zymosan challenge. The effects of IT liposome 
administration were studied in 3 groups of 20 mice each. The experimental 
groups received liposomes either 3 days before or 4 days after zymosan 
challenge. Three groups of similar size were used to examine the effects of IP 
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liposome administration, for which the experimental groups received 
liposomes either both 4 and I days before or I and 4 days after zymosan 
challenge 
In all mice, body weight and rectal temperature were measured daily The 
clinical condition with the following possible symptoms such as loss of 
hemorrhagic fluid from the nose, conjunctiva and mouth, lethargy, anorexia, 
hyperventilation, ruffled fur and loss of liquid stools and mortality rate were 
monitored On day 12, all surviving mice were bled and killed by cervical 
dislocation, the lungs with the trachea, kidneys, liver and spleen were 
dissected free and weighed Relative organ weights (ROWs) were calculated 
by the following formula R O W = (organ weight/body weight) χ 100 % 
Statistical analysis 
Comparisons were only made between treatment groups and their specific 
control groups Statistical analysis of biological parameters (body temperature 
and body weight) was performed using the distribution-free curve analysis 
according to Koziol et al 2 9 Since the zymosan-mduced illness is characterized 
by distinct phases, comparisons were made separately for the course of the 
biological parameters in the acute phase (days 0 - 4 ) and late phase (days 8 -
12) of the model The non-parametric Kruskal-Wallis and Wi lcoxon two 
sample tests were used for statistical analysis of the ROWs Non-continuous 
data (mortality rates) were analyzed by use of the Fisher's exact or Chi-square 
tests when appropriate Differences between groups were considered to be 
statistically significant at p<0 05 
10.4 RESULTS 
Elimination of liver and splenic macrophages was confirmed by the absence 
of acid phosphatase activity of liver and splenic tissue (Figure I) in the mice 
that were treated IV with CI2MBP- containing liposomes Reduction of alveolar 
and peritoneal macrophages was confirmed by quantification of the 
macrophage cell concentration in the alveolar and peritoneal lavage fluid 
respectively Mice that were treated IT with CI2MBP-contammg liposomes 
demonstrated a mean macrophage concentration of 6 4 χ IO5 cells per 
milliliter, while control mice displayed a concentration of 27 0 χ 10s cells per 
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milliliter. IP administration of CI2MBP-containing liposomes achieved a mean 
macrophage concentration of 2.4 χ IO5 cells per milliliter, while a 
concentration of 40.7 χ IO5 cells per milliliter was found in the peritoneal 
lavage fluid of the control mice. 
Figure I 
Acid phosphatase activity of macrophages in mouse splenic tissue 
sections 48 hours after intravenous administration of liposomes that 
contained dichloromethylene bisphosphonate. (A): Section of normal 
mouse spleen (original magnification x80). (B): Section of mouse spleen 
treated withliposomes that contained dichloromethylene 
bisphosphonate. Most macrophages are eliminated; only some 
macrophages in the white pulp remained (original magnification χ 100). 
202 
Intraperitoneal administration of zymosan induced a typical triphasic illness 
in all control animals as described earlier . In the early hyperdynamic phase 
(days 0 - 4 ) the animals became hypothermic, lethargic and anorectic; they 
hyperventilated, lost weight and hemorrhagic fluid from the nostrils and 
conjunctivae and had diarrhea. Thereafter, the condition of the surviving 
animals improved temporarily. However, after 8 days the clinical condition 
worsened progressively. In this late hypodynamic phase (days 8-12) the ani­
mals became more lethargic and hypothermic, hyperventilated and started to 
lose weight and hemorrhagic fluid from the nostrils and conjunctivae again. 
The mortality of the control animals varied among the three experiments, 
with an overall survival rates of 47%, 75% and 50% in the control micewith IV, 
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Figure 2 
Effects of intravenous (IV), intratracheal (IT) and intraperitoneal (IP) 
dichloromethylene bisphosphonate-containing liposomes on survival 
rates. 
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IT, and IP treatment, respectively (figure 2). Inspection of the lungs of the mice 
that died in the late phase or that were killed at day 12 demonstrated 
extremely hyperemic lungs with hemorrhagic spots and occasionally massive 
hemorrhagic infarction. The abdomen showed signs of an extensive 
fibroplastic peritonitis with massive adhesions. The ROWs of the lungs, liver 
and spleen were dramatically increased compared with the control values 
(figure 3). 
Elimination of liver and splenic macrophages by IV administration of 
CI2MBP-containing liposomes before or after challenge with zymosan did not 
induce significant changes in the subsequent course of body weight and 
temperature (data not shown). N o significant changes were observed either in 
the mortality between the control and CI2MBP-containing liposome-treated 
groups: overall survival rates were 47% in the control mice and 60% and 53% 
when mice were treated with liposomes before or after zymosan challenge, 
respectively (figure 2). Intravenous administration of liposomes after zymosan 
challenge led t o significantly increased relative lung weights, while relative liver 
weights were significantly reduced in both groups that were tested with 
liposomes (figure 3). N o significant differences were noticed in relative spleen, 
and kidney weights. 
Intratracheal administration of liposomes that contained CI2MBP before or 
after zymosan challenge did not result in significant differences in the course of 
the biological parameters (data not shown). While 25% of the animals died in 
204 the control group, no deaths occurred in the group which received liposomes 
before zymosan (p=0.04), but elimination of alveolar macrophages after 
zymosan challenge did not significantly reduce the mortality rate (figure 2). 
Organ damage, as measured by the ROWs, was not significantly changed by 
elimination of alveolar macrophages (figure 3). 
Intraperitoneal administration of liposomes that contained Q 2 MBP did not 
significantly change the course of body weight and temperature (data not 
shown). However, administration of CI2MBP-containing liposomes before 
zymosan challenge induced a dramatic mortality rate. While mortality was 
approximately 50% in the control group and the group that received 
liposomes after zymosan, it reached 90% if animals were pretreated with 
liposomes (figure 2, ρ = 0.02). The latter mortality was mainly due t o the fact 
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Figure 3 
Relative organ weights at 12 days after injection of zymosan (Data are 
expressed as mean ± SEM, Wilcoxon's two sample test , *" ρ < 001), 
IV= intravenous, IT^intratracheal, and IP= intraperitoneal 
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that the animals died in the early phase of this model. Wi th only two animals 
surviving in this group, no reliable conclusions could be made with respect to 
organ 
damage. In the animals that were treated with liposomes after zymosan 
challenge, no statistically significant changes in the ROWs were observed 
(figure 3) 
10.5 D I S C U S S I O N 
This study shows that elimination of Kupffer cells and splenic macrophages 
(portal macrophages), either before or after zymosan challenge, is associated 
with lower, although not significantly, late deaths and significantly lower 
relative liver weights, indicating less liver damage. This is consistent with 
studies that have documented that excessive Kupffer cell activation is 
associated with alterations in liver function16. Concomitantly, relative lung 
weights were higher when portal macrophages were eliminated after zymosan 
challenge. The latter observation may be explained in view of other studies 
that have hypothesized that ARDS and MODS could result from 
dysfunctionmg Kupffer cells which spill over endotoxin to the lung and induce 
an excessive activation of alveolar macrophages; this phenomenon has been 
coined the "liver-lung axis" Indeed, alveolar macrophages are releasing much 
more TNF in response to lipopolysacchande than Kupffer cells30. Thus, by this 
206 mechanism, elimination of portal macrophages could lead to an activation of 
alveolar macrophages that results in increased lung damage. 
Our data did not show adverse effects on the mortality rate by eliminating 
portal macrophages This is in contrast with a study in the cecal ligation and 
puncture model, in which Kupffer cell blockade was achieved with gadolinium 
chloride31. Whi le increasing systemic immunity, this method of macrophage 
blockade increased the mortality rate. These discordant results could be 
explained because gadolinium chloride predominantly blocks phagocytic 
activity of Kupffer cells, leaving macrophage secretory activity relatively in-
tact32. The method which we applied, physically eliminates almost all Kupffer 
cells, leaving no function intact33. Furthermore, while the zymosan induced 
generalized inflammation (ZIGI) model is largely independent of bacteria, the 
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cecal ligation and puncture model is a slowly progressive bacteremic model, in 
which an intact host defense against bacteria is probably important24 
Apparently, the effects of manipulating macrophage function on host defense 
can be detrimental in models or clinical situations that depend on the intact 
phagocytic activity of host defense 
In this respect, our data of elimination of peritoneal macrophages are 
illustrative Elimination of peritoneal macrophages before zymosan challenge 
induced a dramatic increase in the mortality rate, suggesting that in the early 
phase of this model the function of peritoneal macrophages is essential for 
host defense against intruding micro-organisms or injurious agents like 
zymosan However, elimination of peritoneal macrophages after zymosan 
challenge did not induce such effects since the mortality rate and ROWs were 
not significantly different So, there appears to be a differential involvement of 
peritoneal macrophages in the development of MODS in this model a 
protective role in the early phase and an indifferent role in the late phase In 
the ZIGI model an early depression of peritoneal macrophage production 
capacity for TNF, mterleukin-l and interleukm-6 was observed during the first 
days after zymosan challenge, while they regained their capacity to produce 
cytokines in the late phase21 Cecal ligation and puncture has also been shown 
to induce an early depression of peritoneal macrophage TNF production 
capacity and antigen presentation3 Furthermore, these observations are 
interesting when comparing them with the observation of an increased 
susceptibility to a septic challenge after hemorrhage, since hemorrhage has 
been shown to decrease antigen presenting and phagocytic activity while 
leaving the ex-vivo secretory capacity of peritoneal macrophages relatively 
intact36 37 Although it remains speculative, it could be that in the early phase 
elimination of peritoneal macrophages before zymosan challenge, enhances the 
effects of this early overall depression of peritoneal macrophage function, 
resulting in an increased mortality rate, comparable with the observed 
increased susceptibility for a septic challenge after hemorrhage Furthermore, 
IP administration of CI2MBP- containing liposomes does not only eliminate IP 
and omental macrophages, but also to a lesser extent liver and splenic 
macrophages28 However, it appears unlikely that the observed effects that are 
seen after IP administration of CI2MBP-contaimng liposomes before zymosan 
CHAPTER 10 
STuD£s ON THE MOTOR or MODS 
challenge could be attributed to partial elimination of these macrophages, 
since elimination of Kupffer cells and splenic macrophages alone did not 
induce adverse effects Hence, it seems that the observed high early mortality 
rate should be specifically attributed to the elimination of peritoneal 
macrophages 
Although not preventing organ damage or altering the course of the 
syndrome, it is striking that the elimination of alveolar macrophages before 
zymosan challenge completely prevented mortality This observation was 
consistently found in several pilot experiments (data not shown) This is in line 
with clinical data that have shown elevated levels of macrophage derived 
cytokines (eg, TNF and interleukm-l) in bronchoalveolar lavage fluids in 
critically ill patients in whom ARDS devops15 However, late elimination of 
alveolar macrophages did not alter the clinical course or mortality rate, nor 
did it influence organ damage Thus, it appears that early alveolar activation is 
associated with mortality, while MODS appears to be independent of late 
alveolar macrophage activation Other investigators, however, have shown 
experimentally that lung injury in the cecal ligation and puncture model was 
associated with a gradual increase in alveolar macrophage activation14 
Evidence for a less important role of the activated alveolar macrophage in the 
evolution of ARDS is supported by the clinical observation that early ARDS 
was associated with an increased number of macrophages while a sustained 
elevated number of macrophages correlated with a decreased risk of death38 
These data suggest that early alveolar macrophage activation is associated with 
the onset of ARDS, while late alveolar macrophage activation is associated 
with a resolution of ARDS 
A ma|or finding of this study was that selective elimination of any 
macrophage subpopulation, either before or after zymosan challenge, could 
not prevent both organ damage and death in this model This could be 
explained by several hypotheses First, during the development of MODS in 
this model, repopulation of some macrophages could already have been 
achieved in the late phase Repopulation from the bone marrow requires 7 
days for Kupffer cells and, depending on the type of macrophage, 7 days (red 
pulp macrophages) to 60 days (marginal zone macrophages) for splenic 
macrophages22 Alveolar macrophage repopulation starts after 5 days and is 
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complete after 18 days . Repopulation of peritoneal macrophages takes 7 
days and of repopulation of macrophages of the omentum takes 7 to 28 
days28. When those macrophages were eliminated before zymosan challenge, 
their reappearance would be almost complete in the late phase, while it would 
be only partial when those macrophages were eliminated after the zymosan 
challenge22. Hence, the reappearance of those macrophages in this phase 
could trigger the development of MODS, if the agents or events which keep 
the macrophages activated are still present. Second, there are also indications 
in other models that the non-depleted macrophages demonstrate an increased 
activity22. So, the elimination of I subpopulation of macrophages could result 
in a compensatory activation of other macrophages or cell populations with an 
enhancement of the inflammatory response. In this respect the observed 
increased lung organ damage after elimination portal macrophages is an 
interesting phenomenon. Furthermore, elimination of peritoneal and alveolar 
macrophage populations was not complete; thus, the remaining macrophages 
could have hypothetically induced MODS in this model. On the other hand, 
the dramatic effects of IT and IP liposomes before zymosan challenge, suggest 
a significant contribution of the depletion of those macrophages to these 
phenomena. 
The results could also be interpreted to support the notion that 
macrophage activation is not an important feature in the development of 
MODS. Indeed the macrophage hypothesis has been questioned because of 
recent clinical data, indicating that preventive enhancement of macrophage 
activity by polyglucotriosyl glucopyranose glucan is beneficial for patients who 
are undergoing major surgery or multiple trauma3 9 , 4 0 . On the other hand, our 
data indicate that elimination of Kupffer cells and splenic macrophages 
attenuates liver damage. Furthermore, elimination of alveolar macrophages 
before zymosan challenge could fully prevent zymosan induced death, 
indicating an important role for these macrophages in the development of 
MODS. 
Our data further show that the elimination of certain macrophage 
subpopulations and the elimination on specific time points in this model has 
differential effects, indicating a differential role of specific macrophage 
subpopulations, either protective or detrimental, in the development of 
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MODS. Peritoneal macrophages appear t o be important in host defense 
mechanisms in the early phase, while contributing t o the development of 
MODS in the late phase of this model. Kupffer cells and splenic macrophages 
appear to play an important pathophysiological role in all phases, while 
alveolar macrophages appear to be detrimental in the early phase. Thus, it 
remains to be determined, which specific macrophage functions or populations 
are essential and need t o be stimulated, while others are detrimental and need 
t o be inhibited 
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I L I I N T R O D U C T I O N 
In order to identify the specific role of cells and mediators in the 
development of MODS, the studies presented in this thesis describe various 
interventions in the excessive inflammatory response leading to MODS. This 
has been achieved by eliminating or blocking various cells or mediators. 
Furthermore, the common pathway of a generalized inflammatory response, 
i.e. generalized endothelial damage with subsequent generalized permeability 
changes has been described. The objective for these interventions was 
twofold. Firstly, t o achieve more insight in the pathophysiological role of some 
cells, mediators and mechanisms in the development of MODS. Secondly, t o 
achieve an attenuation or prevention of MODS, if possible. Of course we 
should be careful t o extrapolate data from our experimental studies to the 
clinical situation. However, experimental studies are the basis for evidence 
based medicine. Clinical studies have the major drawback that patient 
populations are diverse and that variables are numerous, making them less 
suitable for studying pathophysiological mechanisms. However, they are 
invaluable to identify the problems, which have to be elucidated in the 
laboratory. MODS is a clinical problem of our ICU patients, and not of our 
experimental mice. Moreover, clinical studies are indispensable to validate 
pathophysiological mechanisms and therapies which have been developed in 
the laboratory'. 
214 The conclusions of the experimental studies on the role of the selected 
mediators, cells and mechanisms in the excessive inflammatory response 
leading t o MODS will be discussed below. 
I 1.2 V A S C U L A R P E R M E A B I L I T Y C H A N G E S 
If MODS is the result of an excessive inflammatory response, then one of 
the major targets of this inflammatory response i.e. the endothelium has t o 
demonstrate a generalized damage, with subsequently vascular permeability 
changes2. Our permeability study shows that vascular permeability is increased 
in almost every organ, especially early after zymosan challenge. Moreover, an 
early increased permeability appears t o precede organ damage in this model. 
CHAPTER / / 
G F N E R A L DISCUSSION 
Furthermore, it is remarkable that vascular permeability is decreased after this 
early increase, in almost every organ. This pattern has been confirmed by 
clinical studies in patients with post-traumatic ARDS Shortly after trauma, an 
increase in pulmonary vascular permeability was observed, with a peak after 
48 hours This stage was followed by a decrease in permeability, but with an 
increase in extravascular lung water, ι e interstitial edema Apparently, in the 
late MODS phase, endothelial permeability does not necessarily have to be 
increased anymore to fuel the ongoing inflammatory response. The 
inflammatory response has been transformed to a self-perpetuating 
dysregulated inflammatory process outside the vascular barrier In this respect, 
plasma concentrations of inflammatory mediators do not necessarily represent 
the inflammatory state of the host Local concentrations of those mediators 
and the mRNA contents of extravascular inflammatory cells, are probably 
more important denominators of the inflammatory response4 Hence, the 
elimination or attenuation of those inflammatory cells or mediators on a local 
level provides more insight in the importance of those cells and their released 
mediators in the inflammatory response leading t o MODS. 
After some 20 years, the discussion on the use of macromolecular colloidal 
fluids in the resuscitative phase of critically ill patients in the ICU is still going 
on 5 . The data from this study support a critical appraisal of the use of those 
fluids While macromolecules can easily pass the leaky endothelial barrier in 
the initial phase, they probably can not leave the mterstitium due t o a 
decreased permeability in the late MODS phase 
I 1.3 T H E ROLE O F C O M P L E M E N T A C T I V A T I O N 
Both clinical and experimental data have suggested a relationship between 
activation of the complement system and the pathogenesis of septic shock, 
ARDS and MODS6"1 ' During septic shock, most clinical studies have shown an 
activation of C5a 1 2 However, data are conflicting when C5 is correlated t o 
prognosis or the development of ARDS or MODS 1 3 " 1 6 . Our experiments with 
C5-deficient mice show that, blocking (part of) the complement cascade can 
attenuate the early hyperdynamic SIRS-like response. However, the late 
hypodynamic MODS phase and organ damage remained unaltered. So, m the 
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late phase, an activation of the inflammatory cascade by microbial or non-
microbial activation via the complement system appears not to be mandatory 
anymore. This is in line with the general perception that the inflammatory 
response is dysregulated, self-perpetuating, and does not need a specific 
stimulus anymore17. Since the regulation of the inflammatory response highly 
depends on macrophage activation, our attention was directed towards the 
macrophage . 
I 1.4 T H E ROLE OF M A C R O P H A G E S 
It has been hypothesized that an excessive activation of macrophages is 
one of the pivotal mechanisms in the pathophysiology of MODS . Excessive 
activation of macrophages has been shown to induce the release of various 
pro-inflammatory cytokines and a profound immunosuppression20,21. Most 
studies on the role of macrophages in the development of MODS have 
focused on the release of various products by the activated macrophage. 
Indeed, the important involvement of macrophages has been demonstrated by 
the identification of a concomitant release of pro-inflammatory macrophage 
derived products such as TNF, IL-1, IL-6, IL-8 and neopterin22"26. However, a 
positive correlation with the development of ARDS, MODS and mortality, has 
only been consistently observed for IL-6 . In addition, experimental studies 
have shown a protective effect of anti-cytokine strategies. However, those 
216 anti-cytokine strategies have failed to positively influence outcome or the 
prevention of ARDS and MODS in the clinical situation28. The pleiotropic, 
synergistic and antagonistic activities of cytokines within the cytokine network, 
make it probably impossible to ascribe a clinical syndrome such as MODS to 
the activation of one particular c y t o k i n e . Hence, from these studies the 
question remains unresolved whether or not the activated macrophage is an 
important mediator in the development of MODS. 
Our studies have used a completely different approach. Whi le others have 
blocked certain macrophage functions, we have physically eliminated specific 
macrophage subpopulations, in order to determine their role in the 
pathophysiology of MODS30 . CI2MBP liposome mediated elimination of liver 
and spleen macrophages attenuate the first hyperdynamic phase, and 
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decreases mortality However, the study that focused more on the late 
consequences of macrophage elimination demonstrates that organ damage still 
occurs in the late phase. This failure to prevent organ damage could be due to 
the activation of other macrophage subpopulations or inflammatory cells, or 
to a repopulation from the bone marrow that could have had occurred during 
the development of MODS in this model30 
The same technique was used to study the role of other macrophage 
subpopulations before and after zymosan challenge. Clinical data have 
demonstrated elevated levels of macrophage derived cytokines as TNF and IL-
I in bronchoalveolar lavage fluids in critically ill patients developing ARDS, 
with a positive correlation with outcome, suggesting an important role for the 
alveolar macrophage31 32 Our studies have shown a remarkable prevention of 
mortality by elimination of alveolar macrophages before zymosan challenge. 
However, again, late organ damage could not be prevented This demonstrates 
a pivotal role for the alveolar macrophage in the inflammatory response. 
Further studies should focus on the specific role of these cells. The dramatic 
increase in mortality by the elimination of peritoneal macrophages before 
zymosan challenge, demonstrates the importance of other macrophage 
subpopulations in host defense. More importantly, our studies show that the 
pathophysiological involvement of macrophages is time, site and population 
specific. 
I 1.5 T H E ROLE O F B A C T E R I A L T R A N S L O C A T I O N A N D 
T H E G U T 
As discussed in chapter 2, bacterial translocation occurs both in humans 
and in animals. However, the relationship between bacterial translocation and 
the development of SIRS, ARDS and MODS has only been suggested from 
animal studies and a causal relationship has never been demonstrated17. 
Clinical studies have failed to prove a positive correlation between infection, 
bacterial translocation and MODS. In our macrophage elimination studies, we 
observed an increase of systemic bacterial translocation, while systemic signs 
of inflammation and mortality decreased. We thus concluded that systemic 
bacterial translocation is not a determinant for mortality. However, this 
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statement requires a critical appraisal. The use of classical cultunng techniques 
can be disputed, since they underestimate the actual bacterial translocation3 3 
However, if the actual systemic bacterial translocation was more extensive 
than what we measured in our experiments, our conclusion would still be 
valid. Furthermore, we do not conclude that bacterial translocation is of no 
importance, but we conclude that the systemic spread of bacteria is of minor 
importance for systemic signs and mortality Still, we realize that macrophages 
have t o be activated by certain stimuli, like bacteria or endotoxin. The effects 
of eliminating activated macrophages might be determined by the macrophage 
itself as well as by the stimulus that activates the macrophage. There are 
various lines of observation that support the hypothesis that the gut is an 
important activator of macrophages It has been hypothesized that bacteria 
and LPS entering the portal system might activate macrophages34 
Furthermore, when portal macrophages are dysfunctional, distant 
macrophages, such as alveolar macrophages might be activated by those 
stimuli, a process which has been referred as the "liver-lung axis"3 5 In 
addition it has been demonstrated recently, that the gut is an active cytokine 
generating system, which subsequently may activate portal and other 
macrophages36 3 7 On the other hand, the importance of these observations 
are questioned by clinical studies on trauma patients, in which catheters were 
placed in the portal vein during an emergency laparotomy. These studies did 
not reveal a correlation between portal endotoxemia, bacteremia or 
218 cytokinemia and subsequent survival or the development of MODS 3 8 
I 1.6 B A C K T O T H E F U T U R E 
The studies presented in this thesis have enlarged our insight in the role of 
inflammatory cells and mediators in the cascade leading to MODS. The 
inflammatory response of the host has the potential to be "good", "bad" or 
"ugly" It is good or beneficial if the inflammatory response is taken place in a 
localized finely tuned, well regulated manner. It is bad or detrimental when 
many excessive signals from macrophages are received by the PMNs leading t o 
a generalized endothelial damage and an excessive inflammatory response, ι e 
SIRS. It is ugly or disastrous when a chaotic dysregulated inflammatory res-
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ponse and a suppressed immune system lead to nosocomial infections, organ 
injury and MODS. In this respect we have to discriminate the terms excessive 
and dysregulated 39 . 
It appears from clinical studies that the incidence of MODS has a bimodal 
distribution . In a study of 457 high-risk trauma patients, MODS developed in 
39% of the patients shortly after trauma, while in 6 1 % the presentation was 
delayed. Early MODS patients died faster, showed signs of an excessive 
inflammatory response and a high incidence of cardiovascular and pulmonary 
failure. Late MODS patients, however, displayed a severe immunodepression 
while concurrent infections appeared to precipitate fatal outcome, with organ 
dysfunction being distributed among more organs40. Others have 
demonstrated that macrophage activation shows the same temporal pattern, 
with an immediate excessive activation, shown by the excessive release of 
pro-inflammatory cytokines shortly after the injurious event, followed by 
paralysis and subsequent recruitment of immature macrophages after 3-5 days, 
with a decreased regulatory capacity41. It is remarkable that signs, symptoms 
and mortality in our ZIGI-model show the same triphasic time-pattern42. 
Moreover, TNF plasma concentrations displayed a remarkably similar pattern, 
while production capacity of the macrophages for other cytokines was highly 
depressed . Our macrophage elimination studies showed that the elimination 
of any subpopulation after zymosan challenge did not essentially change the 
late clinical syndrome. Hence, in this phase it does not appear that 
macrophage hyperactivation is of major importance. However, in the early 219 
phase, mortality was decreased by elimination of alveolar and portal 
macrophages. This concept is supported by the observation of the greatest 
increase in permeability in the early phase, suggesting the highest inflammatory 
activity in this phase. Recent studies have related the late dysfunctional state of 
macrophages in MODS to increased apoptosis44. 
Furthermore, it remains to be elucidated why one patient develops MODS 
and the other doesn't, even when they have the same pre-injury clinical 
condition and extent of injury. This biological variation in injury-response has 
been proposed to be the result of a genetic predisposition for the 
development of MODS45 . Indeed, outcome in critically ill patients has been 
recently shown to be related to the presence of a genomic marker for an 
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increased TNF response 
Hence, the question remains whether or not the inflammatory response is 
"good", "bad" or "ugly" for our critically ill patient Actually, this may depend 
on "where", "when" and "how" For example, elimination of peritoneal 
macrophages in the early phase increased mortality dramatically, supporting 
the concept that shortly after the insult, on this specific site, a strong 
inflammatory response is beneficial, because it is probably essential for host 
defense This was not the case for alveolar macrophages, where an activation 
appears to be harmful in the early phase As discussed above, in the late phase 
macrophage elimination did not change the response Because of these time-
and place-dependent mechanisms, our future approach in elucidating the role 
of the inflammatory response in MODS has to be much more differentiated 
On certain time points and locations, we have to augment the inflammatory 
response, while on other places and time points the inflammatory response 
may need to be inhibited It will be one of the major goals of research in the 
future to determine which functions and cells need to be inhibited and which 
need to be augmented at any specific time point of the development of 
MODS This supports a further plea for changing the denomination multiple 
organ failure to multiple organ dysfunction47 
The evolutional question remains whether or not we can fool mother 
nature48 Originally, this excessive inflammatory response has been developed 
to localize injury, prevent further damage of the host and initiate repair 
220 mechanisms When the stimulus was too strong, like in peritonitis, multiple 
trauma, the host would not survive However presently, by progress in organ 
support, patients are surviving these initial insults, while an ongoing excessive 
inflammatory response induces the development of MODS Because technical 
progress develops faster than evolutional mechanisms, the human race has 
never had - and probably never will have - the time to develop feedback 
mechanisms for such an excessive inflammatory response This is why 
progress in critical care has been questioned, being not wor th the money, 
because it has only given us longer but not higher survival However, still 
patients survive and recent studies have shown that after long term ICU-
admissions, the quality of life is acceptable, and worth the effort49 
On the other hand, the recently described genomic polymorphism within 
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the TNF locus4 6 may be a sign of the changing evolutional genetic 
heterogeneity of our human species. We have t o use this mutation of mother 
nature to further identify patients with a possible genetic makeup for an 
exaggerated inflammatory response, which are at risk of developing MODS. 
Furthermore, we could use this mutation for new therapies like gene therapy 
for MODS 5 0 . From the time that Eve has eaten the forbidden apple, it is the 
destination of the human being to constantly fool mother nature. Hence, we 
have to maintain our efforts t o fight the battle and search for new strategies 
against MODS. 
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STUDIES ON THE MOTOR OF MODS 
12.1 S U M M A R Y 
Currently, the incidence of the multiple organ dysfunction syndrome 
(MODS) has reached epidemic proportions in most intensive care units 
(ICUs). Since the initial description some 25 years ago, MODS remains the 
leading cause of death on the ICU and mortality rates have not changed 
essentially. Despite the enormous scientific effort, the conundrum of the 
pathogenesis and treatment of MODS remains unresolved. Because various 
insults can lead to MODS, a common pathophysiological mechanism has been 
suggested. It has been hypothesized that MODS is the final expression of an 
excessive generalized autodestructive inflammatory response. The question 
remains whether this inflammatory response is the true motor of MODS and 
if so, whether this response is excessive or inadequate. In this thesis, the 
specific in-vivo role of various inflammatory mediators and cells in the 
development of MODS has been studied in an experimental model for MODS. 
In chapter I MODS and clinically related entities like inflammation, 
infection, bacteremia, SIRS, sepsis, and ARDS are defined. Furthermore the 
epidemiological problem of MODS in our critically ill patients is discussed in 
an historical perspective. 
Chapter 2 discusses the gut-hypothesis in which the gut and gut-derived 
infections are postulated to be the real motor of MODS. Abnormal 
226 colonization, infections of gut origin (nosocomial infections), bacterial 
translocation are all signs of gut failure that have been implicated in the 
pathogenesis of MODS. Nosocomial infections, which are often caused by 
enteric bacteria, are a major problem in critically ill patients, but it remains 
unclear to what extent these infections are related to the development of 
MODS or to mortality in the ICU. Clearly, in some patients infection seems to 
be directly related to the development of MODS and mortality, while in 
others it is a secondary phenomenon and a symptom rather than a cause of 
MODS. Bacterial translocation is a phenomenon, which has been 
demonstrated to occur both experimentally and clinically under various 
pathological conditions. However, its pathophysiological importance is 
uncertain and needs further study. Studies on selective decontamination of the 
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digestive tract (SDD) vary considerably in study design and methods, but it 
seems to be clear that SDD reduces nosocomial colonization and respiratory 
tract infections The beneficial effect on cost reduction, length of stay in the 
ICU, days on the ventilator and mortality, are not proven and remain to be 
resolved in well conducted, prospective, double blind, placebo-controlled 
studies Serious concerns have been raised about the emergence of bacterial 
resistance and difficult to treat Gram-positive infections So, from a risk 
benefit point of view no legitimate argument can be made to implement SDD 
routinely on an ICU with mixed groups of patients, although certain 
homogenous subpopulations may benefit In conclusion, it appears that in 
some patients it is clear that loss of intestinal barrier function or the onset of 
infection precedes the development of MODS In other patients, however, this 
relationship is not so clear and it seems that these phenomena reflect the 
failure of the host's immune and mechanical defense systems and are 
epiphenoma of critical illness The causal relation between those phenomena 
and the development of MODS is complex and needs further clarification 
Chapter 3 provides an overview of arguments from the literature for the 
hypothesis that MODS results from an excessive inflammatory response 
Components of the inflammatory response are discussed in relation to the 
development of MODS Indeed, several studies provide support for this 
hypothesis by demonstrating experimental and clinical evidence for a direct 
relationship between the development of MODS and the activation of 
components of the inflammatory response, such as the complement system, 227 
PMN-endothehal interactions, macrophage(subpopulations) and various 
cytokines Most studies examining the role of those inflammatory mediators 
and cells in MODS have focused on studying the release and blockade of 
various products of these cells in relation with the development of MODS An 
alternative method of investigating aspects of those mediators and cells in the 
development of MODS is to evaluate the effect of selective elimination or the 
use of genetically deficient animals This approach is the mam sub|ect of this 
thesis 
The studies of this thesis have been performed in the ZIGI-model, which is 
discussed in chapter 4 In brief, in this unique long term model for MODS, an 
intraperitoneal challenge with zymosan, a particulate cell wall product of the 
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yeast Saccharomyces cerevisiae , induces a typical triphasic illness with an early 
hyperdynamic SIRS-like response with concurrent bacterial translocation from 
the gut and, after a recovery phase, a late bacteria independent hypodynamic 
MODS-hke phase with a generalized inflammatory response and organ 
damage. 
Chapter 5 outlines the main questions and aims of this thesis. In brief, we 
aimed t o answer the following questions in the ZIGI model: 
1 Does a generalized endothelial damage, as represented by permeability 
changes measured using scintigraphic methods occur in various organs 
(hart, muscle, lung, liver, spleen, ileum, colon and mesenteric lymph node 
complex)? Is there a certain temporal pattern and do permeability changes 
have a relationship with subsequent organ damage? 
2 Does activation of the complement system, especially factor C5, play a 
pivotal role in the development of MODS? Can we prevent or attenuate 
the clinical syndrome, organ damage or mortality by using genetically C5-
deficient animals' 
3. Does elimination of hepatic and splenic macrophages by intravenous 
dichloromethylene-bisphosphonate (CI2MBP)-hposomes prevent or 
attenuate the early response in this model?. Moreover, would these 
observations change if bacterial overgrowth is induced?. 
Does CljMBP-hposome mediated elimination of certain subpopulations of 
macrophages (i.e. hepatic, alveolar, splenic and peritoneal macrophages) 
228 before and after zymosan challenge affect the late hypodynamic MODS 
phase?. 
4. What are the effects of macrophage elimination on the concurrent spread 
of bacteria (bacterial translocation) and does this relate to the 
development of MODS?. 
In chapter 6 the serial evolution of vascular permeability as measured by 
protein extravasation in various organs during the development of MODS in 
the ZIGI model was demonstrated by measuring the biodistribution of 
' " i n d i u m labeled non-specific polyclonal immunoglobulin G ("Ίη- lgG). Mice 
were sacrificed 2, 5, 8 and 12 days after intraperitoneal challenge with 
zymosan suspended in paraffin, and heart, liver, spleen, kidneys, MLN and 
tissue samples of muscle, ileum and colon were dissected free and weighed. 24 
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Hours before sacrifice, Ίη-lgG was injected intravenously. Relative organ 
weights (ROW), wet t o dry weight ratios (WDR) and a permeability index (PI) 
were calculated. ROW, as a marker of organ damage, increased gradually until 
day 12. W D R , as a marker of tissue edema, also increased gradually in most 
organs. Lung W D R , however, initially increased with a subsequent return to 
normal. Splenic W D R did not change over time. Liver, spleen, ileum and colon 
PI were the highest on day 2, followed by a decrease towards normal. Lung PI 
showed a triphasic course with peak values at days 2 and 12. MLN-PI was 
continuously elevated. This study showed that W D R (tissue edema) and PI 
(protein extravasation) have different courses in various organs. Most organs 
displayed an early increase in PI, followed by a late decrease to normal values, 
while R O W (organ damage) were still increasing. Hence, it appeared that 
organ damage was preceded by an increased protein extravasation. 
Chapter 7 describes a study in which the role of complement factor C5 in 
the ZIGI model has been evaluated by comparing the development of MODS 
in genetically C5-deficient (B2DI0/Old) and C5-sufficient (B2DI0/New) mice. 
On day 0 all mice received an intraperitoneal injection with zymosan 
suspended in paraffin. Between day 0 and 12, biological parameters 
(temperature, body weight and clinical condition) were measured daily and 
mortality was monitored. Clinical condition was assessed as a symptom score 
by blindly grading the degree of symptoms. On day 12 all surviving mice were 
sacrificed and R O W of lungs, liver, spleen and kidneys were calculated. 
Zymosan administration induced the typical triphasic illness in all mice. 229 
Deterioration of the clinical condition in the acute phase, as indicated by the 
symptom score and the decrease in temperature and body weight, was 
significantly less severe in C5-deficient mice. In the late phase, however, no 
differences could be demonstrated in the courses of these biological parame­
ters. Overall mortality was 8% in C5-deficient mice and 32% in C5-sufficient 
mice, a difference mainly due to the acute phase. R O W did not show any 
statistical differences for any organ between both strains. Thus, it appears that 
complement factor C5 plays an important role in the acute hyperdynamic 
SIRS-like response in this model but deficiency of C5 could not prevent organ 
damage in the late MODS phase. This suggests that other factors must be 
more important in the development of the late inflammatory response leading 
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to MODS 
The central question being tested in chapter 8 was whether elimination of 
hepatic and splenic macrophages would influence zymosan induced bacterial 
translocation and the zymosan induced generalized inflammatory response. 
Elimination of those macrophages was accomplished by intravenous injection 
of a CL2MBP-liposome suspension. Control mice received an intravenous 
injection with phosphate buffered saline Two days later the animals were 
challenged intraperitoneal^ with zymosan (either 0 I, 0.5 or 1.0 mg/g body 
weight) suspended in paraffin Twenty four hours after zymosan challenge 
systemic signs and symptoms were determined by a symptom score, and 
bacterial translocation to the mesenteric lymph node (MLN), liver, spleen, lung 
and blood was measured A separate mortality study was performed with a 
zymosan dose of 1.0 mg/g. The incidence of systemic spread of bacteria was 
significantly increased in the macrophage depleted mice Although systemic 
bacterial translocation was promoted by macrophage elimination, the systemic 
toxic response was significantly decreased in all depleted groups. In these 
groups, 12 day mortality was 0%, and 27% in the control group. Hence, the 
lethal and toxic effects of zymosan appeared to be more related to the 
excessive activation of macrophages than to the systemic spread of bacteria. 
Since bacterial overgrowth is a frequently occurring phenomenon in 
critically ill patients, we evaluated in chapter 9 whether or not CL2MBP-
liposome mediated elimination of liver and splenic macrophages would 
230 influence zymosan induced bacterial translocation and the zymosan induced 
generalized inflammatory response in a model in which bacterial translocation 
to the MLN was already induced by bacterial overgrowth. Bacterial 
overgrowth was effectuated by decontaminating the gut with penicillin G 
sodium and streptomycin sulfate in the drinking water during 4 days, followed 
by monoassociation by adding life Exoli CIS to the drinking water. Elimination 
of macrophages was accomplished by intravenous injection with СЦМВР-
hposome suspension. Control mice received an intravenous injection with 
phosphate buffered saline. Two days later the animals were challenged 
intraperitoneal^ with zymosan at a dose of 0.5 or I 0 mg/g. Symptom scores, 
bacterial translocation to the MLN, liver, spleen, lung and blood and cecal 
population levels were determined 24 and 48 hours after zymosan challenge. 
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A separate mortality study was performed with a dose of 1.0 mg/g. The 
incidence of systemic spread of bacteria was significantly increased in the 
macrophage depleted mice as compared to the control mice, especially after 
48 hours and with the lower zymosan dose. Symptom scores were 
significantly decreased in the macrophage elimination groups. Early mortality 
after 48 hours was 0% in the macrophage elimination groups and 33 % in the 
control group. After 12 days, mortality was 20% and 53 %, respectively. Thus, 
in this model where intestinal bacterial population levels were increased and 
bacterial translocation was already established to the MLN, macrophage 
elimination also decreased mortality and systemic signs of inflammation, even 
though bacterial translocation was increased. Again, macrophage elimination 
disassociated zymosan induced bacterial translocation from zymosan induced 
toxicity. 
So far, the effects of elimination of hepatic and splenic macrophages before 
zymosan challenge on aspects of the early phase in the ZIGI model were 
studied. Chapter 10 describes a study in which the role of various specific 
macrophage subpopulations on the development of zymosan induced MODS 
in the ZIGI-model is examined. This had been achieved by CI2MBP-mediated 
selective elimination of hepatic, splenic, alveolar and peritoneal macrophages 
before and after zymosan challenge. Intravenous (IV) administration induced 
an elimination of hepatic and splenic macrophages, intratracheal (IT) 
administration elimination of alveolar macrophages and intraperitoneal (IP) 
administration elimination of peritoneal and omental macrophages. Zymosan 
(1.0 mg/g) was injected IP at day 0. CI2MBP-liposomes were administered 2 
days before and 4 days after zymosan challenge. A t day 12, all surviving mice 
were sacrificed. Body weight, temperature and mortality were monitored 
daily. ROW were calculated of the lungs, liver, spleen and kidneys after 
sacrifice. IV CI^MBP-liposomes before or after zymosan challenge did not 
induce significant changes in body weight, temperature or mortality. Liver 
R O W was significantly decreased in both treatment groups. Furthermore, 
elimination of hepatic and splenic macrophages after zymosan challenge 
induced increased lung R O W and decreased liver ROW. Despite the fact that 
body weight, temperature and R O W were not changed, mortality was 
completely prevented by elimination of alveolar macrophages before zymosan 
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challenge. IP CI2MBP-liposomes did not change body weight, temperature or 
ROW. IP CI2MBP-liposomes before zymosan challenge increased mortality 
dramatically from 50% to 90%. These data demonstrate that the elimination of 
specific macrophage subpopulations and the elimination on specific time points 
in this model had differential effects. This indicates a differential role for 
specific macrophage subpopulations at certain time points, which may either 
be protective or detrimental, in the development of MODS. 
Finally, in chapter I /, the results of the presented studies are discussed. 
The good, the bad and the ugly aspects of an inflammatory response are 
discussed in relation to the development of MODS. It appears that on certain 
time points and locations in the host, we have to augment the inflammatory 
response, while on other locations and time points the inflammatory response 
needs to be inhibited. It will be one of the major goals of research in the 
future to identify those functions and cells that need to be inhibited and which 
that need to be augmented. 
232 
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12.2 S A M E N V A T T I N G 
Heden ten dage heeft het multiple organ dysfunction syndrome (MODS) 
epidemische proporties aangenomen op de meeste intensive care units (ICUs). 
Mortaliteitspercentages zijn nauwelijks veranderd de laatste 25 jaar en MODS 
blijft de voornaamste doodsoorzaak van intensive care patiënten. Omdat 
verschillende oorzaken kunnen leiden to t MODS, is er een gemeenschappelijk 
pathofysiologisch mechanisme gesuggereerd. Een van deze voorgestelde 
mechanismen is de hypothese dat MODS de uiteindelijke expressie is van een 
excessieve gegeneraliseerde zelfdestructieve ontstekingsreactie. Echter, het 
blijft de vraag of deze ontstekingsreactie de ware motor van MODS is en zo ja, 
of zij te sterk of nog steeds inadequaat is. In dit proefschrift werd de specifieke 
in-vivo rol van mediatoren en cellen in deze onstekingsreactie bestudeerd in 
een experimenteel model voor MODS. 
In hoofdstuk I worden MODS en gerelateerde termen zoals ontsteking, 
infectie, SIRS en ARDS gedefinieerd. Daarnaast wordt het klinische probleem 
MODS besproken in een historische perspectief. 
Hoofdstuk 2 bespreekt de darmhypothese waarin de darm en infecties door 
darm-gerelateerde bacteriën (nosocomiale infecties) als de motor van MODS 
worden gezien. Abnormale kolonisatie, nosocomiale infecties en bacteriële 
translocatie zijn allen tekenen van een falende darmfunctie, die mogelijk 
betrokken zijn in de Pathogenese van MODS. Experimentele en klinische 233 
studies die geprobeerd hebben een correlatie tussen het optreden of de 
preventie (door selectieve darmdecontaminatie (SDD)) van deze fenomenen 
en de ontwikkeling van MODS of mortaliteit op de ICU hebben proberen te 
vinden zijn samengevat in dit hoofdstuk. Nosocomiale infecties, die vaak 
worden veroorzaakt door darmbacterien, zijn een belangrijk probleem op de 
ICU. Op grond van literatuurgegevens blijft het echter onduidelijk of deze 
infecties gerelateerd zijn aan MODS of aan mortaliteit op de ICU. Bij sommige 
patiënten zouden infecties mogelijk direct gerelateerd kunnen zijn aan MODS 
en mortaliteit, echter bij anderen lijkt het slechts een secundair verschijnsel en 
meer een symptoom dan een oorzaak van MODS. Bacteriële translocatie is 
een fenomeen, wat zowel bij dieren als mensen aangetoond is op te treden 
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ti)dens meerdere pathologische omstandigheden, echter de pathofysiologische 
betekenis ervan is nog steeds onduidelijk en vraagt om verdere bestudering 
SDD studies wisselen enorm wat betreft hun patiënten en methoden, echter 
op grond van meerdere studies lijkt het wel bewezen dat SDD de mcidentie 
van nosocomiale kolonisatie en luchtweginfecties verminderd Een positief 
effect op kostenbesparing, opname duur, beademmgsdagen en mortaliteit is 
echter met duidelijk en dient nog aangetoond te worden in goede prospectief 
dubbelblind placebo-gecontroleerde gerandomiseerde studies Daarnaast is de 
ontwikkeling van bactenele resistentie en moeilijk behandelbare gram-posi-
tieve infecties door SDD reeds beschreven Dus, met betrekking tot de kosten 
en baten, is er tot nu toe geen legitieme reden om SDD routinematig op de 
ICU toe te passen, alhoewel misschien nog nader te bepalen homogene 
patiënten subgroepen enig voordeel zouden kunnen genieten 
Concluderend lijkt het erop dat bij sommige patiënten het falen van de darm 
of darm-gerelateerde infecties de ontwikkeling van MODS voorafgaan Bi| 
ander patiënten is deze relatie niet zo duidelijk en lijkt het erop dat deze 
verschijnselen een epifenomeen zijn van MODS en meer een teken zijn van 
een falende afweer in het kader van het falen van meerdere orgaansystemen 
De causale relatie tussen deze fenomenen en MODS is zeer complex en 
vraagt om verdere bestudering 
Hoofdstuk 3 geeft een overzicht van argumenten uit de literatuur voor de 
hypothese dat MODS het resultaat zou kunnen zijn van een excessieve 
234 ontstekingsreactie Onderdelen van deze ontstekingsreactie worden bespro-
ken in relatie met de ontwikkeling van MODS Meerdere studies leveren een 
bewi|s voor deze hypothese door een relatie aan te tonen tussen de ontwik-
keling van MODS en de activatie van onderdelen van deze ontstekingsreactie, 
zoals het complement systeem, PMN-endotheel interacties of macrofagen met 
hun producten De meeste studies richten zich echter op de bestudering van 
de release en blokkade van deze mediatoren en producten van deze cellen in 
relatie to t de ontwikkeling van MODS Een alternatieve benadering is de 
bestudering van het effect van selectieve eliminatie of selectieve genetische 
deficiëntie van deze cellen of mediatoren op de ontwikkeling van MODS Deze 
benadering is het belangrijkste onderwerp van dit proefschrift 
De studies in dit proefschrift zi|n uitgevoerd in het, in hoofdstuk 4 bespro-
CHAPTER 12 
SUMMARY AND FINAL WORDS 
ken, zymosan induced generalized inflammation (ZIGI)-model In dit model 
heeft een intraperitoneale injectie met zymosan, een product van de celwand 
van de gist Saccharomyces cerevisiae, een uniek driefasisch ziektebeeld to t 
gevolg Dit ziektebeeld wordt gekarakteriseerd door een vroege 
hyperdynamische SIRS-achtige respons met geh|ktijdige bactenele translocatie, 
een daarop volgende herstelfase met aansluitend een late hypodynamische 
MODS-achtige fase In deze late fase zien we een gegeneraliseerde 
onstekmgsreactie en orgaanfalen 
Hoofdstuk 5 beschritt de doelstellingen en vragen van dit proefschrift Deze 
zijn 
1 Is er sprake van een gegeneraliseerde endotheelschade, zich uitende in 
permeabihteitsveranderingen, gemeten door scmtigrafische methoden' Is er 
een specifiek tijdspatroon te herkennen in relatie met de daaropvolgende 
orgaanschade' 
2 Speelt de activatie van het complement systeem een belangrijke rol in de 
Pathogenese van MODS' Kunnen we de Symptomatologie, orgaanschade 
of mortaliteit afremmen door gebruik te maken van C5-deficiente muizen' 
3 Treedt er een vermindering of preventie op van de vroege 
hyperdynamische respons door eliminatie van lever en milt macrofagen 
door middel van intraveneus dichloromethylene-bisphosphonate (CIjMBP)-
hposomen suspensie' Veranderen onze bevindingen door het instellen van 
bactenele overgroei ' Tenslotte, beïnvloed eliminatie van verschillende 
macrofaagsubpopulaties (lever-, milt-, alvéolaire en peritoneale macrofagen) 235 
voor en na zymosan toediening de late MODS-fase van dit model ' 
4 Beïnvloedt macrofaag eliminatie de verspreiding van bacteriën en hoe is 
deze gerelateerd aan de ontwikkeling van MODS' 
In hoofdstuk 6 wordt de opeenvolgende ontwikkeling van de vasculaire 
permeabihteit in het ZIGI model beschreven Dit werd bepaald door de 
biodistnbutie van extravasculair ' ' ' indium gelabeld niet specifiek polyclonaal 
Immunoglobuline G (' ' Ίη-lgG) over verschillende organen te bepalen Muizen 
werden op dag 2,5,8 en 12 na toediening van zymosan opgeofferd en hart, 
longen, lever, milt, nieren, het mesentenaal lymfeklieren complex (MLN) en 
weefsel fragmenten van spier, ileum en colon werden verwijderd en gewogen 
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Ίη-lgG werd intraveneus ingespoten 24 uur voor opoffering Relatieve 
orgaan gewichten (ROW), nat/droog gewicht ratio's (WDR) en de 
permeabiliteitsindex (PI) werden bepaald In de meeste organen namen het 
R O W als marker voor orgaanschade, en het W D R als marker voor weefsel-
oedeem beiden geleidelijk toe t o t dag 12 Milt-WDR veranderde overigens 
niet gedurende de observatieperiode Lever, milt, ileum en colon PI waren het 
hoogst op dag 2 Long-PI het een dnefasisch patroon zien, met piek waarden 
op dag 2 en 12 MLN-PI was continue verhoogd Deze studie laat zien dat 
vereandenngen in weefsel oedeem (WDR) en vasculaire permeabiliteit (PI) 
een verschillend beloop hebben tijdens de ontwikkeling van MODS De 
meeste organen heten een vroege toename van de PI gevolgd door een late 
terugkeer naar normaalwaarden zien, terwijl R O W (orgaan schade) continue 
bleven stijgen Dus, het lijkt erop dat orgaanschade voorafgegaan wordt door 
een toename in vasculaire permeabiliteit 
Hoofdstuk 7 beschrijft een studie waarin de rol van complement factor C5 
in de ontwikkeling van MODS wordt onderzocht Dit werd bewerkstelligd 
door de reactie van C5-deficiente (B2DI0/Old) en C5 sufficiente (B2DI07 
New) muizen in het ZIGI-model te bestuderen. Op dag 0 kregen alle muizen 
een intraperitoneale injectie met zymosan gesuspendeerd in paraffine Tussen 
dag 0 en 12 werden dagelijks lichaamstemperatuur, gewicht, klinische conditie 
en mortaliteit bepaald. De klinische conditie werd bepaald door middel van 
een sconngssysteem, waarbij de ernst van de symptomen blind werd ge-
236 scoord Op dag 12 werden alle overlevende muizen opgeofferd en werden 
R O W van de longen, lever, milt en nieren bepaald Zymosan toediening 
resulteerde in dit experiment in het typische dnefasische ziektebeeld bi| beide 
muizenstammen, echter in de acute fase waren de ernst van de symptomen, 
de daling van temperatuur en lichaamsgewicht significant minder in de C5-
deficiente muizen In de late fase echter, werden geen verschillen meer gezien 
tussen beide muizestammen De totale mortaliteit was 8% bij de C5-deficiente 
muizen en 32% bij de C5-sufficiente muizen Dit verschil was echter voorna­
melijk toe te schrijven aan verschillen in de acute fase Orgaan schade (ROW) 
het geen significante verschillen zien voor welk orgaan dan ook Dus, het h|kt 
erop dat complement factor C5 een belangrijke rol speelt in de acute 
hyperdynamische SIRS-fase, echter niet in de late hypodynamische MODS-fase 
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Dit suggereert dat andere factoren meer van belang zijn in de ontstekings-
reactie die to t MODS leidt. 
De centrale vraag in hoofdstuk 8 was wat de invloed zou zijn van CI2MBP-
liposomen gemediéerde eliminatie van lever en milt macrofagen op de 
zymosan geïnduceerde bacteriéle translocatie en de ernst van de 
inflammatoire respons. Eliminatie van lever en milt macrofagen werd to t stand 
gebracht door middel van een intraveneuze injectie met CI2MBP-liposomen 
suspensie. Twee dagen later werd zymosan toegediend in een dosis van 0.1, 
0.5 en 1.0 mg/g. Vierentwintig uur na zymosan toediening werden systemische 
symptomen gescoord en werd de bacteriéle translocatie naar de MLN, lever, 
milt, long en de circulatie gemeten. Een aparte mortaliteitstudie werd verricht 
met een dosis van 1.0 mg/g. De incidentie van de systemische bacteriéle 
translocatie was significant verhoogd bij macrofaag geëlimineerde muizen. De 
systemische inflammatoire respons echter, was significant verminderd door de 
macrofaag eliminatie. Bovendien was in de macrofaag geëlimineerde groep de 
mortaliteit na 12 dagen 0%, terwij l deze in de controle groep 27% was. Dus de 
letale en toxische effecten van zymosan leken in dit experiment meer gerela-
teerd aan de excessieve activatie van macrofagen dan aan de systemische 
verspreiding van bacteriën. 
Omdat bacteriéle overgroei een vaak voorkomend verschijnsel is bij 
intensive care patiënten, werd in hoofdstuk 9 het effect van eliminatie van lever 
en milt macrofagen op de zymosan geïnduceerde bacteriéle translocatie en 
inflammatoire respons geëvalueerd. Dit werd verricht in een model waarin 237 
bacteriéle translocatie naar de MLN al aanwezig was ten gevolge van bacteriéle 
overgroei. Bacteriéle overgroei werd bewerkstelligd door 
darmdecontaminatie , na 4 dagen gevolgd door toevoeging van levende Lcoli 
CIS aan het drinkwater. Eliminatie van lever en milt macrofagen werd to t 
stand gebracht door middel van een intraveneuze injectie met CI2MBP-
liposomen suspensie. Controle muizen kregen een intraveneuze injectie met 
phosphate buffered saline (PBS). Twee dagen later kregen alle muizen een 
intraperitoneale injectie met 0.5 of 1.0 mg/g zymosan. Symptoomscores, 
bacteriéle translocatie naar de MLN, lever, milt, long en bloed en bacteriéle 
concentraties in het coecum werden bepaald 24 en 48 uur na zymosan 
toediening. Een aparte mortaliteitstudie werd verricht met een dosis van 1.0 
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mg/g zymosan suspensie. De ¡ncidentie van de systemische verspreiding van 
bacteriën was significant hoger in de macrofaag geëlimineerde muizen, met 
name na 48 uur en bij de lagere zymosan dosis. Symptoomscores echter, 
waren significant lager in de macrofaag geëlimineerde groepen. Vroege morta-
liteit na 48 uur was 0% in de macrofaag geëlimineerde muizen en 33% in de 
controle muizen. Na 12 dagen was de mortaliteit respectievelijk 20% en 53%. 
Dus ook in dit experiment, waar intestinale bacteriéle concentraties veel 
hoger waren dan in het vorige experiment en bovendien bacteriéle 
translocatie reeds aanwezig was naar het MLN, verminderde macrofaag 
eliminatie mortaliteit en systemische symptomen, zelfs al was de systemische 
bacteriéle translocatie verhoogd. Macrofaag eliminatie scheidde dus ook in dit 
experiment de mogelijke effecten van zymosan geïnduceerde bacteriële 
translocatie van zymosan geïnduceerde inflammatoire respons. 
Tot dan toe waren alleen de effecten van macrofaag eliminatie op de 
vroege fase van het ZIGI model onderzocht. Daarnaast waren alleen lever en 
milt macrofagen vóór zymosan toediening geëlimineerd. Hoofdstuk 10 be-
schrijft daarom een studie waarin de rol van specifieke macrofaag sub-
populaties op de ontwikkeling van MODS in de late fase van het ZIGI model 
werd onderzocht. Dit werd bewerkstelligd door selectieve eliminatie van 
lever, milt, alvéolaire en peritoneale macrofagen vóór en na zymosan. Intrave-
neuze (IV) toediening van CI2MBP-liposomen elimineerde lever en milt 
macrofagen, intratracheale (IT) toediening alvéolaire macrofagen en 
238 intraperitoneale (IP) toediening peritoneale en omentum macrofagen. 
Zymosan I mg/g werd intraperitoneaal toegediend op dag 0. CI2MBP-
liposomen werden 2 dagen vóór of 4 dagen na zymosan injectie toegediend. 
Op dag 12 werden alle overlevende muizen opgeofferd. Lichaamsgewicht, 
temperatuur en mortaliteit werden dagelijks bepaald. R O W werden na opoffe-
ring bepaald van de longen, lever, milt en nieren. CI2MBP-liposomen IV vóór of 
na zymosan liet geen verandering zien in lichaamsgewicht, temperatuur of 
mortaliteit. Lever R O W was significant verlaagd in beide G2MBP-liposomen IV 
groepen. Eliminatie van lever en milt macrofagen na zymosan toediening liet 
significante verhoging van het long R O W en een significante vermindering van 
het lever R O W zien. Ondanks dat lichaamsgewicht, temperatuur en R O W 
niet werden beïnvloed, werd sterfte volledig voorkomen door eliminatie van 
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alvéolaire macrofagen vóór zymosan toediening. G2MBP-liposomen IP veran-
derde niet het lichaamsgewicht, temperatuur en R O W CI2MBP-liposomen IP 
vóór zymosan toediening leidde to t een dramatische verhoging van de mortali-
teit, van 50 naar 90%. Deze gegevens tonen aan dat eliminatie van specifieke 
macrofaag subpopulaties op specifieke tijdsmomenten ten opzichte van 
zymosan toediening in het ZIGI model, verschillende effecten kan hebben 
Activatie van de verschillende macrofaag subpopulaties lijkt ofwel een bescher-
mende dan wel beschadigende rol te hebben op specifieke tijdsmomenten 
tijdens de ontwikkeling van MODS in het ZIGI model 
Tenslotte worden in hoofdstuk 11 de resultaten van bovengenoemde 
experimenten bediscussieerd. Verschillende aspecten van een inflammatoire 
respons worden besproken in relatie to t de ontwikkeling van MODS Het lijkt 
erop dat we op bepaalde tijdstippen en plaatsen de ontstekingsreactie zouden 
moeten versterken, terwi|l op andere plaatsen en tijdstippen we deze respons 
zouden moeten afremmen Eén van de voornaamste doelstellingen van het 
toekomstige onderzoek zou de nadere identificatie moeten zi|n van welke 
functies en cellen geremd en welke versterkt dienen te worden 
239 
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12.4 D A N K W O O R D 
Onder de titel van dit proefschrift staat slechts één naam. Natuurlijk maak 
je een proefschrift niet alleen. Het is het resultaat van de samenwerking tussen 
mij en velen die me daarbij direct en indirect hebben geholpen. Een dank-
woord is daarom zeker op zijn plaats!. 
Allereerst wil ik mijn vrouw Chantal bedanken. De ruimte, flexibiliteit, 
begrip en liefde die je me hebt gegeven, is bewonderenswaardig en getuigt van 
een groot empatisch vermogen. Je relativerende en soms ontnuchterende 
opstelling ten aanzien van mijn ambities bracht me weer terug onder de 
mensen. Chantal, ik hou van je. 
Daarnaast mijn promotor, prof. dr. R.J.A. Goris. Beste Jan, door jouw 
enthousiasme is er bij mij een gegeneraliseerde excessieve en gelukkig ook 
autonome respons opgewekt om me in het mysterie van het multiple organ 
dysfunction syndrome te gaan verdiepen. Jij hebt me alle mogelijkheden gege-
ven om dit onderzoek te doen en me bij vele mensen geïntroduceerd. Ik 
bewonder je vooruitziende blik om originele hypothesen te ontwikkelen en je 
vasthoudendheid om erin te blijven geloven. Het ZIGI model bleek niet alleen 
een model te zijn maar ook een neerslag van een zeer originele hypothese. Na 
al die jaren ben ik die twinkeling in je ogen gaan begrijpen als weer een groep 
met ons model ging werken. Yes, it rings a bell! 
Mijn co-promotor, Dr. Th. Hendriks. Beste Thijs, je licht ironische kijk op 
mijn onderzoek was een zeer welkome kritische noot, die van een groot 
relativerend belang was naast het haast ongelimiteerd enthousiasme van mijn 
promotor. De aanmerkingen met het rode pennetje bij mijn manuscripten 
hadden een grote toegevoegde waarde op het uiteindelijke resultaat. Veel 
dank! 
Prof. dr. E.A. Deitch, dear Edwin. Thanks for giving me the opportunity to 
taste the american way of doing research, which means not to delegate but to 
understand and perform every part of an experiment by yourself. I have never 
seen so many agar-agar plates, bacteria and mice in so little time!. You were a 
real companion in doing research and your original view on results and 
manuscripts was indispensable. Prof. dr. R.D. Berg, dear Rodney, thanks for 
your hospitality in your lab and the discussions about jazz, food and the Mac. 
Martha Love, thanks for being a great help in performing the experiments. Dr. 
Y. Haskel, dear Yuval, we were partners in the same lonesome situation, 
thanks for your moral support. Prof. dr. I.H. Chaudry, I am honored by your 
kindness for being a member of the manuscript committee. 
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Leo Geeraedts, |e hebt veel experimenteel werk voor me verricht en bent bi| 
veel niet-gepubliceerde, maar daardoor met minder belangrijke, pilotstudies 
voor dit proefschrift betrokken geweest. Bovendien was je een animerende en 
enthousiaste persoonlijkheid die vaak een vroli|ke noot bracht op het lab. Veel 
dank! Maarten Knapen, | i | hebt een |aar lang voor mij op het lab gewerkt en 
verdient dan ook een bijzonder woord van dank. Zonder JOUW niet aflatende 
hulp was veel experimenteel werk met gelukt. Door alle tegenslagen, heb |ij 
met name kunnen merken dat zeker in experimenteel onderzoek Murphy's 
laws geldig zi|n Bewondering voor je doorzettingsvermogen! Wil lem Sanders, 
Desiree Meyer en Ronald van Ingen, ook veel dank voor het vele werk op het 
lab ti|dens jullie wetenschappelijke stage. Monique Jansen, fijn om iemand te 
hebben die in de zelfde onderzoekslijn zat. Dit maakte het voor mij een stuk 
gemakkelijker Deel I is nu klaar, deel 2 komt hopelijk snel! Veel succes! Ben 
de Man, dank voor de aanmaak van hposomen Nico van Rooijen, dank voor je 
"macrophage suicide technique" en de liposomen die je zelfs naar de USA 
opstuurde. Dank ook aan alle medewerkers van het centraal dieren-
laboratorium Ni|megen met wie ik heb samengewerkt- Jan Koedam, Alex 
Hanssen, Gerne Grutters, Monique Bakker en Margot van de Brink en vele 
anderen Rob van Schie, dank voor je geduldige introductie in het geheim van 
macrofagen. Theo de Boo en Wim Lemmens, dank voor jullie statistische hulp 
W im Ooijen, dank voor een prettige en vruchtbare samenwerking met de 
nucleaire geneeskunde. Loek Leenen, dank voor het maken van de scans en 
Argé Nieuwenhuijzen voor de grafische ondersteuning Miranda van Tits, Gary 
wants to thank you for everything. Vooral voor de afgang op TV en het fìjne 
bad van Gons Caroline Smeets, dank voor |e koerierschap tussen Tilburg 
en Nijmegen. Mijn manuscripten konden met sneller heen en weer. Paranimfen 
Astrid de W i t en Daan van Baarsen, dank voor jullie bereidheid mij bij te staan 
in deze spannende ti jd. Jullie werk komt nu! 
Collega assistenten, stafleden en bazen uit het Academisch Ziekenhuis 
Nijmegen en St Elisabeth Ziekenhuis Tilburg, dit onderzoek zal zeker zijn 
weerslag hebben gehad op mijn fysieke en psychische betrokkenheid bij de 
groep en de klinische werkzaamheden. Dank voor jullie vermogen om het zo 
weinig te laten merken. 
Daarnaast wil ik iedereen die een bi|drage heeft geleverd aan de totstand-
koming van dit proefschrift en met expliciet genoemd is, hartelijk bedanken. 
Als laatste wil ik mijn ouders bedanken, zij hebben mij alti|d onvoorwaar-
delijk gesteund en mij geleerd in mezelf en in mijn ambities te geloven. 
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2.5 C U R R I C U L U M V I T A E 
Grard Nieuwenhuijzen werd op 6 april 1962 geboren te Sprang-Capelle. 
In 1980 behaalde hij het eindexamen Atheneum В aan het Wil lem van Oranje 
College te Waalwijk. Van 1980 t o t 1982 studeerde hij aan de Technische 
Universiteit Eindhoven afdeling Bouwkunde. Vanaf 1982 studeerde hij Genees­
kunde aan de Katholieke Universiteit van Nijmegen. Tijdens zijn studie werkte 
hij als explicateur in het anatomisch museum te Nijmegen en als ambulance 
verpleegkundige bij de GGD te Oss. In 1986 verbleef hij, in het kader van een 
exchange programma, enkele maanden in het All India Institute of Medical 
Sciences, New Delhi, India. Als co-assistent werkte hij in 1989 in het 
Sengerema Hospital, Sengerema, Tanzania. In hetzelfde jaar werd een weten­
schappelijke stage verricht op de afdeling heelkunde van het Academische 
Ziekenhuis Nijmegen onder begeleiding van prof. dr. R.J.A. Goris en dr. I.P.T. 
van Bebber alwaar de interesse w e r d gewekt voor het Multiple Organ 
Dysfunction Syndrome. In 1990 w e r d vervolgens het arts-examen met goed 
gevolg afgelegd. 
Van 1990 t o t 1991 was hij als A G N I O werkzaam op de afdeling Heel­
kunde van het Academische Ziekenhuis Nijmegen. In 1991 kreeg hij de 
travelling fellowship van de Surgical Infection Society-Europe waardoor hij 
experimenteel onderzoek kon verrichten in het laboratorium van prof. dr. E.A. 
Deitch, Louisiana State University Medical Center, Shreveport, LA, USA. 
Op I februari 1992 startte hij de opleiding t o t algemeen chirurg in het 
Academische Ziekenhuis Nijmegen (hoofd: prof. dr. RJA Goris). Het vervolg 
van zijn opleiding vond plaats in het Sint Elisabeth Ziekenhuis te Tilburg (hoofd: 
dr. J.A. Roukema), alwaar hij op I februari 1998 zijn opleiding hoopt te vol­
tooien. Vanaf I februari 1998 zal hij zich differentieren in de chirurgische 
oncologie op de afdeling Chirurgische Oncologie van de Daniel den Hoed 
kliniek (hoofd: dr. Th. Wiggers). 
Het dierexperimenteel onderzoek van dit proefschrift werd tijdens en vóór 
zijn opleiding to t algemeen chirurg verricht in het Louisiana State University 
Medical Center, Shreveport, LA, USA onder begeleiding van prof.dr. E.A. 
Deitch en op de afdeling heelkunde van het Academische Ziekenhuis Nijmegen 
onder begeleiding van prof. dr. R.J.A. Goris en dr. Th. Hendriks. 
Hij is getrouwd met Chantal Abeln. Zij hebben 3 kinderen: Tom, Floor en Joris. 
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1. Het ZIGI-model is het enige model voor MODS. 
2. Het routinematig toepassen van SDD op een intensive care 
afdeling dient te worden vermeden. 
3. Er is meer onderzoek gedaan naar de vraag wanneer 
bacteriële translocatie ontstaat, dan naar de vraag waarom 
het bestaat. 
4. De diagnose pneumonie op de intensive care is lastig en 
wordt vaak ten onrechte gesteld. 
5. De definitie van SIRS is zo inadequaat dat als iemand de 
liefde bedrijft, hij last krijgt van SIRS. 
6. Er is dringend behoefte aan een eenduidige definitie van 
orgaan falen of dysfunctie in het kader van MODS. 
7. MODS in het ZIGI model gaat gepaard met een gegenerali-
seerde verhoogde microvasculaire permeabiliteit, die vooraf 
gaat aan orgaanschade. 
8. Blokkade van de complement cascade vermindert alleen de 
hyperdynamische fase in het ZIGI model, echter niet het 
ontstaan van MODS. 
9. MODS is niet het gevolg van een excessieve activatie van 
één macrofaag populatie, noch van één cytokine of een 
andere mediator. MODS is mogelijk het gevolg van een 
dysbalans van meerdere mediatoren. 
10. Veel retrospectief onderzoek is het herstellen van een 
gebrekkige prospectieve registratie. 
I I. Het immuunsysteem zou weleens veel meer belang kunnen 
hechten aan het herkennen van gevaar en potentiële des-
tructie dan aan het onderscheid tussen eigen en niet-eigen 
(hypothese van Polly Matzinger). In deze context zou men 
MODS kunnen beschouwen als een ontregelde gevaar-
herkenning van het immuunsysteem. 
12. Intensiever gebruik van on-line literatuuronderzoek en de 
gegevens van evidence-based medicine kan de opnameduur 
en kosten in de gezondheidszorg verminderen. Medici zou-
den dus meer moeten surfen. 
I 3. Een zeer besmettelijke ziekte verspreidt zich in de 
wetenschapswereld: Polyauthoritis giftosa. Een variant hier-
van, die zich snel ontwikkelt, is de Polyabstractitis identicus. 
14. De totale mesorectale excisie van het rectumcarcinoom 
vermindert de kans op een locaal recidief, maar verhoogt de 
kans op een naadlekkage. 
15. De term "versterving" illustreert hoe onze maatschappij 
vervreemd is van het natuurlijk sterfproces. 
16. Mac 85 > Windows 95: eenvoud is het kenmerk van het 
ware! 
17. Het routine gebruik van de Stifneck™ bij traumapatiënten 
dient stijfkoppig te worden volgehouden. 
18. Promoveren is soms halsbrekend! 
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